FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Dutra, BM
   Rodrigues, NLD
   Fonseca, FRM
   de Moura, TR
   de Almeida, RP
   de Jesus, AR
   Abreu, TM
   Pompeu, MMD
   Teixeira, CR
   Teixeira, MJ
AF Dutra, Brunheld Maia
   Rodrigues, Naya Lucia de Castro
   Fonseca, Francisco Rafael Marciano
   de Moura, Tatiana Rodrigues
   Pacheco de Almeida, Roque
   de Jesus, Amelia Ribeiro
   Abreu, Ticiana Monteiro
   Pompeu, Margarida Maria de Lima
   Teixeira, Clarissa Romero
   Teixeira, Maria Jania
TI CXCL10 immunomodulatory effect against infection caused by an antimony
   refractory isolate of Leishmania braziliensis in mice
SO PARASITE IMMUNOLOGY
LA English
DT Article; Early Access
DE antimony resistance; CXCL10; Leishmania braziliensis; treatment
ID CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS; INTERFERON-GAMMA;
   AMAZONENSIS; PROTECTION; CHEMOKINES; CELL; IMMUNOCHEMOTHERAPY; VECTOR;
   IP-10
AB Leishmania braziliensis is the main causative agent of American tegumentary leishmaniasis in Brazil. Current treatment includes different drugs that have important side effects and identification of cases of parasite resistance to treatment support the search for new therapeutic strategies. Recent findings have indicated that CXCL10, a chemokine that recruits and activates Th1 cells, NK cells, macrophages, dendritic cells and B lymphocytes, is a potential alternative to treat Leishmania infection. Here, we tested CXCL10 immunotherapy against experimental infection caused by an antimony-resistant isolate of Leishmania braziliensis. Following infection, mice were treated with CXCL10 for 7 days after onset of lesions. We demonstrate that mice treated with CXCL10 controlled lesion progression and parasite burden more efficiently comparing to controls. An increased IFN-gamma, IL-10, TGF-beta and low IL-4 production combined with a distinct inflammatory infiltrate composed by activated macrophages, lymphocytes and granulomas was observed in the CXCL10-treated group comparing to controls. However, CXCL10 and Glucantime combined therapy did not improve CXCL10-induced protective effect. Our findings reinforce the potential of CXCL10 immunotherapy as an alternative treatment against infection caused by L. braziliensis resistant to conventional chemotherapy.
C1 [Dutra, Brunheld Maia; Rodrigues, Naya Lucia de Castro; Fonseca, Francisco Rafael Marciano; Abreu, Ticiana Monteiro; Pompeu, Margarida Maria de Lima; Teixeira, Maria Jania] Univ Fed Ceara, Dept Pathol & Legal Med, Fortaleza, Ceara, Brazil.
   [de Moura, Tatiana Rodrigues; Pacheco de Almeida, Roque; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Internal Med & Pathol, Aracaju, Brazil.
   [Teixeira, Clarissa Romero] Fundacao Oswaldo Cruz, Fiocruz Ceara, Eusebio, Brazil.
RP Teixeira, MJ (corresponding author), Univ Fed Ceara, Dept Pathol & Legal Med, Fortaleza, Ceara, Brazil.
EM mjteixeira601@gmail.com
FU Conselho Nacional de Pesquisa (CNPq)National Council for Scientific and
   Technological Development (CNPq); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES; Fundacao Cearense de Apoio ao
   Desenvolvimento Cientifico e Tecnologico (FUNCAP)
FX This work was supported by Brazilian grants from Conselho Nacional de
   Pesquisa (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES) and Fundacao Cearense de Apoio ao Desenvolvimento
   Cientifico e Tecnologico (FUNCAP).
CR Abdoli A, 2017, COMP IMMUNOL MICROB, V51, P15, DOI 10.1016/j.cimid.2017.02.001
   Almeida RP, 2005, AM J TROP MED HYG, V73, P79, DOI 10.4269/ajtmh.2005.73.79
   BADARO R, 1993, J INFECT DIS, V167, pS13, DOI 10.1093/infdis/167.Supplement_1.S13
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   Burza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140-6736(18)31204-2
   Conceicao J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004715
   Costa DL, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000965
   Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]
   de Moura TR, 2005, INFECT IMMUN, V73, P5827, DOI 10.1128/IAI.73.9.5827-5834.2005
   de Oliveira CI, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00145
   Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195
   El-On J, 2009, ISR MED ASSOC J, V11, P623
   Figueiredo WME, 2017, MEM I OSWALDO CRUZ, V112, P561, DOI 10.1590/0074-02760160529
   Figueiredo WME, 2019, EXP PARASITOL, V207
   Gupta G, 2011, MED MICROBIOL IMMUN, V200, P241, DOI 10.1007/s00430-011-0197-y
   Gupta G, 2009, J INFECT DIS, V200, P1300, DOI 10.1086/605895
   Hailu A, 2004, AM J TROP MED HYG, V71, P561, DOI 10.4269/ajtmh.2004.71.561
   Kevric I, 2015, DERMATOL CLIN, V33, P579, DOI 10.1016/j.det.2015.03.018
   Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001
   Diaz NL, 2013, MEM I OSWALDO CRUZ, V108, P446, DOI 10.1590/S0074-0276108042013008
   Majumder S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048727
   Mastroianni A, 2004, Infez Med, V12, P197
   Minodier Philippe, 2007, Travel Med Infect Dis, V5, P150, DOI 10.1016/j.tmaid.2006.09.004
   Montakhab-Yeganeh H, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12461
   Muller K, 2001, MED MICROBIOL IMMUN, V190, P73
   Peters NC, 2009, CELL MICROBIOL, V11, P1290, DOI 10.1111/j.1462-5822.2009.01348.x
   Ribeiro-Gomes FL, 2004, J IMMUNOL, V172, P4454, DOI 10.4049/jimmunol.172.7.4454
   Silva SC, 2018, ACTA TROP, V178, P34, DOI 10.1016/j.actatropica.2017.10.010
   Silveira FT, 2009, PARASITE IMMUNOL, V31, P423, DOI 10.1111/j.1365-3024.2009.01116.x
   Singh Sarman, 2004, Journal of Infection and Chemotherapy, V10, P307, DOI 10.1007/s10156-004-0348-9
   Souza AS, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-209
   SQUIRES KE, 1993, AM J TROP MED HYG, V48, P666, DOI 10.4269/ajtmh.1993.48.666
   SUNDAR S, 1995, J INFECT DIS, V171, P992, DOI 10.1093/infdis/171.4.992
   Taslimi Y, 2018, PARASITOLOGY, V145, P497, DOI 10.1017/S003118201600216X
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521
   Vargas-Inchaustegui DA, 2010, INFECT IMMUN, V78, P301, DOI 10.1128/IAI.00959-09
   Vasquez RE, 2008, INFECT IMMUN, V76, P161, DOI 10.1128/IAI.00825-07
   Vasquez RE, 2006, INFECT IMMUN, V74, P6769, DOI 10.1128/IAI.01073-06
NR 39
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-9838
EI 1365-3024
J9 PARASITE IMMUNOL
JI Parasite Immunol.
AR e12805
DI 10.1111/pim.12805
EA NOV 2020
PG 8
WC Immunology; Parasitology
SC Immunology; Parasitology
GA OS6QQ
UT WOS:000590286300001
PM 33131089
DA 2020-12-08
ER

PT J
AU Carmen, M
   Sanchez, A
   Celeste, BJ
   Lindoso, JAL
   Fujimori, M
   de Almeida, RP
   Fortaleza, CMCB
   Druzian, AF
   Lemos, APF
   de Melo, VCA
   Paniago, AMM
   Queiroz, IT
   Goto, H
AF Carmen, Maria
   Sanchez, Arroyo
   Celeste, Beatriz Julieta
   Lauletta Lindoso, Jose Angelo
   Fujimori, Mahyumi
   de Almeida, Roque Pacheco
   Castelo Branco Fortaleza, Carlos Magno
   Druzian, Angelita Fernandes
   Freitas Lemos, Ana Priscila
   Andrade de Melo, Vanessa Campos
   Miranda Paniago, Anamaria Mello
   Queiroz, Igor Thiago
   Goto, Hiro
TI Performance of rK39-based immunochromatographic rapid diagnostic test
   for serodiagnosis of visceral leishmaniasis using whole blood, serum and
   oral fluid (vol 15, e0230610, 2020)
SO PLOS ONE
LA English
DT Correction
RI Lindoso, Jose Angelo Lauletta/E-9339-2012
OI Lindoso, Jose Angelo Lauletta/0000-0002-4405-4401
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil
   (CAPES)CAPES [001]
FX This study was also supported by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior-Brasil (CAPES)-Finance Code 001.
CR Sanchez MCA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230610
NR 1
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 29
PY 2020
VL 15
IS 4
AR e0232727
DI 10.1371/journal.pone.0232727
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LS8ZG
UT WOS:000536668200074
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Sanchez, MCA
   Celeste, BJ
   Lindoso, JAL
   Fujimori, M
   de Almeida, RP
   Fortaleza, CMCB
   Druzian, AF
   Lemos, APF
   de Melo, VCA
   Paniago, AMM
   Queiroz, IT
   Goto, H
AF Arroyo Sanchez, Maria Carmen
   Celeste, Beatriz Julieta
   Lauletta Lindoso, Jose Angelo
   Fujimori, Mahyumi
   de Almeida, Roque Pacheco
   Castelo Branco Fortaleza, Carlos Magno
   Druzian, Angelita Fernandes
   Freitas Lemos, Ana Priscila
   Andrade de Melo, Vanessa Campos
   Miranda Paniago, Anamaria Mello
   Queiroz, Igor Thiago
   Goto, Hiro
TI Performance of rK39-based immunochromatographic rapid diagnostic test
   for serodiagnosis of visceral leishmaniasis using whole blood, serum and
   oral fluid
SO PLOS ONE
LA English
DT Article
ID DIRECT AGGLUTINATION-TEST; RK39 ANTIGEN; FIELD; STATISTICS
AB Background
   The development of rK39-based immunochromatographic rapid diagnostic tests represents an important advance for serodiagnosis of visceral leishmaniasis, being cheap and easy to use at the point of care (POC). Although the use of rK39 have considerably improved the sensitivity and specificity of serological tests compared with total antigens, great variability in sensitivity and specificity was reported. This study aimed at the evaluation of "Kalazar Detect (TM) Rapid Test, Whole Blood" (Kalazar Detect RDT) for Visceral Leishmaniasis (VL) diagnosis using oral fluid, whole blood and serum specimens collected at different endemic areas of VL of Brazil.
   Methodology
   To evaluate Kalazar Detect RDT, oral fluid, whole blood and serum specimens from 128 VL patients, 85 healthy individuals, 22 patients with possible cross-reactivity diseases and 20 VL/aids coinfected patients were collected and assayed at the POC.
   Principal findings and conclusions
   The performance of Kalazar Detect RDT in whole blood and serum was similar; however, using oral fluid, the sensitivity was low. Particularly in samples from the city of Natal, Rio Grande do Norte state in Northeastern Brazil, we observed low sensitivity, 80.0% (95% CI: 62.7-90.5), using whole blood and serum, and poor sensitivity, 43.3% (95% CI: 27.4-60.8) with oral fluid. Those values were much lower than in the other regions, where sensitivity ranged from 92.7-96.3% in whole blood and serum, and 80.0-88.9% in oral fluid. Besides, in VL/aids coinfected patients, lower sensitivity was achieved compared with VL patients. In samples from Natal, the sensitivity was 0.0% (95% CI: 0.0-49.0) and 25.0% (95% CI: 4.6-69.9), using oral fluid and serum/whole blood, respectively; in samples from the other regions, the sensitivity ranged from 40.0-63.6% and 80.0-81.8%, respectively. As for specificity, high values were observed across the fluids, 100.0% (95% CI: 96.5-100.0) in whole blood, 96.3% (95% CI: 90.8-98.5) in serum, and 95.3% (95% CI: 89.5-98.0) in oral fluid; across localities, specificity ranged from 85.7-100.0%. Serum samples sent by the collaborating centers to Instituto de Medicina Tropical (n = 250) were tested by Kalazar Detect RDT, Direct Agglutination Test, Indirect immunofluorescence assay, Enzyme-linked immunosorbent assay, and IT-Leish (R) RDT. The regional difference in the performance of rK39-based RDT and lower sensitivity in Leishmania/HIV coinfected patients raise concern on the routine use of these products for the diagnosis of VL.
C1 [Arroyo Sanchez, Maria Carmen; Celeste, Beatriz Julieta; Fujimori, Mahyumi; Goto, Hiro] Univ Sao Paulo, Inst Med Trop, Lab Soroepidemiol & Imunobiol, Fac Med, Sao Paulo, SP, Brazil.
   [Lauletta Lindoso, Jose Angelo] Univ Sao Paulo, Fac Med, Dept Doencas Infecciosas & Parasitarias, Sao Paulo, SP, Brazil.
   [Lauletta Lindoso, Jose Angelo] Inst Infectol Emilio Ribas, Secretaria Estado Saude, Sao Paulo, SP, Brazil.
   [de Almeida, Roque Pacheco] Univ Fed Sergipe, Hosp Univ EBSERH, Dept Med Interna & Patol, Aracaju, SE, Brazil.
   [Castelo Branco Fortaleza, Carlos Magno] Univ Estadual Paulista, Dept Doencas Trop & Diagnost Imagem, Botucatu, SP, Brazil.
   [Druzian, Angelita Fernandes] Univ Fed Mato Grosso, Hosp Univ Maria Aparecida Pedrossian, Campo Grande, MS, Brazil.
   [Freitas Lemos, Ana Priscila] Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, Natal, RN, Brazil.
   [Andrade de Melo, Vanessa Campos; Queiroz, Igor Thiago] Hosp Giselda Trigueiro, Secretaria Estadual Seguranca Publ, Natal, RN, Brazil.
   [Miranda Paniago, Anamaria Mello] Univ Fed Mato Grosso do Sul, Fac Med, Campo Grande, MS, Brazil.
   [Goto, Hiro] Univ Sao Paulo, Fac Med, Dept Med Prevent, Sao Paulo, SP, Brazil.
RP Sanchez, MCA (corresponding author), Univ Sao Paulo, Inst Med Trop, Lab Soroepidemiol & Imunobiol, Fac Med, Sao Paulo, SP, Brazil.
EM arroyo@usp.br
RI Goto, Hiro/B-5745-2009; Fujimori, Mahyumi/AAH-4746-2020; Lindoso, Jose
   Angelo Lauletta/E-9339-2012; Fortaleza, Carlos Magno C. B./C-3807-2013;
   Paniago, Anamaria/B-7747-2012
OI Goto, Hiro/0000-0001-7048-562X; Fujimori, Mahyumi/0000-0001-7790-9827;
   Lindoso, Jose Angelo Lauletta/0000-0002-4405-4401; Fortaleza, Carlos
   Magno C. B./0000-0003-4120-1258; Celeste, Beatriz
   Julieta/0000-0003-0815-359X; Paniago, Anamaria/0000-0002-8925-7712
FU Ministry of Health, Brazil [084727/2010]; Laboratorio de Investigacao
   Medica Hospital das Clinicas da Faculdade de Medicina da Universidade de
   Sao Paulo [LIM-38]; Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq)
FX This study was supported by Ministry of Health, Brazil (SICONV N omicron
   084727/2010) and Laboratorio de Investigacao Medica (LIM-38) Hospital
   das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo. HG
   recieved research fellowship from Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alvar J, 2004, ADV PARASIT, V57, P1, DOI 10.1016/S0065-308X(04)57001-X
   [Anonymous], 2019, LEISHMANIOSE VISCERA
   [Anonymous], 2000, LETALIDADE LEISHMANI
   [Anonymous], 2019, CASOS CONFIRMADOS LE
   Attia J, 2002, AUSTR PRESCRIBER, P26
   Bangert M, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006277
   Banoo S, 2010, NAT REV MICROBIOL, pS17, DOI [10.1038/nrmicro1523, 10.1038/nrmico1523]
   Bhattacharyya T, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002057
   da Silva MRB, 2018, PARASITOL RES, V117, P419, DOI 10.1007/s00436-017-5716-3
   BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775
   Celeste Beatriz Julieta, 1998, Revista do Instituto de Medicina Tropical de Sao Paulo, V40, P287, DOI 10.1590/S0036-46651998000500004
   Chappuis F, 2006, TROP MED INT HEALTH, V11, P31, DOI 10.1111/j.1365-3156.2005.01533.x
   Chappuis F, 2005, J CLIN MICROBIOL, V43, P5973, DOI 10.1128/JCM.43.12.5973-5977.2005
   Cota GF, 2013, AM J TROP MED HYG, V89, P570, DOI 10.4269/ajtmh.13-0239
   Cunningham J, 2012, CLIN INFECT DIS, V55, P1312, DOI 10.1093/cid/cis716
   da Silva MRB, 2015, TROP BIOMED, V32, P247
   Deeks JJ, 2004, BRIT MED J, V329, P168, DOI 10.1136/bmj.329.7458.168
   El Safi SH, 2007, NATURE REV MICROBIOL, V5, pS30, DOI DOI 10.1038/NRMICRO1766
   ELHARITH A, 1988, J CLIN MICROBIOL, V26, P1321, DOI 10.1128/JCM.26.7.1321-1325.1988
   Fleiss J.L., 2003, STAT METHODS RATES P
   Freire ML, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007484
   Furukawa TA, 2008, USERS GUIDES MED LIT, P195
   Galai Y, 2011, J CLIN MICROBIOL, V49, P3150, DOI 10.1128/JCM.00267-11
   Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7
   Grimes DA, 2002, LANCET, V359, P881, DOI 10.1016/S0140-6736(02)07948-5
   GUIMARAES MCS, 1989, B WORLD HEALTH ORGAN, V67, P643
   Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2
   LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786
   Lindoso JAL, 2012, RES REP TROP MED, V3, P69, DOI 10.2147/RRTM.S24764
   Maia Z, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001484
   Ferreira GEM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036242
   Mikaeili Fattaneh, 2007, Iran J Immunol, V4, P116
   Mohapatra S, 2016, J ARTHROPOD-BORNE DI, V10, P87
   Motoie G, 2013, INFECT GENET EVOL, V18, P48, DOI 10.1016/j.meegid.2013.04.031
   Pedras MJ, 2008, T ROY SOC TROP MED H, V102, P172, DOI 10.1016/j.trstmh.2007.11.004
   Peruhype-Magalhaes V, 2012, MEM I OSWALDO CRUZ, V107, P951, DOI 10.1590/S0074-02762012000700019
   Ritmeijer K, 2006, AM J TROP MED HYG, V74, P76, DOI 10.4269/ajtmh.2006.74.76
   SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V
   Singh DP, 2010, J HEALTH POPUL NUTR, V28, P281
   Srivastava P, 2011, T ROY SOC TROP MED H, V105, P1, DOI 10.1016/j.trstmh.2010.09.006
   Srividya G, 2012, PARASITOL RES, V110, P1065, DOI 10.1007/s00436-011-2680-1
   Sundar S, 1998, LANCET, V351, P563, DOI 10.1016/S0140-6736(97)04350-X
   Vaish M, 2012, AM J TROP MED HYG, V86, P598, DOI 10.4269/ajtmh.2012.11-0127
   van Griensven J, 2019, INFECT DIS CLIN N AM, V33, P79, DOI 10.1016/j.idc.2018.10.005
   World Health Organization (WHO), 2019, LEISHMANIASIS
NR 45
TC 2
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2020
VL 15
IS 4
AR e0230610
DI 10.1371/journal.pone.0230610
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LR8KJ
UT WOS:000535945000032
PM 32240188
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Valadares, M
   Pedroso, ACLO
   Santana, A
   da Silva, AM
   Costa, IS
   Almeida, MLD
   de Almeida, RP
AF Valadares, Marco
   Pedroso, Anne Carolyne Lelis Oliveira
   Santana, Alessandro
   da Silva, Angela Maria
   Costa, Isabela Soares
   Almeida, Maria Luiza Doria
   de Almeida, Roque Pacheco
TI Ocular Findings in Infants with Microcephaly Caused by Presumed
   Congenital Infection by Zika Virus in Sergipe
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BRAZIL; TRANSMISSION; CHILD
AB This study aims at identifying ocular findings in infants with microcephaly associated with presumed intrauterine infection by ZIKV. A cross-sectional study included 62 outpatient infants with congenital microcephaly, presumably secondary to maternal ZIKV infection. The included infants had head circumference below -2 standard deviations, with negative maternal serology for toxoplasmosis, rubella, cytomegalovirus, syphilis, and HIV. Assessment of ocular alterations was performed through review of their medical records. Forty two (67.7%) of the children analyzed presented some degree of ocular alteration. Findings in the posterior segment occurred in 29 (46.8%) patients, including atrophy of the retinal pigmentary epithelium in 15 (24.2%) patients, chorioretinal scars in 14 (22.6%) patients, retinal coloboma in 6 (9.7%) patients, and punctate retinal hemorrhage in 1 (1.6%) patient. Other ocular alterations were seen in 15 (24.2%) patients, including pathological strabismus in 11 (17.7%) patients, congenital cataracts in 2 (3.2%) patients, and nystagmus in 2 (3.2%) patients. Functional alterations were seen in four (6.5%) children. More than one change occurred in 11 (17.7%) children, eight of whom had head circumferences below -3 standard deviations. Changes in both the eyes occurred in 22 (35.5%) children, while 20 (32.3%) children had unilateral involvement. Among the 42 children with any ocular alteration, 27 (64.3%) children presented with severe microcephaly (head circumference with standard deviation lower than -3). The majority of children with microcephaly, presumably secondary to maternal ZIKV infection, present ocular alterations, with a higher frequency of involvement in the fundus. Severe ocular alterations are related to severe microcephaly.
C1 [Valadares, Marco; Pedroso, Anne Carolyne Lelis Oliveira; Santana, Alessandro; da Silva, Angela Maria; Costa, Isabela Soares; Almeida, Maria Luiza Doria; de Almeida, Roque Pacheco] Univ Fed Sergipe, Dept Med, BR-49060100 Sergipe, Brazil.
RP Costa, IS (corresponding author), Univ Fed Sergipe, Dept Med, BR-49060100 Sergipe, Brazil.
EM valadaresmarco@uol.com.br; annepedroso@hotmail.com;
   alessandro-santana@uol.com.br; angelmar@infonet.com.br;
   isasoarescosta@hotmail.com; luiza.doria@gmail.com;
   roquepachecoalmeida@gmail.com
CR [Anonymous], 2016, 43 SECR EST SAUD SER
   Ashwal S, 2009, NEUROLOGY, V73, P887, DOI 10.1212/WNL.0b013e3181b783f7
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Bogoch II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   de Miranda HA, 2016, OPHTHALMOLOGY, V123, P1788, DOI 10.1016/j.ophtha.2016.05.001
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Faye O, 2008, J CLIN VIROL, V43, P96, DOI 10.1016/j.jcv.2008.05.005
   Freitas BD, 2016, JAMA OPHTHALMOL, V134, P529, DOI 10.1001/jamaophthalmol.2016.0267
   Karabatsos N., 1985, INT CATALOGUE ARBOVI, V1147
   Ministerio da Saude (BR), 2016, B EPIDEMIOLOGICO, V46, P1
   Ministerio da Saude (BR), 2016, B EPIDEMIOLOGICO, V47
   PAHO/WHO, 2016, ZIK EP UPD 14 APR 20
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   Victora CG, 2016, LANCET, V387, P621, DOI 10.1016/S0140-6736(16)00273-7
   Woods CG, 2004, CURR OPIN NEUROBIOL, V14, P112, DOI 10.1016/j.conb.2004.01.003
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 20
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD APR 1
PY 2020
VL 2020
AR 7092432
DI 10.1155/2020/7092432
PG 5
WC Medicine, Research & Experimental; Ophthalmology
SC Research & Experimental Medicine; Ophthalmology
GA LE7VB
UT WOS:000526930500011
PM 32318282
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Reynolds, CJ
   Watber, P
   Santos, CNO
   Ribeiro, DR
   Alves, JC
   Fonseca, ABL
   Bispo, AJB
   Porto, RLS
   Bokea, K
   de Jesus, AMR
   de Almeida, RP
   Boyton, RJ
   Altmann, DM
AF Reynolds, Catherine J.
   Watber, Patricia
   Santos, Camilla Natalia Oliveira
   Ribeiro, Danielle Rodrigues
   Alves, Juliana Cardoso
   Fonseca, Adriana B. L.
   Bispo, Ana J. B.
   Porto, Roseane L. S.
   Bokea, Kalliopi
   De Jesus, Amelia Maria Ribeiro
   De Almeida, Roque Pacheco
   Boyton, Rosemary J.
   Altmann, Daniel M.
TI Strong CD4 T Cell Responses to Zika Virus Antigens in a Cohort of Dengue
   Virus Immune Mothers of Congenital Zika Virus Syndrome Infants
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE zika virus; dengue virus; T cell epitope; flavivirus; cross-reactivity;
   microcephaly; adaptive immunity
ID ANTIBODY-DEPENDENT ENHANCEMENT; CROSS-REACTIVITY; PROFILE
AB Background: There is an urgent need to understand the complex relationship between cross-reactive anti-viral immunity, disease susceptibility, and severity in the face of differential exposure to related, circulating Flaviviruses. Co-exposure to Dengue virus and Zika virus in Brazil is a case in point. A devastating aspect of the 2015-2016 South American Zika outbreak was the dramatic increase in numbers of infants born with microcephaly to mothers exposed to Zika virus during pregnancy. It has been proposed that this is more likely to ensue from Zika infection in women lacking cross-protective Dengue immunity. In this case series we measure the prevalence of Dengue immunity in a cohort of mothers exposed to Zika virus during pregnancy in the 2015-2016 Zika outbreak that gave birth to an infant affected by microcephaly and explore their adaptive immunity to Zika virus.
   Results: Fifty women from Sergipe, Brazil who gave birth to infants with microcephaly following Zika virus exposure during the 2015-16 outbreak were tested for serological evidence of Dengue exposure and IFN gamma ELISpot spot forming cell (SFC) response to Zika virus. The majority (46/50) demonstrated Dengue immunity. IFN gamma ELISpot responses to Zika virus antigens showed the following hierarchy: Env>NS1>NS3>C protein. Twenty T cell epitopes from Zika virus Env were identified. Responses to Zika virus antigens Env and NS1 were polyfunctional with cells making IFN gamma, TNF alpha, IL-4, IL-13, and IL-10. In contrast, responses to NS5 only produced the immune regulatory TGF beta 1 cytokine. There were SFC responses against Zika virus Env (1-20) and variant peptide sequences from West Nile virus, Dengue virus 1-4 and Yellow Fever virus.
   Conclusion: Almost all the women in our study showed serological evidence of Dengue immunity, suggesting that microcephaly can occur in DENV immune mothers. T cell immunity to Zika virus showed a multifunctional response to the antigens Env and NS1 and immune regulatory responses to NS5 and C protein. Our data support an argument that different viral products may skew the antiviral response to a more pro or anti-inflammatory outcome, with an associated impact on immunopathogenesis.
C1 [Reynolds, Catherine J.; Watber, Patricia; Bokea, Kalliopi; Boyton, Rosemary J.] Imperial Coll London, Fac Med, Dept Infect Dis, London, England.
   [Santos, Camilla Natalia Oliveira; Ribeiro, Danielle Rodrigues; Alves, Juliana Cardoso] Univ Fed Sergipe, Grad Program Hlth Sci, Mol Biol Lab, Univ Hosp, Aracaju, Brazil.
   [Fonseca, Adriana B. L.; Bispo, Ana J. B.; Porto, Roseane L. S.] Univ Fed Sergipe, Pediat Div, Microcephaly Clin, Univ Hosp, Aracaju, Brazil.
   [De Jesus, Amelia Maria Ribeiro; De Almeida, Roque Pacheco] Univ Fed Sergipe, Dept Med, Mol Biol Lab, Univ Hosp, Aracaju, Brazil.
   [Altmann, Daniel M.] Imperial Coll London, Fac Med, Dept Immunol & Inflammat, London, England.
RP Boyton, RJ (corresponding author), Imperial Coll London, Fac Med, Dept Infect Dis, London, England.; Altmann, DM (corresponding author), Imperial Coll London, Fac Med, Dept Immunol & Inflammat, London, England.
EM r.boyton@imperial.ac.uk; d.altmann@imperial.ac.uk
FU MRC-Newton Wellcome Trust/FAPESP Zika Rapid Response Project
   [ZK/16-104]; Innovate UK [87242-544164]; NIH NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272201400049C, UWSC9568]; FINEP grant (Financiadora de Estudos e
   Projetos) [0116005600]; Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior-Brazil (CAPES)CAPES [001]; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX This research was supported by the following grants: MRC-Newton Wellcome
   Trust/FAPESP Zika Rapid Response Project (ZK/16-104), Innovate UK
   (87242-544164), and the NIH NIAID (Contract Number: HHSN272201400049C,
   Subcontract number: UWSC9568). This study was supported in part by a
   FINEP grant (Financiadora de Estudos e Projetos) number 0116005600 and
   the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brazil
   (CAPES)-Finance Code 001. AJ and RA are sponsored by CNPq. The funding
   bodies had no role in the design of the study, data collection,
   analysis, and interpretation of data, writing the manuscript or decision
   to publish.
CR Baud D, 2017, LANCET, V390, P2099, DOI [10.1016/S0140-6736(17)31450-2, 10.1016/s0140-6736(17)31450-2]
   Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558
   Brown JA, 2019, IMMUNITY, V50, P751, DOI 10.1016/j.immuni.2019.01.005
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   GRIFONI A, 2017, J VIROL, V91, DOI DOI 10.1128/JVI.01469-17
   Grifoni A, 2018, J IMMUNOL, V201, P3487, DOI 10.4049/jimmunol.1801090
   Herrera BB, 2018, J VIROL, V92, DOI 10.1128/JVI.01992-17
   Jayaratne HE, 2018, IMMUNOLOGY, V154, P89, DOI 10.1111/imm.12863
   Jurado KA, 2018, NAT MICROBIOL, V3, P141, DOI 10.1038/s41564-017-0060-z
   Kam YW, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92428
   Kempen JH, 2011, AM J OPHTHALMOL, V151, P7, DOI 10.1016/j.ajo.2010.08.047
   Koblischke M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01196
   Messina JP, 2016, ELIFE, V5, DOI 10.7554/eLife.15272
   Ngono AE, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007474
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Pardy RD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006184
   Pedroso C, 2019, EMERG INFECT DIS, V25, P1485, DOI 10.3201/eid2508.190113
   Regla-Nava JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05458-0
   Reynolds CJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18781-1
   Steinhagen K, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.50.30426
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Tillu H, 2016, EUR J CLIN MICROBIOL, V35, P453, DOI 10.1007/s10096-015-2561-0
   Wen J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01669-z
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
   Wilder-Smith Annelies, 2017, Lancet Infect Dis, V17, pe101, DOI 10.1016/S1473-3099(16)30518-7
   Xu Xiaojun, 2016, PLoS Curr, V8, DOI 10.1371/currents.outbreaks.9aa2e1fb61b0f632f58a098773008c4b
NR 26
TC 1
Z9 1
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD FEB 18
PY 2020
VL 11
AR 185
DI 10.3389/fimmu.2020.00185
PG 11
WC Immunology
SC Immunology
GA KS9CQ
UT WOS:000518605700001
PM 32132999
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Bispo, AJB
   Almeida, MLD
   de Almeida, RP
   Neto, JB
   Brito, AVD
   Franca, CM
AF Barreto Bispo, Ana Jovina
   Doria Almeida, Maria Luiza
   de Almeida, Roque Pacheco
   Neto, Jose Bispo
   de Oliveira Brito, Allan Valadao
   Franca, Camila Mendonca
TI Pulmonary involvement in human visceral leishmaniasis: Clinical and
   tomographic evaluation
SO PLOS ONE
LA English
DT Article
ID INTERSTITIAL PNEUMONITIS; CLASSIFICATION; DIAGNOSIS
AB Visceral leishmaniasis (VL) is a severe, systemic and potentially lethal parasitosis. The lung, like any other organ, can be affected in VL, and interstitial pneumonitis has been described in past decades. This research aimed to bring more recent knowledge about respiratory impairment in VL, characterizing pulmonary involvement through clinical, radiographic and tomographic evaluation. This is an observational, cross-sectional study that underwent clinical evaluation, radiography and high-resolution computed tomography of the chest in patients admitted with the diagnosis of VL in a university service in Northeast Brazil, from January 2015 to July 2018. The sample consisted of 42 patients. Computed tomography was considered abnormal in 59% of patients. Images compatible with pulmonary interstitial involvement were predominant (50%). The most observed respiratory symptom was cough (33.3%), followed by tachypnea (14.1%). Chest radiography was altered in only four patients. VL is a disease characterized by systemic involvement and broad spectrum of clinical manifestations. The respiratory symptoms and tomographic alterations found show that the involvement of respiratory system in VL deserves attention because it is more common than previously thought. Chest X-ray may not reveal this impairment.
C1 [Barreto Bispo, Ana Jovina; Doria Almeida, Maria Luiza; de Almeida, Roque Pacheco] Univ Fed Sergipe, Postgrad Program Hlth Sci, Aracaju, Sergipe, Brazil.
   [Doria Almeida, Maria Luiza; de Almeida, Roque Pacheco; Franca, Camila Mendonca] Univ Fed Sergipe, Dept Med, Med Coll, Aracaju, Sergipe, Brazil.
   [Neto, Jose Bispo; de Oliveira Brito, Allan Valadao] Univ Fed Sergipe, Radiol Serv, Univ Hosp, Aracaju, Sergipe, Brazil.
RP Bispo, AJB (corresponding author), Univ Fed Sergipe, Postgrad Program Hlth Sci, Aracaju, Sergipe, Brazil.
EM anajovina70@gmail.com
OI BARRETO BISPO, ANA JOVINA/0000-0002-6228-768X
CR Ahmed MAA, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3875-2
   Athayde ASC, 2003, THESIS
   Azevedo ABC, 2005, RADIOL BRAS, V38
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   Braga ASC, REV SOC BRAS MED TRO, V46, P55
   Brasil. Ministerio da Saude, 2011, LEISHM VISC REC CLIN
   Burza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140-6736(18)31204-2
   Dasgupta S, 2014, LUNG INDIA, V31, P56, DOI 10.4103/0970-2113.125913
   de Alvarenga DG, 2010, REV SOC BRAS MED TRO, V43, P194, DOI 10.1590/S0037-86822010000200017
   de Oliveira JM, 2010, REV SOC BRAS MED TRO, V43, P188, DOI 10.1590/S0037-86822010000200016
   Diamantino TCC, 2010, LEISHM VISC AV REP C
   DUARTE MIS, 1984, T ROY SOC TROP MED H, V78, P683, DOI 10.1016/0035-9203(84)90242-6
   DUARTE MIS, 1989, T ROY SOC TROP MED H, V83, P73, DOI 10.1016/0035-9203(89)90712-8
   Elicker Brett, 2008, J. bras. pneumol., V34, P715, DOI 10.1590/S1806-37132008000900013
   Foti G, 2019, BJR CASE REP, V5, DOI 10.1259/bjrcr.20180088
   Georgiadou SP, 2015, J TRANSL INTERN MED, V3, P43, DOI 10.1515/jtim-2015-0002
   Ministerio da Saude, 2014, MAN VIG CONTR LEISHM
   Ministerio Da Saude. Secretaria de Vigilacia em Saude, 2016, COORD EP SERV GUIA V
   Queiroz Márcia J. A., 2004, J. Pediatr. (Rio J.), V80, P141, DOI 10.1590/S0021-75572004000200012
   Raina S, 2010, ONLINE J HLTH ALLIED, V9, P13
   Russo R, 2003, ANN TROP MED PARASIT, V97, P99, DOI 10.1179/000349803225002570
   Sakkas H, 2016, J VECTOR DIS, V53, P8
   Sena I., 2015, THESIS
   SHIDDO SA, 1995, T ROY SOC TROP MED H, V89, P361, DOI 10.1016/0035-9203(95)90008-X
   Silva CIS, 2005, RADIOL BRAS, V38
   SISLEISH-OPAS/OMS, 2019, DAD REP PEL PROGR NA
   Sverzellati N, 2015, RADIOGRAPHICS, V35, P1849, DOI 10.1148/rg.2015140334
   Torres-Guerrero Edoardo, 2017, F1000Res, V6, P750, DOI 10.12688/f1000research.11120.1
   Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST
   Urbano-Aranda Y, 2012, RESPIRATION, V84, P246, DOI 10.1159/000338118
   Xavier-Gomes LM, 2009, REV BRAS EPIDEMIOL, V4, P549
NR 31
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 30
PY 2020
VL 15
IS 1
AR e0228176
DI 10.1371/journal.pone.0228176
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LP9CB
UT WOS:000534612400051
PM 31999729
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Santos, CNO
   Ribeiro, DR
   Alves, JC
   Cazzaniga, RA
   Magalhaes, LS
   de Souza, MSF
   Fonseca, ABL
   Bispo, AJB
   Porto, RLS
   dos Santos, CA
   da Silva, AM
   Teixeira, MM
   de Almeida, RP
   de Jesus, AR
AF Santos, Camilla N. O.
   Ribeiro, Danielle R.
   Alves, Juliana Cardoso
   Cazzaniga, Rodrigo A.
   Magalhaes, Lucas S.
   de Souza, Mercia S. F.
   Fonseca, Adriana B. L.
   Bispo, Ana J. B.
   Porto, Roseane L. S.
   dos Santos, Cliomar Alves
   da Silva, Angela M.
   Teixeira, Mauro M.
   de Almeida, Roque P.
   de Jesus, Amelia R.
TI Association Between Zika Virus Microcephaly in Newborns With the
   rs3775291 Variant in Toll-Like Receptor 3 and rs1799964 Variant at Tumor
   Necrosis Factor-alpha Gene
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE congenital Zika syndrome; microcephaly; polymorphism; TLR3; TNF alpha
ID POLYMORPHISM; TLR3
AB Congenital Zika syndrome (CZS) is a cluster of malformation, and the mechanisms that lead it are still unclear. Using hypothesis-driven candidate genes and their function in viral infections, single-nucleotide polymorphisms (SNPs) were genotyped by quantitative polymerase chain reaction in a sample population from Sergipe State, Brazil. This study shows that rs3775291 SNP at Toll-like receptor 3, which triggers type I interferon antiviral responses in mothers infected by Zika virus during pregnancy, is associated with CZS occurrence (odds ratio [OR], 2.19; 95% confidence interval [CI], 1.158-4.148). Moreover, rs1799964 SNP at tumor necrosis factor-alpha gene in CZS babies is associated with severe microcephaly (OR, 2.63; 95% CI, 1.13-6.21).
C1 [Santos, Camilla N. O.; Alves, Juliana Cardoso; Magalhaes, Lucas S.; de Almeida, Roque P.; de Jesus, Amelia R.] Univ Fed Sergipe, Univ Hosp, Med Biol Lab, Aracaju, Brazil.
   [Santos, Camilla N. O.; Alves, Juliana Cardoso; Magalhaes, Lucas S.; de Almeida, Roque P.; de Jesus, Amelia R.] Univ Fed Sergipe, Univ Hosp, Grad Program Hlth Sci, Aracaju, Brazil.
   [Ribeiro, Danielle R.; Cazzaniga, Rodrigo A.] Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Aracaju, Brazil.
   [Fonseca, Adriana B. L.; Bispo, Ana J. B.; Porto, Roseane L. S.] Univ Fed Sergipe, Univ Hosp, Microcephaly Clin, Pediat Div, Aracaju, Brazil.
   [da Silva, Angela M.] Univ Fed Sergipe, Univ Hosp, Infect Dis Div, Aracaju, Brazil.
   [de Almeida, Roque P.; de Jesus, Amelia R.] Univ Fed Sergipe, Univ Hosp, Dept Med, Aracaju, Brazil.
   [de Souza, Mercia S. F.] Secretaria Estado Saude Sergipe, Aracaju, Brazil.
   [dos Santos, Cliomar Alves] Cent Publ Hlth Lab Sergipe, Aracaju, Brazil.
   [Teixeira, Mauro M.] Univ Fed Minas Gerais, Immunopharmacol, Belo Horizonte, MG, Brazil.
RP de Jesus, AR (corresponding author), Univ Fed Sergipe, Hosp Univ, Lab Imunol & Biol Mol, Predio Patol,Rua Claudio Batista S-N, BR-19060108 Aracaju, Sergipe, Brazil.
EM ameliaribeirodejesuse@gmail.com
RI Teixeira, Mauro M/A-4587-2008; Cazzaniga, Rodrigo/AAV-6694-2020
OI Teixeira, Mauro M/0000-0002-6944-3008; 
FU Financiadora de Estudos e Projetos -BrazilCiencia Tecnologia e Inovacao
   (FINEP) [0116005600]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior - BrasilCAPES; Conselho Nacional de Pesquisa e Desenvolvimento
   Cientifico e TecnologicoNational Council for Scientific and
   Technological Development (CNPq); Conselho Nacional de Desenvolvimento
   Cientifico e TecnologicoNational Council for Scientific and
   Technological Development (CNPq)
FX This work was funded by the Financiadora de Estudos e Projetos -Brazil
   (Grant Number 0116005600), Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior - Brasil (fellowship to C. N. O. S., J. C. A., and R. A.
   C.), Conselho Nacional de Pesquisa e Desenvolvimento Cientifico e
   Tecnologico (fellowship to D. R. R.), and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (to A. R. d. J., R. P. d. A.,
   and M. M. T.).
CR Alagarasu K, 2015, IMMUNOBIOLOGY, V220, P164, DOI 10.1016/j.imbio.2014.09.020
   Bayer A, 2016, CELL HOST MICROBE, V19, P705, DOI 10.1016/j.chom.2016.03.008
   Caires LC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03497-1
   Dang J, 2016, CELL STEM CELL, V19, P258, DOI 10.1016/j.stem.2016.04.014
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Higuchi T, 1998, TISSUE ANTIGENS, V51, P605, DOI 10.1111/j.1399-0039.1998.tb03002.x
   Kasztelewicz B, 2017, EUR J CLIN MICROBIOL, V36, P1811, DOI 10.1007/s10096-017-2996-6
   Kindberg E, 2011, J INFECT DIS, V203, P523, DOI 10.1093/infdis/jiq082
   Phillips JA, 2016, WORKPLACE HEALTH SAF, V64, P396, DOI 10.1177/2165079916657109
   Pierson TC, 2018, NATURE, V560, P573, DOI 10.1038/s41586-018-0446-y
   Sironi M, 2012, J IMMUNOL, V188, P818, DOI 10.4049/jimmunol.1102179
   Studzinska M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169420
   SWINGLER S, 1994, BIOCHEM BIOPH RES CO, V203, P623, DOI 10.1006/bbrc.1994.2228
   Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258
NR 14
TC 4
Z9 4
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC
PY 2019
VL 220
IS 11
BP 1797
EP 1801
DI 10.1093/infdis/jiz392
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA JI4XB
UT WOS:000493469600012
PM 31352487
DA 2020-12-08
ER

PT J
AU Ramacciotti, E
   Agati, LB
   Aguiar, VCR
   Wolosker, N
   Guerra, JC
   de Almeida, RP
   Alves, JC
   Lopes, RD
   Wakefield, TW
   Comerota, AJ
   Walenga, J
   Fareed, J
AF Ramacciotti, Eduardo
   Agati, Leandro B.
   Aguiar, Valeria C. R.
   Wolosker, Nelson
   Guerra, Joao C.
   de Almeida, Roque P.
   Alves, Juliana Cardoso
   Lopes, Renato D.
   Wakefield, Thomas W.
   Comerota, Anthony J.
   Walenga, Jeanine
   Fareed, Jawed
TI Zika and Chikungunya Virus and Risk for Venous Thromboembolism
SO CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
LA English
DT Article
DE Zika virus; Chikungunya virus; deep venous thrombosis
AB A variety of viral infections are associated with hypercoagulable states and may be linked to the development of deep venous thrombosis and pulmonary embolism. The Zika and Chikungunya viral infections spread through the South and Central American continents, moving to North America in 2016, with severe cases of polyarthralgia, fever, and Guillain-Barre syndrome leading eventually to death. A decreased trend for both infections was reported in the first quarter of 2017. In this article, we report the possible association of venous thromboembolic events associated with Zika infection. After 2 cases of deep venous thrombosis in patients with acute Zika infections, D-dimer levels were measured in 172 consecutive patients who presented to the emergency department of a university hospital in an endemic region of Brazil with either Zika or Chikungunya infections confirmed by polymerase chain reaction tests. D-dimer levels were increased in 19.4% of 31 patients with Zika and in 63.8% of 141 patients with Chikungunya infections. The mechanisms behind this association are yet to be elucidated as well as the potential for venous thromboembolism prevention strategies for in-hospital patients affected by Zika and Chikungunya infections.
C1 [Ramacciotti, Eduardo; Agati, Leandro B.; Aguiar, Valeria C. R.] Hosp & Maternidade Dr Christovao da Gama, Santo Andre, SP, Brazil.
   [Wolosker, Nelson; Guerra, Joao C.] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil.
   [de Almeida, Roque P.; Alves, Juliana Cardoso] Univ Fed Sergipe, Aracaju, SE, Brazil.
   [Lopes, Renato D.] Duke Univ Hosp, Duke Clin, Durham, NC USA.
   [Wakefield, Thomas W.] Univ Michigan, Michigan Med, Cardiovasc Ctr, Ann Arbor, MI 48109 USA.
   [Comerota, Anthony J.] Mercy St Vincent Med Ctr, Toledo, OH USA.
   [Walenga, Jeanine; Fareed, Jawed] Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
RP Ramacciotti, E (corresponding author), Hosp & Maternidade Dr Christovao da Gama, Santo Andre, SP, Brazil.
EM eduardoramacciotti@gmail.com
RI WOLOSKER, NELSON/E-2591-2013
OI Cardoso Alves, Juliana/0000-0001-9294-3257
FU Hospital e Maternidade Dr. Christovao da Gama, SP, Brazil; Albert
   Einstein Israeli Hospital, SP, Brazil; FINEP grant (Financiadora de
   Estudos e Projetos) [0116005600]; "Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior"-Brazil (CAPES)CAPES [001]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was self-funded by Hospital e Maternidade Dr. Christovao da Gama, SP,
   Brazil and Albert Einstein Israeli Hospital, SP, Brazil. Roque Almeida
   reports a FINEP grant (Financiadora de Estudos e Projetos) number
   0116005600. Juliana Alves reports that this study was financed in part
   by the "Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior"-Brazil (CAPES)-Finance Code 001. Laboratory kits were provided
   by Loyola University Medical Center, Maywood, Illinois.
CR Avnon LS, 2015, EUR J INTERN MED, V26, P596, DOI 10.1016/j.ejim.2015.08.017
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Broutet N, 2016, NEW ENGL J MED, V374, P1506, DOI 10.1056/NEJMp1602708
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Goeijenbier M, 2012, J MED VIROL, V84, P1680, DOI 10.1002/jmv.23354
   Johansson MA, 2016, NEW ENGL J MED, V375, P1, DOI 10.1056/NEJMp1605367
   Li H., 2016, BMJ-BRIT MED J, V19, P593
   Marques Marcos Arêas, 2017, J. vasc. bras., V16, P60, DOI 10.1590/1677-5449.009616
   Morens DM, 2014, NEW ENGL J MED, V371, P885, DOI 10.1056/NEJMp1408509
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Wang CC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001585
NR 11
TC 17
Z9 17
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1076-0296
EI 1938-2723
J9 CLIN APPL THROMB-HEM
JI Clin. Appl. Thromb.-Hemost.
PD JAN 28
PY 2019
VL 25
AR 1076029618821184
DI 10.1177/1076029618821184
PG 5
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA HJ4AH
UT WOS:000457115300001
PM 30808213
OA Other Gold, Green Published
DA 2020-12-08
ER

PT J
AU Ribeiro, AR
   Santos, CN
   Ribeiro, DR
   Cardoso, JA
   Cazzaniga, RA
   Magalhaes, LS
   de Souza, MS
   Fonseca, AB
   Bispo, AJ
   Porto, RL
   dos Santos, CA
   da Silva, AM
   Teixeira, MM
   de Almeida, RP
AF Ribeiro, Amelia R.
   Santos, Camilla N.
   Ribeiro, Danielle R.
   Cardoso, Juliana A.
   Cazzaniga, Rodrigo A.
   Magalhaes, Lucas S.
   de Souza, Mercia S.
   Fonseca, Adriana B.
   Bispo, Ana J.
   Porto, Roseane L.
   dos Santos, Cliomar A.
   da Silva, Angela M.
   Teixeira, Mauro M.
   de Almeida, Roque P.
TI ASSOCIATION BETWEEN ZIKA VIRUS MICROCEPHALY IN THE NEWBORN WITH THE
   RS3775291 VARIANT AT TOLL-LIKE RECEPTOR 3 AND RS1799964 VARIANT AT TNFA
   GENES
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 68th Annual Meeting of the
   American-Society-for-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 20-24, 2019
CL National Harbor, MD
SP Amer Soc Trop Med & Hyg, Bill & Melinda Gates Fdn, Bavarian Nord, GSK, Takeda, Integrum Sci, Celgene, Vulcan, Plos Neglected Trop Dis, Elsevier
C1 [Ribeiro, Amelia R.; Santos, Camilla N.; Ribeiro, Danielle R.; Cardoso, Juliana A.; Cazzaniga, Rodrigo A.; Magalhaes, Lucas S.; de Souza, Mercia S.; Fonseca, Adriana B.; Bispo, Ana J.; Porto, Roseane L.; dos Santos, Cliomar A.; da Silva, Angela M.; de Almeida, Roque P.] Univ Fed Sergipe, Aracaju, Sergipe State, Brazil.
   [Teixeira, Mauro M.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
RI Teixeira, Mauro M/A-4587-2008; Cazzaniga, Rodrigo/AAV-6694-2020
OI Teixeira, Mauro M/0000-0002-6944-3008; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2019
VL 101
SU 5
MA 1949
BP 600
EP 601
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA KC7PF
UT WOS:000507364505069
DA 2020-12-08
ER

PT J
AU Bezerra-Santos, M
   do Vale-Simon, M
   Barreto, AS
   Cazzaniga, RA
   de Oliveira, DT
   Barrios, MR
   Ferreira, AR
   Santos-Bio, NC
   Reed, SG
   de Almeida, RP
   Correa, CB
   Duthie, MS
   de Jesus, AR
AF Bezerra-Santos, Marcio
   do Vale-Simon, Marise
   Barreto, Aline Silva
   Cazzaniga, Rodrigo Anselmo
   de Oliveira, Daniela Teles
   Barrios, Monica Rueda
   Ferreira, Alex Ricardo
   Santos-Bio, Nanci C.
   Reed, Steven G.
   de Almeida, Roque Pacheco
   Correa, Cristiane Bani
   Duthie, Malcolm S.
   de Jesus, Amelia Ribeiro
TI Mycobacterium leprae Recombinant Antigen Induces High Expression of
   Multifunction T Lymphocytes and Is Promising as a Specific Vaccine for
   Leprosy
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE leprosy; Mycobacterium leprae; ML2028; Multifunctional T cells;
   immunopathogenesis
ID IMMUNE-RESPONSES; CELLS; PROTECTION; CYTOKINES; DIAGNOSIS; TH17
AB Leprosy is a chronic disease caused by M. leprae infection that can cause severe neurological complications and physical disabilities. A leprosy-specific vaccine would be an important component within control programs but is still lacking. Given that multifunctional CD4 T cells [i.e., those capable of simultaneously secreting combinations of interferon (IFN)-gamma, interleukin (IL)-2, and tumor necrosis factor (TNF)] have now been implicated in the protective response to several infections, we tested the hypothesis if a recombinant M. leprae antigen-specific multifunctional T cells differed between leprosy patients and their healthy contacts. We used whole blood assays and peripheral blood mononuclear cells to characterize the antigen-specific T cell responses of 39 paucibacillary (PB) and 17 multibacillary (MB) leprosy patients and 31 healthy household contacts (HHC). Cells were incubated with either crude mycobacterial extracts (M. leprae cell sonicate-MLCS) and purified protein derivative (PPD) or recombinant ML2028 protein, the homolog of M. tuberculosis Ag85B. Multiplex assay revealed antigen-specific production of IFN-gamma and IL-2 from cells of HHC and PB, confirming a Th1 bias within these individuals. Multiparameter flow cytometry then revealed that the population of multifunctional ML2028-specific T cells observed in HHC was larger than that observed in PB patients. Taken together, our data suggest that these multifunctional antigen-specific T cells provide a more effective response against M. leprae infection that prevents the development of leprosy. These data further our understanding of M. leprae infection/leprosy and are instructive for vaccine development.
C1 [Bezerra-Santos, Marcio; do Vale-Simon, Marise; Barreto, Aline Silva; Cazzaniga, Rodrigo Anselmo; de Oliveira, Daniela Teles; Barrios, Monica Rueda; Ferreira, Alex Ricardo; Santos-Bio, Nanci C.; de Almeida, Roque Pacheco; Correa, Cristiane Bani; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Lab Immunol & Mol Biol, Aracaju, Brazil.
   [Bezerra-Santos, Marcio] Univ Fed Sergipe, Dept Hlth Educ, Lagarto, Brazil.
   [Ferreira, Alex Ricardo; Santos-Bio, Nanci C.; de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Infect Dis Res Inst, Seattle, WA USA.
   [Reed, Steven G.; Duthie, Malcolm S.] INCT CNPq, Inst Invest Imunol, Sao Paulo, Brazil.
   [de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Med, Aracaju, Brazil.
RP Bezerra-Santos, M (corresponding author), Univ Fed Sergipe, Lab Immunol & Mol Biol, Aracaju, Brazil.; Bezerra-Santos, M (corresponding author), Univ Fed Sergipe, Dept Hlth Educ, Lagarto, Brazil.
EM bio_marcio2006@hotmail.com
RI Correa, Cristiane Bani/AAR-9384-2020; Cazzaniga, Rodrigo/AAV-6694-2020
OI Duthie, Malcolm/0000-0002-8515-5516
FU Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq); CNPqNational Council for Scientific and
   Technological Development (CNPq) [12/2009, 019.203.02712/2009-8];
   MCTI/CNPQ/Universal [454848/2014-5]
FX Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Grants: CNPq no 12/2009, no
   019.203.02712/2009-8 (AdJ). AdJ and RPA are CNPq investigators.
   MCTI/CNPQ/Universal 14/2014, no 454848/2014-5 (AdJ).
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P501
   Attia EAS, 2014, ARCH DERMATOL RES, V306, P793, DOI 10.1007/s00403-014-1486-2
   Balaram P, 2009, INT J MED MICROBIOL, V299, P177, DOI 10.1016/j.ijmm.2008.08.004
   Santos MLB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00227
   Boer MC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00217
   Carrillo E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00750
   Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   Fonseca ABD, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/s40249-016-0229-3
   de Oliveira DT, 2012, GEOSPAT HLTH, V6, P130, DOI [10.4081/gh.2012.130, DOI 10.4081/GH.2012.130]
   de Sousa JR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01635
   Dupnik KM, 2015, J INFECT DIS, V211, P1658, DOI 10.1093/infdis/jiu612
   Duthie MS, 2008, CLIN VACCINE IMMUNOL, V15, P1659, DOI 10.1128/CVI.00234-08
   Duthie MS, 2007, CLIN VACCINE IMMUNOL, V14, P1400, DOI 10.1128/CVI.00299-07
   Duthie MS, 2016, APPL MICROBIOL BIOT, V100, P3267, DOI 10.1007/s00253-016-7328-8
   Duthie MS, 2014, INFECT IMMUN, V82, P3979, DOI 10.1128/IAI.02145-14
   Duthie MS, 2012, MEM I OSWALDO CRUZ, V107, P190, DOI 10.1590/S0074-02762012000900027
   Duthie MS, 2011, HUM VACCINES, V7, P1172, DOI 10.4161/hv.7.11.16848
   Escamilla-Tilch M, 2014, INT J GENOMICS, V2014, DOI 10.1155/2014/920491
   Guha R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006406
   Kim WS, 2016, ONCOTARGET, V7, P24962, DOI 10.18632/oncotarget.8771
   Kohli S, 2015, INT J MED MICROBIOL, V305, P322, DOI 10.1016/j.ijmm.2015.01.001
   Leung-Theung-Long S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143552
   Lichtner M, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/217287
   Nascimento MSL, 2015, J INFECT DIS, V211, P1015, DOI 10.1093/infdis/jiu531
   Macedo ABB, 2012, CLIN EXP IMMUNOL, V167, P505, DOI 10.1111/j.1365-2249.2011.04536.x
   Mazini PS, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00658
   Merle CSC, 2010, EXPERT REV VACCINES, V9, P209, DOI [10.1586/erv.09.161, 10.1586/ERV.09.161]
   Omosa-Manyonyi G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125954
   Polycarpou A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00233
   Raman VS, 2009, INFECT IMMUN, V77, P5623, DOI 10.1128/IAI.00508-09
   Reyes PR, 2016, INT J MED MICROBIOL, V306, P624, DOI 10.1016/j.ijmm.2016.10.002
   Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255
   Saini C, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004592
   Sampaio LH, 2012, EUR J CLIN MICROBIOL, V31, P1443, DOI 10.1007/s10096-011-1462-0
   Santos MB, 2017, SCAND J IMMUNOL, V86, P40, DOI 10.1111/sji.12558
   Santos MB, 2017, RESPOSTA IMUNE ANTIG
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Simon M, 2011, DRUG DEVELOP RES, V72, P509, DOI 10.1002/ddr.20457
   Singh OP, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001874
   Stober CB, 2005, J IMMUNOL, V175, P2517, DOI 10.4049/jimmunol.175.4.2517
   Talker SC, 2015, VET RES, V46, DOI 10.1186/s13567-015-0182-3
NR 42
TC 1
Z9 1
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD DEC 12
PY 2018
VL 9
AR 2920
DI 10.3389/fimmu.2018.02920
PG 10
WC Immunology
SC Immunology
GA HE2IY
UT WOS:000453101300001
PM 30631322
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Caires, LC
   Goulart, E
   Melo, US
   Araujo, BHS
   Alvizi, L
   Soares-Schanoski, A
   de Oliveira, DF
   Kobayashi, GS
   Griesi-Oliveira, K
   Musso, CM
   Amaral, MS
   daSilva, LF
   Astray, RM
   Suarez-Patino, SF
   Ventini, DC
   da Silva, SG
   Yamamoto, GL
   Ezquina, S
   Naslavsky, MS
   Telles-Silva, KA
   Weinmann, K
   van der Linden, V
   van der Linden, H
   de Oliveira, JRM
   Arrais, NMR
   Melo, A
   Figueiredo, T
   Santos, S
   Meira, JGC
   Passos, SD
   de Almeida, RP
   Bispo, AJB
   Cavalheiro, EA
   Kalil, J
   Cunha-Neto, E
   Nakaya, H
   Andreata-Santos, R
   Ferreira, LCD
   Verjovski-Almeida, S
   Ho, PL
   Passos-Bueno, MR
   Zatz, M
AF Caires-Junior, Luiz Carlos
   Goulart, Ernesto
   Melo, Uira Souto
   Silva Araujo, Bruno Henrique
   Alvizi, Lucas
   Soares-Schanoski, Alessandra
   de Oliveira, Danyllo Felipe
   Kobayashi, Gerson Shigeru
   Griesi-Oliveira, Karina
   Musso, Camila Manso
   Amaral, Murilo Sena
   daSilva, Lucas Ferreira
   Astray, Renato Mancini
   Suarez-Patino, Sandra Fernanda
   Ventini, Daniella Cristina
   da Silva, Sergio Gomes
   Yamamoto, Guilherme Lopes
   Ezquina, Suzana
   Naslavsky, Michel Satya
   Telles-Silva, Kayque Alves
   Weinmann, Karina
   van der Linden, Vanessa
   van der Linden, Helio
   Mendes de Oliveira, Joao Ricardo
   Rodrigues Arrais, Nivia Maria
   Melo, Adriana
   Figueiredo, Thalita
   Santos, Silvana
   Castro Meira, Joanna Goes
   Passos, Saulo Duarte
   de Almeida, Roque Pacheco
   Barreto Bispo, Ana Jovina
   Cavalheiro, Esper Abrao
   Kalil, Jorge
   Cunha-Neto, Edecio
   Nakaya, Helder
   Andreata-Santos, Robert
   de Souza Ferreira, Luis Carlos
   Verjovski-Almeida, Sergio
   Ho, Paulo Lee
   Passos-Bueno, Maria Rita
   Zatz, Mayana
TI Discordant congenital Zika syndrome twins show differential in vitro
   viral susceptibility of neural progenitor cells (vol 9, 2018)
SO NATURE COMMUNICATIONS
LA English
DT Correction
C1 [Caires-Junior, Luiz Carlos; Goulart, Ernesto; Melo, Uira Souto; Alvizi, Lucas; de Oliveira, Danyllo Felipe; Kobayashi, Gerson Shigeru; Griesi-Oliveira, Karina; Musso, Camila Manso; Yamamoto, Guilherme Lopes; Ezquina, Suzana; Naslavsky, Michel Satya; Telles-Silva, Kayque Alves; Weinmann, Karina; Figueiredo, Thalita; Passos-Bueno, Maria Rita; Zatz, Mayana] Univ Sao Paulo, Biosci Inst, Human Genome & Stem Cell Res Ctr, Dept Genet & Evolutionary Biol, BR-05508900 Sao Paulo, SP, Brazil.
   [Silva Araujo, Bruno Henrique] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Biosci Natl Lab LNBio, BR-13083970 Campinas, SP, Brazil.
   [Silva Araujo, Bruno Henrique; Cavalheiro, Esper Abrao] Fed Univ Sao Paulo UNIFESP, EPM, Dept Neurol & Neurosurg, Neurosci Lab, BR-04039002 Sao Paulo, SP, Brazil.
   [Soares-Schanoski, Alessandra; Amaral, Murilo Sena; Astray, Renato Mancini; Suarez-Patino, Sandra Fernanda; Ventini, Daniella Cristina; Kalil, Jorge; Verjovski-Almeida, Sergio; Ho, Paulo Lee] Butantan Inst, BR-05503900 Sao Paulo, SP, Brazil.
   [Griesi-Oliveira, Karina; da Silva, Sergio Gomes] Albert Einstein Hosp, BR-05652900 Sao Paulo, SP, Brazil.
   [daSilva, Lucas Ferreira; Verjovski-Almeida, Sergio] Univ Sao Paulo, Inst Chem, Dept Biochem, BR-05508900 Sao Paulo, SP, Brazil.
   [da Silva, Sergio Gomes] Univ Mogi das Cruzes, BR-08780911 Mogi Das Cruzes, SP, Brazil.
   [van der Linden, Vanessa] AACD, BR-50080810 Recife, PE, Brazil.
   [van der Linden, Helio] Rehabil Ctr Dr Henrique Santillo, BR-74653230 Goiania, Go, Brazil.
   [Mendes de Oliveira, Joao Ricardo] Fed Univ Pernambuco UFPE, Neuropsychiat Dept, BR-50670901 Recife, PE, Brazil.
   [Mendes de Oliveira, Joao Ricardo] Fed Univ Pernambuco UFPE, KeizoAsami Lab, BR-50670901 Recife, PE, Brazil.
   [Rodrigues Arrais, Nivia Maria] Fed Univ Rio Grande do Norte UFRN, Dept Pediat, BR-59010180 Natal, RN, Brazil.
   [Melo, Adriana] ISEA, BR-58400220 Campina Grande, PB, Brazil.
   [Santos, Silvana] Paraiba State Univ UEPB, Dept Biol, BR-58429500 Campina Grande, PB, Brazil.
   [Castro Meira, Joanna Goes] Fed Univ Bahia UFBA, BR-40170115 Salvador, BA, Brazil.
   [Passos, Saulo Duarte] Med Sch Jundiai, Infect Pediat Lab, BR-40170115 Jundiai, SP, Brazil.
   [de Almeida, Roque Pacheco; Barreto Bispo, Ana Jovina] Fed Univ Sergipe UFS, Div Immunol, BR-49100000 Aracaju, SP, Brazil.
   [de Almeida, Roque Pacheco; Barreto Bispo, Ana Jovina] Fed Univ Sergipe UFS, Mol Biol Lab, BR-49100000 Aracaju, SP, Brazil.
   [Cunha-Neto, Edecio] Univ Sao Paulo, Fac Med, Heart Inst, BR-05403900 Sao Paulo, SP, Brazil.
   [Nakaya, Helder] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-05508900 Sao Paulo, SP, Brazil.
   [Andreata-Santos, Robert; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Vaccine Dev Lab, BR-05508900 Sao Paulo, SP, Brazil.
RP Zatz, M (corresponding author), Univ Sao Paulo, Biosci Inst, Human Genome & Stem Cell Res Ctr, Dept Genet & Evolutionary Biol, BR-05508900 Sao Paulo, SP, Brazil.
EM mayazatz@usp.br
RI Zatz, Mayana/M-5338-2015; Santos, Silvana/ABF-5893-2020; Kobayashi,
   Gerson/H-4017-2013; Nakaya, Helder/AAF-1738-2020; Cunha-Neto,
   Edecio/B-4157-2009; Passos-Bueno, Maria Rita/I-6796-2016; Goulart,
   Ernesto/AAC-3713-2020; Melo, Adriana S O/H-5650-2016; KALIL,
   JORGE/C-8029-2012; Schanoski, Alessandra/H-8144-2014; Kobayashi, Gerson
   Shigeru/AAB-9113-2019; Verjovski-Almeida, Sergio/E-4082-2012; Amaral,
   Murilo S/G-5769-2013; Cavalheiro, Esper/I-3084-2016; Naslavsky,
   Michel/L-1772-2015
OI Zatz, Mayana/0000-0003-3970-8025; Santos, Silvana/0000-0002-5252-0206;
   Kobayashi, Gerson/0000-0002-6520-5774; Nakaya,
   Helder/0000-0001-5297-9108; Cunha-Neto, Edecio/0000-0002-3699-3345;
   Passos-Bueno, Maria Rita/0000-0002-9248-3008; KALIL,
   JORGE/0000-0001-8415-4274; Schanoski, Alessandra/0000-0002-6514-8458;
   Kobayashi, Gerson Shigeru/0000-0002-6520-5774; Verjovski-Almeida,
   Sergio/0000-0002-6356-2401; Cavalheiro, Esper/0000-0002-0854-3582;
   Goulart, Ernesto/0000-0001-9526-8701; Naslavsky,
   Michel/0000-0002-9068-1713
FU CAPESCAPES; DECIT-MS
FX Financial support from CAPES and DECIT-MS
CR CAIRESJUNIOR LC, 2018, NAT COMM, V0009
NR 1
TC 5
Z9 5
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR 13
PY 2018
VL 9
AR 1114
DI 10.1038/s41467-018-03497-1
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FZ0HK
UT WOS:000427248800003
PM 29535311
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Caires, LC
   Goulart, E
   Melo, U
   Araujo, BSH
   Alvizi, L
   Schanoski, AS
   de Oliveira, DF
   Kobayashi, GS
   Griesi-Oliveira, K
   Musso, CM
   Amaral, M
   dasilva, LF
   Astray, RM
   Suarez-Patino, SF
   Ventini, DC
   da Silva, SG
   Yamamoto, GL
   Ezquina, S
   Naslavsky, MS
   Silva, KTA
   Weinmann, K
   Van der Linden, V
   Van der Linden, H
   de Oliveira, JMR
   Arrais, NRM
   Melo, A
   Figueiredo, T
   Santos, S
   Meira, JCG
   Passos, SD
   de Almeida, RP
   Bispo, AJ
   Cavalheiro, E
   Kalil, J
   Cunha-Neto, E
   Nakaya, H
   Santos, RA
   Ferreira, LCD
   Verjovski-Almeida, S
   Ho, PL
   Passos-Bueno, MR
   Zatz, M
AF de Caires, Luiz Carlos, Jr.
   Goulart, Ernesto
   Melo, UiraSouto
   Henrique Araujo, Bruno Silva
   Alvizi, Lucas
   Schanoski, Alessandra Soares
   de Oliveira, Danyllo Felipe
   Kobayashi, Gerson Shigeru
   Griesi-Oliveira, Karina
   Musso, Camila Manso
   Amaral, MuriloSena
   dasilva, Lucas Ferreira
   Astray, Renato Mancini
   Suarez-Patino, Sandra Fernanda
   Ventini, Daniella Cristina
   da Silva, Sergio Gomes
   Yamamoto, Guilherme Lopes
   Ezquina, Suzana
   Naslavsky, Michel Satya
   Alves Silva, Kayque Telles
   Weinmann, Karina
   Van der Linden, Vanessa
   Van der Linden, Helio
   Ricardo de Oliveira, Joao Mendes
   Maria Arrais, Nivia Rodrigues
   Melo, Adriana
   Figueiredo, Thalita
   Santos, Silvana
   Goes Meira, Joanna Castro
   Passos, Saulo Duarte
   de Almeida, Roque Pacheco
   Bispo, Ana JovinaBarreto
   Cavalheiro, EsperAbrao
   Kalil, Jorge
   Cunha-Neto, Edecio
   Nakaya, Helder
   Santos, Robert Andreata
   de Souza Ferreira, Luis Carlos
   Verjovski-Almeida, Sergio
   Ho, Paulo Lee
   Passos-Bueno, Maria Rita
   Zatz, Mayana
TI Discordant congenital Zika syndrome twins show differential in vitro
   viral susceptibility of neural progenitor cells
SO NATURE COMMUNICATIONS
LA English
DT Article
ID VIRUS-INFECTION; STEM-CELLS; MENTAL-RETARDATION; GENETIC-VARIANTS;
   SEQUENCING DATA; ASSOCIATION; IDENTIFICATION; FLAVIVIRUSES; INTEGRATION;
   EXPRESSION
AB Congenital Zika syndrome (CZS) causes early brain development impairment by affecting neural progenitor cells (NPCs). Here, we analyze NPCs from three pairs of dizygotic twins discordant for CZS. We compare by RNA-Seq the NPCs derived from CZS-affected and CZS-unaffected twins. Prior to Zika virus (ZIKV) infection the NPCs from CZS babies show a significantly different gene expression signature of mTOR and Wnt pathway regulators, key to a neurodevelopmental program. Following ZIKV in vitro infection, cells from affected individuals have significantly higher ZIKV replication and reduced cell growth. Whole-exome analysis in 18 affected CZS babies as compared to 5 unaffected twins and 609 controls excludes a monogenic model to explain resistance or increased susceptibility to CZS development. Overall, our results indicate that CZS is not a stochastic event and depends on NPC intrinsic susceptibility, possibly related to oligogenic and/or epigenetic mechanisms.
C1 [de Caires, Luiz Carlos, Jr.; Goulart, Ernesto; Melo, UiraSouto; Alvizi, Lucas; de Oliveira, Danyllo Felipe; Kobayashi, Gerson Shigeru; Griesi-Oliveira, Karina; Musso, Camila Manso; Yamamoto, Guilherme Lopes; Ezquina, Suzana; Naslavsky, Michel Satya; Alves Silva, Kayque Telles; Weinmann, Karina; Figueiredo, Thalita; Passos-Bueno, Maria Rita; Zatz, Mayana] Univ Sao Paulo, Biosci Inst, Human Genome & Stem Cell Res Ctr, Dept Genet & Evolutionary Biol, BR-05508900 Sao Paulo, SP, Brazil.
   [Henrique Araujo, Bruno Silva] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Biosci Natl Lab LNBio, BR-13083970 Campinas, SP, Brazil.
   [Henrique Araujo, Bruno Silva; Cavalheiro, EsperAbrao] Fed Univ Sao Paulo Univ UNIFESP EPM, Dept Neurol & Neurosurg, Neurosci Lab, BR-04039002 Sao Paulo, SP, Brazil.
   [Schanoski, Alessandra Soares; Amaral, MuriloSena; Astray, Renato Mancini; Suarez-Patino, Sandra Fernanda; Ventini, Daniella Cristina; Kalil, Jorge; Verjovski-Almeida, Sergio; Ho, Paulo Lee] Butantan Inst, BR-05503900 Sao Paulo, SP, Brazil.
   [Griesi-Oliveira, Karina; da Silva, Sergio Gomes] Albert Einstein Hosp, BR-05652900 Sao Paulo, SP, Brazil.
   [dasilva, Lucas Ferreira; Verjovski-Almeida, Sergio] Univ Sao Paulo, Inst Chem, Dept Biochem, BR-05508900 Sao Paulo, SP, Brazil.
   [da Silva, Sergio Gomes] Univ Mogi das Cruzes, BR-08780911 Mogi Das Cruzes, SP, Brazil.
   [Van der Linden, Vanessa] AACD, BR-50080810 Recife, PE, Brazil.
   [Van der Linden, Helio] Rehabil Ctr Dr Henrique Santillo, BR-74653230 Goiania, Go, Brazil.
   [Ricardo de Oliveira, Joao Mendes] Fed Univ Pernambuco UFPE, Neuropsychiat Dept, BR-50670901 Recife, PE, Brazil.
   [Ricardo de Oliveira, Joao Mendes] Fed Univ Pernambuco UFPE, KeizoAsami Lab, BR-50670901 Recife, PE, Brazil.
   [Maria Arrais, Nivia Rodrigues] Fed Univ Rio Grande Norte UFRN, Dept Pediat, BR-59010180 Natal, RN, Brazil.
   [Melo, Adriana] ISEA, BR-58400220 Campina Grande, PB, Brazil.
   [Figueiredo, Thalita] Paraiba State Univ UEPB, Dept Biol, BR-58429500 Campina Grande, PB, Brazil.
   [Goes Meira, Joanna Castro] Fed Univ Bahia UFBA, BR-40170115 Salvador, BA, Brazil.
   [Passos, Saulo Duarte] Med Sch Jundiai, Infect Pediat Lab, BR-13202550 Jundiai, SP, Brazil.
   [de Almeida, Roque Pacheco; Bispo, Ana JovinaBarreto] Fed Univ Sergipe UFS, Div Immunol, BR-49100000 Aracaju, SP, Brazil.
   [de Almeida, Roque Pacheco; Bispo, Ana JovinaBarreto] Fed Univ Sergipe UFS, Mol Biol Lab, BR-49100000 Aracaju, SP, Brazil.
   [Cunha-Neto, Edecio] Univ Sao Paulo, Fac Med, Heart Inst, BR-05403900 Sao Paulo, SP, Brazil.
   [Nakaya, Helder] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-05508900 Sao Paulo, SP, Brazil.
   [Santos, Robert Andreata; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Vaccine Dev Lab, BR-05508900 Sao Paulo, SP, Brazil.
RP Zatz, M (corresponding author), Univ Sao Paulo, Biosci Inst, Human Genome & Stem Cell Res Ctr, Dept Genet & Evolutionary Biol, BR-05508900 Sao Paulo, SP, Brazil.
EM mayazatz@usp.br
RI Cavalheiro, Esper A/I-3084-2016; Naslavsky, Michel/U-6595-2019; da
   Silva, Sergio Gomes/F-1847-2013; Verjovski-Almeida, Sergio/E-4082-2012;
   Kobayashi, Gerson Shigeru/AAB-9113-2019; Schanoski,
   Alessandra/H-8144-2014; Nakaya, Helder/AAF-1738-2020; Nakaya, Helder
   I/A-1397-2010; Santos, Silvana/ABF-5893-2020; KALIL, JORGE/C-8029-2012;
   Kobayashi, Gerson/H-4017-2013; Verjovski-Almeida, Sergio/AAI-2728-2020;
   Araujo, Bruno/B-8741-2013; Passos-Bueno, Maria Rita/I-6796-2016;
   Cunha-Neto, Edecio/B-4157-2009; Amaral, Murilo S/G-5769-2013; Zatz,
   Mayana/M-5338-2015; Naslavsky, Michel/L-1772-2015; Melo, Adriana S
   O/H-5650-2016; Astray, Renato Mancini/N-6627-2013; Goulart,
   Ernesto/AAC-3713-2020; Araujo, Bruno/P-9975-2019; Passos,
   Saulo/C-5166-2012
OI Cavalheiro, Esper A/0000-0002-0854-3582; da Silva, Sergio
   Gomes/0000-0002-9650-809X; Verjovski-Almeida,
   Sergio/0000-0002-6356-2401; Kobayashi, Gerson
   Shigeru/0000-0002-6520-5774; Schanoski, Alessandra/0000-0002-6514-8458;
   Nakaya, Helder/0000-0001-5297-9108; Nakaya, Helder
   I/0000-0001-5297-9108; Santos, Silvana/0000-0002-5252-0206; KALIL,
   JORGE/0000-0001-8415-4274; Kobayashi, Gerson/0000-0002-6520-5774;
   Verjovski-Almeida, Sergio/0000-0002-6356-2401; Araujo,
   Bruno/0000-0003-0012-4217; Passos-Bueno, Maria Rita/0000-0002-9248-3008;
   Cunha-Neto, Edecio/0000-0002-3699-3345; Zatz,
   Mayana/0000-0003-3970-8025; Naslavsky, Michel/0000-0002-9068-1713;
   Astray, Renato Mancini/0000-0002-6983-5298; Araujo,
   Bruno/0000-0003-0012-4217; Goulart, Ernesto/0000-0001-9526-8701; Passos,
   Saulo/0000-0002-0908-2677; Alves Telles Silva,
   Kayque/0000-0002-2994-609X; VAN DER LINDEN JUNIOR,
   HELIO/0000-0002-3123-2264; Alexandrasmello@gmail.com,
   Alexandra/0000-0002-7996-873X
FU FAPESP (CEPID)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2013/08028-1]; FAPESP (INCT) [14/50931-3]; FAPESP (Thematic
   grant) [2014/03620-2]; CNPq (INCT)National Council for Scientific and
   Technological Development (CNPq) [465355/2014-5]; AACD (Recife-PE);
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [440770/2016-5]
FX This study was supported by grants from FAPESP (CEPID number
   2013/08028-1 and INCT number 14/50931-3 to M.Z. and Thematic grant
   number 2014/03620-2 to S.V.-A.) and CNPq (INCT number 465355/2014-5 to
   M.Z.); Luiz Carlos de Caires Junior is a fellow of FAPESP
   (2017/16283-2); Ernesto Goulart is a fellow of FAPESP (2015/14821-1);
   Bruno Araujo is a fellow of FAPESP (2014/08049-1); Vanessa van der
   Linden Mota is supported by AACD (Recife-PE); Joao Ricardo de Oliveira
   is supported by CNPq (440770/2016-5). We are extremely grateful to Dr.
   S. Raia, D. Bertola, M. Vibranoski, P. Cunha, E.L. Durigon, W. Cumpady,
   P. Zanotto, C.R.S. Maia, A.N. Melo, M.T.A.L. Bezerra, D.A.M. de Araujo,
   A. Tanuri, R.S. de Aguiar, and T.R. Gollop for scientific discussions
   and sample collections. L. Suzuki and E. Amaro-Junior for helping with
   CT analysis. N. Lourenco, and M. Aguena for technical support in exome
   sequencing and MLPA assay.
CR Amorim JH, 2010, J VIROL METHODS, V167, P186, DOI 10.1016/j.jviromet.2010.04.003
   Araujo B. H. S., 2017, MOL NEUROBIOL
   Barbier A, 2013, PEDIATRICS, V131, pE1158, DOI 10.1542/peds.2011-3846
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Chimelli L, 2017, ACTA NEUROPATHOL, V133, P983, DOI 10.1007/s00401-017-1699-5
   Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109
   Cloetta D, 2013, J NEUROSCI, V33, P7799, DOI 10.1523/JNEUROSCI.3294-12.2013
   Datan E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.409
   del Campo M, 2017, AM J MED GENET A, V173, P841, DOI 10.1002/ajmg.a.38170
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Alves RPD, 2016, CLIN VACCINE IMMUNOL, V23, P460, DOI 10.1128/CVI.00081-16
   Edgil D, 2006, J VIROL, V80, P2976, DOI 10.1128/JVI.80.6.2976-2986.2006
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   Homem CCF, 2015, NAT REV NEUROSCI, V16, P647, DOI 10.1038/nrn4021
   Hou PS, 2013, NUCLEIC ACIDS RES, V41, P7753, DOI 10.1093/nar/gkt567
   Huzly D, 2016, EUROSURVEILLANCE, V21, P9, DOI 10.2807/1560-7917.ES.2016.21.16.30203
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jehee FS, 2011, EUR J MED GENET, V54, pE425, DOI 10.1016/j.ejmg.2011.03.007
   Johansson MA, 2016, NEW ENGL J MED, V375, P1, DOI 10.1056/NEJMp1605367
   Joubert PE, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005091
   Kassai H, 2014, CELL REP, V7, P1626, DOI 10.1016/j.celrep.2014.04.048
   Kortum F, 2011, J MED GENET, V48, P396, DOI 10.1136/jmg.2010.087528
   Kumamoto T, 2017, DEV GROWTH DIFFER, V59, P258, DOI 10.1111/dgd.12367
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liang QM, 2016, CELL STEM CELL, V19, P663, DOI 10.1016/j.stem.2016.07.019
   Marceau CD, 2016, NATURE, V535, P159, DOI 10.1038/nature18631
   McGrath EL, 2017, STEM CELL REP, V8, P715, DOI 10.1016/j.stemcr.2017.01.008
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Naslavsky MS, 2017, HUM MUTAT, V38, P751, DOI 10.1002/humu.23220
   Okita K, 2013, STEM CELLS, V31, P458, DOI 10.1002/stem.1293
   Quang D, 2015, BIOINFORMATICS, V31, P761, DOI 10.1093/bioinformatics/btu703
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Savidis G, 2016, CELL REP, V16, P232, DOI 10.1016/j.celrep.2016.06.028
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Sham PC, 2000, AM J HUM GENET, V66, P1616, DOI 10.1086/302891
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tripathi S, 2015, CELL HOST MICROBE, V18, P723, DOI 10.1016/j.chom.2015.11.002
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Werner H, 2016, PRENATAL DIAG, V36, P785, DOI 10.1002/pd.4860
   Zhang FR, 2016, NUCLEIC ACIDS RES, V44, P8610, DOI [10.1093/nar/gkw765, 10]
   Zhang R, 2016, NATURE, V535, P164, DOI 10.1038/nature18625
NR 45
TC 11
Z9 12
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB 2
PY 2018
VL 9
AR 475
DI 10.1038/s41467-017-02790-9
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FU7VL
UT WOS:000424060700001
PM 29396410
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Magalhaes, LS
   Bomfim, LGS
   Mota, SG
   Cruz, GS
   Correa, CB
   Tanajura, DM
   Lipscomb, MW
   Borges, VM
   de Jesus, AR
   de Almeida, RP
   de Moura, TR
AF Magalhaes, Lucas S.
   Bomfim, Lays G. S.
   Mota, Sthefanne G.
   Cruz, Geydson S.
   Correa, Cristiane B.
   Tanajura, Diego M.
   Lipscomb, Michael W.
   Borges, Valeria M.
   de Jesus, Amelia R.
   de Almeida, Roque P.
   de Moura, Tatiana R.
TI Increased thiol levels in antimony-resistant Leishmania infantum
   isolated from treatment-refractory visceral leishmaniasis in Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Leishmania; visceral leishmaniasis; antimony; drug resistance
ID DRUG-RESISTANCE; NITRIC-OXIDE; DONOVANI; CHEMOTHERAPY; SUSCEPTIBILITY;
   PROMASTIGOTES; TRANSPORTER; VERAPAMIL
AB BACKGROUND Treatment-refractory visceral leishmaniasis (VL) has become an important problem in many countries.
   OBJECTIVES We evaluated the antimony-resistance mechanisms of Leishmania infantum isolated from VL patients refractory or responsive to treatment with pentavalent antimony.
   METHODS Strains isolated from antimony-refractory patients (in vitro antimony-resistant isolates) and antimony-responsive patients (in vitro antimony-sensitive isolates) were examined. Morphological changes were evaluated by transmission electron microscopy after trivalent antimony exposure. P-glycoprotein (P-gp) efflux pump activity was evaluated using the pump-specific inhibitor verapamil hydrochloride, and the role of thiol in trivalent antimony resistance was investigated using the enzymatic inhibitor L-buthionine sulfoximine.
   FINDINGS Antimony treatment induced fewer alterations in the cellular structure of L. infantum resistant isolates than in that of sensitive isolates. P-gp efflux activity was not involved in antimony resistance in these isolates. Importantly, the resistant isolates contained higher levels of thiol compared to the sensitive isolates, and inhibition of thiol synthesis in the resistant isolates recovered their sensitivity to trivalent antimony treatment, and enhanced the production of reactive oxygen species in promastigotes exposed to the drug.
   MAIN CONCLUSIONS Our results demonstrate that isolates from patients with antimony-refractory VL exhibited higher thiol levels than antimony-sensitive isolates. This indicates that redox metabolism plays an important role in the antimony-resistance of New World VL isolates.
C1 [Magalhaes, Lucas S.; Bomfim, Lays G. S.; Mota, Sthefanne G.; Cruz, Geydson S.; Correa, Cristiane B.; Tanajura, Diego M.; de Jesus, Amelia R.; de Almeida, Roque P.; de Moura, Tatiana R.] Univ Fed Sergipe, Hosp Univ, Lab Biol Mol, Aracaju, SE, Brazil.
   [Lipscomb, Michael W.] Howard Univ, Dept Biol, Washington, DC 20059 USA.
   [Borges, Valeria M.] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Goncalo Moniz, Salvador, BA, Brazil.
RP de Moura, TR (corresponding author), Univ Fed Sergipe, Hosp Univ, Lab Biol Mol, Aracaju, SE, Brazil.
EM tmoura.ufs@gmail.com
RI Cruz, Geydson S/O-6835-2017; Borges, Valeria/G-2009-2014; Borges,
   Val/N-6647-2019; Correa, Cristiane Bani/AAR-9384-2020; Cruz,
   Geydson/AAM-8400-2020
OI Borges, Val/0000-0002-2775-5409; Cruz, Geydson/0000-0001-9392-0321;
   Santos Bomfim, Lays Gisele/0000-0002-4773-6889; Sousa Magalhaes,
   Lucas/0000-0002-2169-7463
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [MCTI/CNPQ/Universal 14/2014 (460743/2014-7), PROCAD/CASADINHO
   (552721/2011-5)]; FAPITEC/SE/FUNTEC/CNPq [12/2009
   (019.203.02712/2009-8)]; CAPESCAPES; Programa Nacional de Incentivo a
   Pesquisa em Parasitologia Basica [032/2010]; NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [SC2GM103741]; Department of Defense (DOD)United States Department of
   Defense [W911NF-14-1-0123]; National Science Foundation (NSF)National
   Science Foundation (NSF) [1428768]; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [SC2GM103741, SC2GM103741,
   SC2GM103741] Funding Source: NIH RePORTER
FX CNPq, MCTI/CNPQ/Universal 14/2014 (460743/2014-7 TRM) and
   PROCAD/CASADINHO (552721/2011-5 RPA); FAPITEC/SE/FUNTEC/CNPq No. 12/2009
   (019.203.02712/2009-8 ARJ); CAPES; Programa Nacional de Incentivo a
   Pesquisa em Parasitologia Basica, Edital No. 032/2010 (ARJ); NIH (grant
   # SC2GM103741 - MWL); the Department of Defense (DOD) (grant #
   W911NF-14-1-0123 - MWL); and the National Science Foundation (NSF)
   (grant # 1428768 - MWL).
CR Bocedi A, 2010, FASEB J, V24, P1035, DOI 10.1096/fj.09-146407
   Borges VM, 2005, PARASITOL RES, V95, P90, DOI 10.1007/s00436-004-1248-8
   Campos R, 2017, GEOSPATIAL HEALTH, V12, P67, DOI 10.4081/gh.2017.503
   Croft SL, 2011, CLIN MICROBIOL INFEC, V17, P1478, DOI 10.1111/j.1469-0691.2011.03630.x
   da Luz RI, 2011, J ANTIMICROB CHEMOTH, V66, P677, DOI 10.1093/jac/dkq508
   de Moura TR, 2016, PARASITOL RES, V115, P713, DOI 10.1007/s00436-015-4793-4
   Essodaigui M, 1999, MOL BIOCHEM PARASIT, V100, P73, DOI 10.1016/S0166-6851(99)00036-5
   Fonseca-Silva F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014666
   Forster S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033253
   Frezard F, 2009, MOLECULES, V14, P2317, DOI 10.3390/molecules14072317
   Jeddi F, 2014, ANTIMICROB AGENTS CH, V58, P4866, DOI 10.1128/AAC.02521-13
   Kapoor P, 2000, TROP MED INT HEALTH, V5, P438, DOI 10.1046/j.1365-3156.2000.00565.x
   Mandal G, 2007, PARASITOLOGY, V134, P1679, DOI 10.1017/S0031182007003150
   Manzano JI, 2013, ANTIMICROB AGENTS CH, V57, P3719, DOI 10.1128/AAC.00211-13
   Martins-Melo FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093770
   Messaritakis I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065467
   Mishra J, 2007, CURR MED CHEM, V14, P1153, DOI 10.2174/092986707780362862
   Mukherjee A, 2007, J ANTIMICROB CHEMOTH, V59, P204, DOI 10.1093/jac/dkl494
   Mukherjee B, 2013, P NATL ACAD SCI USA, V110, pE575, DOI [10.1073/pnas.1213839110, 10.]
   NEAL RA, 1989, T ROY SOC TROP MED H, V83, P197, DOI 10.1016/0035-9203(89)90642-1
   Ouellette M, 1998, DRUG RESIST UPDATE, V1, P43, DOI 10.1016/S1368-7646(98)80213-6
   Perez-Victoria Jose M., 2001, International Microbiology, V4, P159
   Ponte-Sucre A, 2013, DRUG RESISTANCE LEIS
   Rai S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074862
   Santos DM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003275
   Santos PL, 2012, NITRIC OXIDE-BIOL CH, V27, P67, DOI 10.1016/j.niox.2012.04.004
   Sarkar A, 2009, EXP PARASITOL, V122, P299, DOI 10.1016/j.exppara.2009.04.012
   Seblova V, 2014, ANTIMICROB AGENTS CH, V58, P6273, DOI 10.1128/AAC.02406-13
   Singh N, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0596-1
   Valiathan R, 2006, EXP PARASITOL, V114, P103, DOI 10.1016/j.exppara.2006.02.015
   Vannier-Santos MA, 2009, CURR DRUG TARGETS, V10, P246, DOI 10.2174/138945009787581168
   WHO, 2010, M WHO EXP COMM CONTR
NR 32
TC 3
Z9 3
U1 0
U2 3
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD FEB
PY 2018
VL 113
IS 2
BP 119
EP 125
DI 10.1590/0074-02760170289
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA FP8AM
UT WOS:000417861700007
PM 29236925
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Peres, NTD
   Cunha, LCS
   Barbosa, MLA
   Santos, MB
   de Oliveira, FA
   de Jesus, AMR
   de Almeida, RP
AF de Aguiar Peres, Nalu Teixeira
   Seraphim Cunha, Luana Celina
   Almeida Barbosa, Meirielly Lima
   Santos, Marcio Bezerra
   de Oliveira, Fabricia Alvise
   Ribeiro de Jesus, Amelia Maria
   de Almeida, Roque Pacheco
TI Infection of Human Macrophages by Leishmania infantum Is Influenced by
   Ecto-Nucleotidases
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE Leishmania infantum; macrophage; infection; ecto-nucleotidase;
   extracellular nucleotides
ID NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE; TRYPANOSOMA-CRUZI;
   IMMUNE-RESPONSE; EXTRACELLULAR NUCLEOTIDES; VISCERAL LEISHMANIASIS;
   PURINE STARVATION; ATPASE ACTIVITY; AMAZONENSIS; PARASITES;
   IMMUNOLOCALIZATION
AB Ecto-nucleotidase activity is involved in the infection process of Leishmania and various other parasites that enables modulation of host immune responses to promote disease progression. One of the enzymes responsible for this activity is the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase). The enzyme hydrolyzes nucleotides tri- and/or di-phosphate into monophosphate products, which are subsequently hydrolyzed into adenosine. These nucleotides can serve as purinergic signaling molecules involved in diverse cellular processes that govern immune responses. Given the importance of the extracellular metabolism of these nucleotides during intracellular pathogen infections, this study evaluates the role of ecto-nucleotidase activity during Leishmania infantum (L. infantum) infection in human macrophages. E-NTPDase protein expression and activity was evaluated in L. infantum during purine starvation, adenosine-enriched medium, or in the presence of an inhibitor of ecto-nucleotidases. Results show that E-NTPDase is expressed in L. infantum parasites, including on the cell membrane. Furthermore, functional activity of the enzyme was modulated according to the availability of adenosine in the medium. Purine starvation increased the hydrolytic capacity of nucleotides leading to higher infectivity, while growth in adenosine-enriched medium led to lower infectivity. Moreover, inhibiting E-NTPDase function decreased L. infantum infection in macrophages, suggesting the enzyme may serve as a ligand. Taken together, the ability of L. infantum to hydrolyze nucleotides is directly associated with increased infectivity in macrophages.
C1 [de Aguiar Peres, Nalu Teixeira; Seraphim Cunha, Luana Celina; Almeida Barbosa, Meirielly Lima; Santos, Marcio Bezerra; de Oliveira, Fabricia Alvise; Ribeiro de Jesus, Amelia Maria; de Almeida, Roque Pacheco] Univ Fed Sergipe, Univ Hosp, Dept Med, Lab Mol Biol, Sao Cristovao, Brazil.
   [de Aguiar Peres, Nalu Teixeira] Univ Fed Sergipe, Dept Morphol, Biol & Hlth Sci Ctr, Aracaju, Brazil.
   [Santos, Marcio Bezerra] Univ Fed Sergipe, Dept Hlth Sci, Aracaju, Brazil.
   [Ribeiro de Jesus, Amelia Maria; de Almeida, Roque Pacheco] CNPq, Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Nacionais Ciencia & Tecnol, Inst Invest Imunol, Brasilia, DF, Brazil.
RP de Almeida, RP (corresponding author), Univ Fed Sergipe, Univ Hosp, Dept Med, Lab Mol Biol, Sao Cristovao, Brazil.; de Almeida, RP (corresponding author), CNPq, Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Nacionais Ciencia & Tecnol, Inst Invest Imunol, Brasilia, DF, Brazil.
EM roquepachecoalmeida@gmail.com
FU Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe-FAPITEC/SE/Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPq; EDITAL FAPITEC/SE/FUNTEC/CNPq (Programa de Nucleos de
   Excelencia-PRONEX) [019.203.02712/2009-8]; CAPES ParasitologyCAPES
   [23038.005304/2011-01]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [552721/2011-5]
FX This work was supported by the Fundacao de Apoio a Pesquisa e a Inovacao
   Tecnologica do Estado de Sergipe-FAPITEC/SE/Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico-CNPq, EDITAL
   FAPITEC/SE/FUNTEC/CNPq (Programa de Nucleos de Excelencia-PRONEX),
   Process no. 019.203.02712/2009-8; CAPES Parasitology, Process no.
   23038.005304/2011-01. CNPq Process no. 552721/2011-5.
CR Berredo-Pinho M, 2001, ARCH BIOCHEM BIOPHYS, V391, P16, DOI 10.1006/abbi.2001.2384
   Bisaggio DFR, 2003, PARASITOL RES, V91, P273, DOI 10.1007/s00436-003-0965-8
   Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006
   Carter NS, 2010, MOL MICROBIOL, V78, P92, DOI 10.1111/j.1365-2958.2010.07327.x
   Chaves MM, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1781-1
   Collin S, 2004, CLIN INFECT DIS, V38, P612, DOI 10.1086/381203
   Coutinho-Silva R, 2012, MICROBES INFECT, V14, P1271, DOI 10.1016/j.micinf.2012.05.009
   de Figueiredo AB, 2016, BIOMED J, V39, P244, DOI 10.1016/j.bj.2016.08.004
   de Souza MC, 2010, ACTA TROP, V115, P262, DOI 10.1016/j.actatropica.2010.04.007
   de Souza RF, 2013, ACTA TROP, V125, P60, DOI 10.1016/j.actatropica.2012.09.011
   DeMarco R, 2003, BIOCHEM BIOPH RES CO, V307, P831, DOI 10.1016/S0006-291X(03)01268-3
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   Di Virgilio F, 2007, PURINERG SIGNAL, V3, P1, DOI 10.1007/s11302-006-9048-5
   Di Virgilio Francesco, 2005, Purinergic Signal, V1, P205, DOI 10.1007/s11302-005-6312-z
   Di Virgilio F, 2015, AUTON NEUROSCI-BASIC, V191, P117, DOI [10.1016/j.autneu2015.04.011, 10.1016/j.autneu.2015.04.011]
   Di Virgilio F, 2009, CURR OPIN PHARMACOL, V9, P507, DOI 10.1016/j.coph.2009.06.021
   Dutra PML, 2001, PHYTOPATHOLOGY, V91, P408, DOI 10.1094/PHYTO.2001.91.4.408
   EKMAN P, 1993, ANAL BIOCHEM, V214, P138, DOI 10.1006/abio.1993.1468
   Fietto JLR, 2004, BIOCHEM BIOPH RES CO, V316, P454, DOI 10.1016/j.bbrc.2004.02.071
   Freitas-Mesquita AL, 2017, EXP PARASITOL, V179, P1, DOI 10.1016/j.exppara.2017.06.001
   Gomes RS, 2015, MICROBES INFECT, V17, P295, DOI 10.1016/j.micinf.2014.12.009
   GOTTLIEB M, 1985, SCIENCE, V227, P72, DOI 10.1126/science.2981117
   Maioli TU, 2004, PARASITOL RES, V94, P207, DOI 10.1007/s00436-004-1193-6
   Marques-da-Silva C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025356
   Marques-da-Silva ED, 2008, MICROBES INFECT, V10, P850, DOI 10.1016/j.micinf.2008.04.016
   Martin JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003938
   MeyerFernandes JR, 1997, ARCH BIOCHEM BIOPHYS, V341, P40, DOI 10.1006/abbi.1997.9933
   Sansom FM, 2007, CELL MICROBIOL, V9, P1922, DOI 10.1111/j.1462-5822.2007.00924.x
   Sansom FM, 2008, MICROBIOL MOL BIOL R, V72, P765, DOI 10.1128/MMBR.00013-08
   Santos PL, 2012, NITRIC OXIDE-BIOL CH, V27, P67, DOI 10.1016/j.niox.2012.04.004
   Santos RF, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000387
   SCHENKMAN S, 1991, INFECT IMMUN, V59, P645, DOI 10.1128/IAI.59.2.645-654.1991
   Serafim TD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001833
   Silverman JA, 1998, J BIOL CHEM, V273, P12352, DOI 10.1074/jbc.273.20.12352
   Vasconcellos RD, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003309
   Werneck Guilherme L., 2010, Cad. Saúde Pública, V26, P644, DOI 10.1590/S0102-311X2010000400001
   Yegutkin GG, 2014, CRIT REV BIOCHEM MOL, V49, P473, DOI 10.3109/10409238.2014.953627
   Zimmermann H, 1999, TRENDS PHARMACOL SCI, V20, P231, DOI 10.1016/S0165-6147(99)01293-6
NR 38
TC 3
Z9 3
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JAN 11
PY 2018
VL 8
AR 1954
DI 10.3389/fimmu.2017.01954
PG 8
WC Immunology
SC Immunology
GA FS4UD
UT WOS:000419787500001
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Carrillo, E
   Fernandez, L
   Ibarra-Meneses, AV
   Santos, MLB
   Nico, D
   de Luca, PM
   Correa, CB
   de Almeida, RP
   Moreno, J
   Palatnik-de-Sousa, CB
AF Carrillo, Eugenia
   Fernandez, Laura
   Ibarra-Meneses, Ana Victoria
   Santos, Micheli L. B.
   Nico, Dirlei
   de Luca, Paula M.
   Correa, Cristiane Bani
   de Almeida, Roque Pacheco
   Moreno, Javier
   Palatnik-de-Sousa, Clarisa B.
TI F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase
   Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured
   Patients and in Asymptomatic Individuals Living in an Endemic Area of
   Leishmaniasis
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE human visceral leishmaniasis; cutaneous leishmaniasis; nucleoside
   hydrolase; B cell epitopes; T cell epitopes; adaptive immunity
ID CANINE VISCERAL LEISHMANIASIS; FUCOSE-MANNOSE LIGAND; T-CELL; DNA
   VACCINE; CYTOKINE RESPONSES; BALB/C MICE; FML-VACCINE; PROTECTION;
   INFECTION; DIAGNOSIS
AB The Leishmania (Leishmania) donovani nucleoside hydrolase NH36 is the main antigen of the Leishmune (R) vaccine and one of the promising candidates for vaccination against visceral leishmaniasis. The antigenicity of the N-terminal (F1), the central (F2), or the C-terminal recombinant domain (F3) of NH36 was evaluated using peripheral blood mononuclear cells (PBMC) from individuals infected with L. (L.) infantum from an endemic area of visceral leishmaniasis of Spain. Both NH36 and F1 domains significantly increased the PBMC proliferation stimulation index of cured patients and infected asymptomatic individuals compared to healthy controls. Moreover, F1 induced a 19% higher proliferative response than NH36 in asymptomatic exposed subjects. In addition, in patients cured from visceral leishmaniasis, proliferation in response to NH36 and F1 was accompanied by a significant increase of IFN-gamma and TNF-alpha secretion, which was 42-43% higher, in response to F1 than to NH36. The interleukin 17 (IL-17) secretion was stronger in asymptomatic subjects, in response to F1, as well as in cured cutaneous leishmaniasis after NH36 stimulation. While no IL-10 secretion was determined by F1, a granzyme B increase was detected in supernatants from cured patients after stimulation with either NH36 or F1. These data demonstrate that F1 is the domain of NH36 that induces a recall cellular response in individuals with acquired resistance to the infection by L. (L.) infantum. In addition, F1 and NH36 discriminated the IgG3 humoral response in patients with active visceral leishmaniasis due to L. (L.) donovani (Ethiopia) and L. (L.) infantum (Spain) from that of endemic and non-endemic area controls. NH36 showed higher reactivity with sera from L. (L.) donovani-infected individuals, indicating species specificity. We conclude that the F1 domain, previously characterized as an inducer of the Th1 and Th17 responses in cured/exposed patients infected with L. (L.) infantum chagasi, may also be involved in the generation of a protective response against L. (L.) infantum and represents a potential vaccine candidate for the control of human leishmaniasis alone, or in combination with other HLA epitopes/antigens.
C1 [Carrillo, Eugenia; Fernandez, Laura; Ibarra-Meneses, Ana Victoria; Moreno, Javier] Inst Salud Carlos III, WHO Collaborating Ctr Leishmaniasis, Ctr Nacl Microbiol, Madrid, Spain.
   [Santos, Micheli L. B.; de Almeida, Roque Pacheco] Hosp Univ Fed Sergipe, Dept Med, Aracaju, Brazil.
   [Nico, Dirlei; Palatnik-de-Sousa, Clarisa B.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Rio De Janeiro, Brazil.
   [de Luca, Paula M.] Inst Oswaldo Cruz, Lab Imunoparasitol, Rio De Janeiro, Brazil.
   [Correa, Cristiane Bani] Univ Fed Sergipe, Dept Morfol, Aracaju, Brazil.
   [de Almeida, Roque Pacheco; Palatnik-de-Sousa, Clarisa B.] Inst Nacl Ciencia & Tecnol Invest Imunol, Sao Paulo, Brazil.
RP Palatnik-de-Sousa, CB (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Rio De Janeiro, Brazil.; Palatnik-de-Sousa, CB (corresponding author), Inst Nacl Ciencia & Tecnol Invest Imunol, Sao Paulo, Brazil.
EM immgcpa@micro.ufrj.br
RI Correa, Cristiane Bani/AAR-9384-2020; Ibarra-Meneses, Ana
   Victoria/AAZ-8118-2020; Carrillo, Eugenia/F-2058-2018
OI Carrillo, Eugenia/0000-0002-7869-7915; Moreno,
   Javier/0000-0003-0087-4659; Ibarra-Meneses, Ana
   Victoria/0000-0002-2793-4458; Palatnik-de-Sousa, Clarisa
   B./0000-0002-6231-0608
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPQ)National Council for Scientific and Technological Development
   (CNPq) [300639/2003-1, 310977/2014-2, 404400/2012-4]; Fundacao Carlos
   Chagas de Amparo a Pesquisa do Estado de Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ) [E-26-201.583/2014, E-26-102957/2011,
   E-26/111.682/2013, E-26/102415/2010, E-26/201747/2015]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel SuperiorCAPES [23038.005304/2011-0];
   CNPQ-Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe-PRONEX; FAPITEC CNPq-(PRONEX)National Council for Scientific and
   Technological Development (CNPq) [019.203.02712/2009-8]; VII PN I+D+I;
   FEDEREuropean Union (EU) [RICET RD12/0018/0003]
FX This work was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPQ) (fellowships 300639/2003-1 to MP,
   310977/2014-2 to CP-d-S, and grant 404400/2012-4 to CP-d-S, MP, PL, RA,
   JM, EC); Fundacao Carlos Chagas de Amparo a Pesquisa do Estado de Rio de
   Janeiro (FAPERJ) (grant E-26-201.583/2014, E-26-102957/2011, and
   E-26/111.682/2013 to CP-d-S and fellowships E-26/102415/2010 and
   E-26/201747/2015 to DN); Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (grant 23038.005304/2011-0 to MS); CNPQ-Fundacao de Apoio
   a Pesquisa e a Inovacao Tecnologica do Estado de Sergipe-PRONEX
   (12/2009); and FAPITEC CNPq-(PRONEX) (019.203.02712/2009-8) to RA. EC
   was supported by a research contract funded via VII PN I+D+I 2013-2016
   and FEDER Funds (RICET RD12/0018/0003).
CR Aguilar-Be I, 2005, INFECT IMMUN, V73, P812, DOI 10.1128/IAI.73.2.812-819.2005
   Al-Wabel MA, 2007, AM J TROP MED HYG, V77, P1060, DOI 10.4269/ajtmh.2007.77.1060
   Alexander JL, 1997, US patent, Patent No. [WO 1997026784 A1, 1997026784]
   Alves-Silva MV, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00100
   Anam K, 1999, CLIN DIAGN LAB IMMUN, V6, P231, DOI 10.1128/CDLI.6.2.231-235.1999
   Arce A, 2013, EUROSURVEILLANCE, V18, P5, DOI 10.2807/1560-7917.ES2013.18.30.20546
   Santos MLB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00227
   Basu R, 2007, J INFECT DIS, V195, P1373, DOI 10.1086/513439
   Bertholet S, 2009, VACCINE, V27, P7036, DOI 10.1016/j.vaccine.2009.09.066
   Borja-Cabrera GP, 2009, PROCEDIA VACCINOL, V1, P104, DOI 10.1016/j.provac.2009.07.019
   Borja-Cabrera GP, 2012, PROCEDIA VACCINOL, V6, P64, DOI 10.1016/j.provac.2012.04.009
   Cabrera GPB, 1999, AM J TROP MED HYG, V61, P296, DOI 10.4269/ajtmh.1999.61.296
   Carcelen J, 2009, VACCINE, V27, P5964, DOI 10.1016/j.vaccine.2009.07.069
   Carrillo E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004179
   Carrillo E, 2013, TRENDS PARASITOL, V29, P579, DOI 10.1016/j.pt.2013.10.007
   Chamakh-Ayari R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092708
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   Chauhan IS, 2016, EXP PARASITOL, V170, P135, DOI 10.1016/j.exppara.2016.09.010
   Costa MM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001622
   de Souza EP, 2001, VACCINE, V19, P3104, DOI 10.1016/S0264-410X(01)00031-7
   Dye C, 1996, AM J TROP MED HYG, V55, P125, DOI 10.4269/ajtmh.1996.55.125
   Fernandes AP, 2012, CURR OPIN MICROBIOL, V15, P476, DOI 10.1016/j.mib.2012.05.002
   Foroughi-Parvar Faeze, 2014, Adv Prev Med, V2014, P569193, DOI 10.1155/2014/569193
   Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627
   Ibarra-Meneses AV, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.05.021
   Kaye PM, 2011, CLIN MICROBIOL INFEC, V17, P1462, DOI 10.1111/j.1469-0691.2011.03610.x
   KEMP M, 1993, INFECT IMMUN, V61, P1069, DOI 10.1128/IAI.61.3.1069-1073.1993
   Kumar R, 2014, CLIN TRANSL IMMUNOL, V3, DOI 10.1038/cti.2014.4
   Nascimento MSL, 2015, J INFECT DIS, V211, P1015, DOI 10.1093/infdis/jiu531
   Mauricio IL, 1999, PARASITOLOGY, V119, P237, DOI 10.1017/S0031182099004710
   Mauricio IL, 2000, PARASITOL TODAY, V16, P188, DOI 10.1016/S0169-4758(00)01637-9
   Naouar I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147076
   Nico D, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00273
   Nico D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00189
   Nico D, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000866
   Novoa R, 2011, PARASITE IMMUNOL, V33, P132, DOI 10.1111/j.1365-3024.2010.01256.x
   Oliva G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003213
   Palatnik de Sousa CB, 1996, REV SOC BRAS MED TRO, V29, P153
   Palatnik-de-Sousa CB, 2008, EXPERT REV VACCINES, V7, P833, DOI 10.1586/14760584.7.6.833
   Palatnik-De-Sousa CB, 2009, VACCINE, V27, P3505, DOI 10.1016/j.vaccine.2009.03.045
   PALATNIKDESOUSA CB, 1995, T ROY SOC TROP MED H, V89, P390, DOI 10.1016/0035-9203(95)90022-5
   Parra LE, 2007, VACCINE, V25, P2180, DOI 10.1016/j.vaccine.2006.11.057
   Pitta MGR, 2009, J CLIN INVEST, V119, P2379, DOI 10.1172/JCI38813
   REED SG, 1993, CURR OPIN IMMUNOL, V5, P524, DOI 10.1016/0952-7915(93)90033-O
   Rodriguesa MHC, 2005, INT J PARASITOL, V35, P185, DOI 10.1016/j.ijpara.2004.11.003
   Saini DK, 2002, PROTEIN EXPRES PURIF, V25, P203, DOI 10.1006/prep.2002.1628
   Santana DM, 2002, MOL BIOCHEM PARASIT, V120, P315, DOI 10.1016/S0166-6851(02)00010-5
   Saraiva EM, 2006, VACCINE, V24, P2423, DOI 10.1016/j.vaccine.2005.11.061
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Seyed N, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00467
   Singh B, 2012, VACCINE, V30, P3834, DOI 10.1016/j.vaccine.2012.03.068
   Solano Gallego L, 2014, PARASITE VECTOR, V7, P111, DOI [10.1186/1756-3305-7-111, DOI 10.1186/1756-3305-7-111]
   Sordo L, 2012, AM J TROP MED HYG, V86, P955, DOI 10.4269/ajtmh.2012.11-0436
   Zheng W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134835
NR 54
TC 11
Z9 11
U1 0
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 12
PY 2017
VL 8
AR 750
DI 10.3389/fimmu.2017.00750
PG 13
WC Immunology
SC Immunology
GA FA2OF
UT WOS:000405280000001
PM 28747911
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Keesen, TSL
   de Almeida, RP
   Gois, BM
   Peixoto, RF
   Pacha, ASC
   Vieira, FCF
   Cazzaniga, MPR
   Boyton, RJ
   Altmann, DM
AF Lima Keesen, Tatjana Souza
   de Almeida, Roque P.
   Gois, Bruna Macedo
   Peixoto, Rephany Fonseca
   Cysneiros Pacha, Anna Stella
   Fernandes Vieira, Fernanda Carolina
   Rodrigo Cazzaniga, Marcelo Paixao
   Boyton, Rosemary J.
   Altmann, Daniel M.
TI Guillain-Barre syndrome and arboviral infection in Brazil
SO LANCET INFECTIOUS DISEASES
LA English
DT Letter
C1 [Lima Keesen, Tatjana Souza; Gois, Bruna Macedo; Peixoto, Rephany Fonseca] Univ Fed Paraiba, Immunol Infect Dis Lab, Joao Pessoa, Paraiba, Brazil.
   [de Almeida, Roque P.; Rodrigo Cazzaniga, Marcelo Paixao; Boyton, Rosemary J.] Univ Fed Sergipe, Univ Hosp, Lab Biol Mol, Aracaju, Brazil.
   [Cysneiros Pacha, Anna Stella; Fernandes Vieira, Fernanda Carolina] Secretary Hlth Paraiba State, Joao Pessoa, Paraiba, Brazil.
   [Boyton, Rosemary J.; Altmann, Daniel M.] Imperial Coll, Hammersmith Hosp, Dept Med, London W12 0NN, England.
RP Altmann, DM (corresponding author), Imperial Coll, Hammersmith Hosp, Dept Med, London W12 0NN, England.
EM d.altmann@imperial.ac.uk
FU Medical Research CouncilMedical Research Council UK (MRC) [MC_PC_15106]
   Funding Source: Medline
CR Araujo AQC, 2016, BRAIN, V139, P2122, DOI 10.1093/brain/aww158
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Fragoso YD, 2016, ARQ NEURO-PSIQUIAT, V74, P1039, DOI [10.1590/0004-282x20160161, 10.1590/0004-282X20160161]
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Wilder-Smith Annelies, 2017, Lancet Infect Dis, V17, pe101, DOI 10.1016/S1473-3099(16)30518-7
NR 5
TC 4
Z9 4
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUL
PY 2017
VL 17
IS 7
BP 693
EP 694
DI 10.1016/S1473-3099(17)30333-X
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA EY2TW
UT WOS:000403825500022
PM 28653634
OA Bronze
DA 2020-12-08
ER

PT J
AU Santos, MB
   de Oliveira, DT
   Cazzaniga, RA
   Varjao, CS
   dos Santos, PL
   Santos, MLB
   Correia, CB
   Faria, DR
   Simon, MD
   Silva, JS
   Dutra, WO
   Reed, SG
   Duthie, MS
   de Almeida, RP
   de Jesus, AR
AF Santos, M. B.
   de Oliveira, D. T.
   Cazzaniga, R. A.
   Varjao, C. S.
   dos Santos, P. L.
   Santos, M. L. B.
   Correia, C. B.
   Faria, D. R.
   Simon, M. do V.
   Silva, J. S.
   Dutra, W. O.
   Reed, S. G.
   Duthie, M. S.
   de Almeida, R. P.
   de Jesus, A. R.
TI Distinct Roles of Th17 and Th1 Cells in Inflammatory Responses
   Associated with the Presentation of Paucibacillary Leprosy and Leprosy
   Reactions
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID REGULATORY T-CELLS; VISCERAL LEISHMANIASIS; DIFFERENTIATION; EXPRESSION;
   CYTOKINES; DISEASES; VACCINE
AB It is well established that helper T cell responses influence resistance or susceptibility to Mycobacterium leprae infection, but the role of more recently described helper T cell subsets in determining severity is less clear. To investigate the involvement of Th17 cells in the pathogenesis of leprosy, we determined the immune profile with variant presentations of leprosy. Firstly, IL-17A, IFN- and IL-10 were evaluated in conjunction with CD4(+) T cell staining by confocal microscopy of lesion biopsies from tuberculoid (TT) and lepromatous leprosy (LL) patients. Secondly, inflammatory cytokines were measured by multiplex assay of serum samples from Multibacillary (MB, n=28) and Paucibacillary (PB, n=23) patients and household contacts (HHC, n=23). Patients with leprosy were also evaluated for leprosy reaction occurrence: LR+ (n=8) and LR- (n=20). Finally, peripheral blood mononuclear cells were analysed by flow cytometry used to determine the phenotype of cytokine-producing cells. Lesions from TT patients were found to have more CD4(+)IL-17A(+) cells than those from LL patients. Higher concentrations of IL-17A and IL-1 were observed in serum from PB than MB patients. The highest serum IFN- concentrations were, however, detected in sera from MB patients that developed leprosy reactions (MB LR+). Together, these results indicate that Th1 cells were associated with both the PB presentation and also with leprosy reactions. In contrast, Th17 cells were associated with an effective inflammatory response that is present in the PB forms but were not predictive of leprosy reactions in MB patients.
C1 [Santos, M. B.; de Oliveira, D. T.; Cazzaniga, R. A.; Varjao, C. S.; dos Santos, P. L.; Santos, M. L. B.; Correia, C. B.; Simon, M. do V.; de Almeida, R. P.; de Jesus, A. R.] Univ Fed Sergipe, Mol Biol Lab, Sao Cristovao, Brazil.
   [Santos, M. B.; Reed, S. G.; Duthie, M. S.] IDRI, Seattle, WA USA.
   [Faria, D. R.; Dutra, W. O.] Univ Fed Minas Gerais, Lab Biol Interacoes Celulares, Dept Morphol, Inst Ciencias Biol, Belo Horizonte, MG, Brazil.
   [Silva, J. S.] Univ Sao Paulo, FMRP, Dept Biochem & Immunol, Ribeirao Preto, Brazil.
   [de Almeida, R. P.; de Jesus, A. R.] UFS, Dept Med, Sergipe, Brazil.
   [de Almeida, R. P.; de Jesus, A. R.] CNPq, Inst Invest Imunol INCT, Sao Paulo, Brazil.
RP Santos, MB (corresponding author), UFS, Mol Biol Lab, Univ Hosp, Rua Claudio Batista S-N, BR-49060100 Aracaju, Sergipe, Brazil.
EM bio_marcio2006@hotmail.com
RI Silva, Joao S/A-4484-2008; Cazzaniga, Rodrigo/AAV-6694-2020
OI Silva, Joao S/0000-0002-3410-3927; Duthie, Malcolm/0000-0002-8515-5516;
   Bezerra-Santos, Marcio/0000-0001-9962-6537
FU Fundacao de Apoioa Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq, Brazil) [12/2009, 019.203.02712/2009-8]
FX This work was funded by Fundacao de Apoioa Pesquisa e a Inovacao
   Tecnologica do Estado de Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil), Grants: CNPq
   no 12/2009, Process no 019.203.02712/2009-8 (ARJ). ARJ and RPA are CNPq
   investigators. MCTI/CNPQ/Universal 14/2014, Process: 454848/2014-5
   (ARJ). We would like to thank also the residents and dermatologists of
   Dermatology Clinic-HU/UFS. The funders had no role in study design, data
   collection and analysis, decision to publish or preparation of the
   manuscript. We also thank Professor Michael W. Lipscomb for excellent
   suggestions on the manuscript.
CR Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050
   Attia EAS, 2014, ARCH DERMATOL RES, V306, P793, DOI 10.1007/s00403-014-1486-2
   Bellemore SM, 2015, CLIN EXP IMMUNOL, V182, P261, DOI 10.1111/cei.12691
   Bi Y, 2012, SCAND J IMMUNOL, V75, P543, DOI 10.1111/j.1365-3083.2012.02686.x
   Bretscher PA, 2014, SCAND J IMMUNOL, V79, P361, DOI 10.1111/sji.12175
   Burgler S, 2009, J ALLERGY CLIN IMMUN, V123, P588, DOI 10.1016/j.jaci.2008.12.017
   Aardo TLD, 2016, MICROB PATHOGENESIS, V90, P64, DOI 10.1016/j.micpath.2015.11.019
   desOliveira DT, 2012, GEOSPAT HLTH, V6, pS125
   Dupnik KM, 2015, J INFECT DIS, V211, P1658, DOI 10.1093/infdis/jiu612
   Duthie MS, 2016, APPL MICROBIOL BIOT, V100, P3267, DOI 10.1007/s00253-016-7328-8
   Duthie MS, 2011, HUM VACCINES, V7, P1172, DOI 10.4161/hv.7.11.16848
   Duthie MS, 2012, MEM I O CRUZ, V2012, P7
   Eysteinsdottir JH, 2013, SCAND J IMMUNOL, V78, P529, DOI 10.1111/sji.12114
   Faleiro RJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002914
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Gulia A, 2010, F1000 MED REP, V2, P1
   Halvorsen EH, 2011, SCAND J IMMUNOL, V73, P243, DOI 10.1111/j.1365-3083.2010.02498.x
   Jadidi-Niaragh F, 2011, SCAND J IMMUNOL, V74, P1, DOI 10.1111/j.1365-3083.2011.02536.x
   Jayakumar A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001204
   Khadge S, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1128-0
   Lee DJ, 2010, J INFECT DIS, V201, P558, DOI 10.1086/650318
   Martiniuk F, 2012, J DRUGS DERMATOL, V11, P5
   Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038
   Netea MG, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000661
   Okada S, 2015, SCIENCE, V349, P606, DOI 10.1126/science.aaa4282
   Palermo ML, 2012, AM J TROP MED HYG, V86, P878, DOI 10.4269/ajtmh.2012.12-0088
   Pitta MGR, 2009, J CLIN INVEST, V119, P2379, DOI 10.1172/JCI38813
   Sadhu S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004338
   Saini C, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004592
   Saini C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002338
   Sampaio LH, 2012, EUR J CLIN MICROBIOL, V31, P1443, DOI 10.1007/s10096-011-1462-0
   Schmidt RL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045186
   Simon M, 2011, DRUG DEVELOP RES, V72, P509, DOI 10.1002/ddr.20457
   Singh OP, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001874
   Soong L, 2012, SEMIN IMMUNOPATHOL, V34, P735, DOI 10.1007/s00281-012-0350-8
   Stober CB, 2005, J IMMUNOL, V175, P2517, DOI 10.4049/jimmunol.175.4.2517
   Torrado E, 2010, CYTOKINE GROWTH F R, V21, P455, DOI 10.1016/j.cytogfr.2010.10.004
   Wang X, 2014, SCAND J IMMUNOL, V80, P180, DOI 10.1111/sji.12201
   Yang C, 2015, SCAND J IMMUNOL, V82, P345, DOI 10.1111/sji.12334
NR 39
TC 5
Z9 5
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD JUL
PY 2017
VL 86
IS 1
BP 40
EP 49
DI 10.1111/sji.12558
PG 10
WC Immunology
SC Immunology
GA EY1JL
UT WOS:000403722100005
PM 28426172
OA Bronze
DA 2020-12-08
ER

PT J
AU Gardinassi, LG
   DeSouza-Vieira, TS
   da Silva, NO
   Garcia, GR
   Borges, VM
   Campos, RNS
   de Almeida, RP
   Santos, IKFD
   Saraiva, EM
AF Gardinassi, Luiz Gustavo
   DeSouza-Vieira, Thiago S.
   da Silva, Naila O.
   Garcia, Gustavo R.
   Borges, Valeria M.
   Campos, Roseane N. S.
   de Almeida, Roque P.
   de Miranda Santos, Isabel K. F.
   Saraiva, Elvira M.
TI Molecular signatures of neutrophil extracellular traps in human visceral
   leishmaniasis
SO PARASITES & VECTORS
LA English
DT Article
DE Neutrophil extracellular traps; NETosis; Leishmania infantum; Visceral
   leishmaniasis; Asymptomatic infection
ID TUBERCULOSIS
AB Background: Infections with parasites of the Leishmania donovani complex result in clinical outcomes that range fromasymptomatic infection to severe and fatal visceral leishmaniasis (VL). Neutrophils are major players of the immune response against Leishmania, but their contribution to distinct states of infection is unknown. Gene expression data suggest the activation of the NETosis pathway during human visceral leishmaniasis. Thus, we conducted an exploratory study to evaluate NET-related molecules in retrospective sera from VL patients, asymptomatic individuals and uninfected endemic controls.
   Results: We demonstrate that VL patients and asymptomatic individuals exhibit differential regulation of molecules associated with neutrophil extracellular traps (NET). These differences were observed at the transcriptional level of genes encoding NET-associated proteins; in quantifications of cell free DNA and metalloproteinase 9; and in enzymatic activity of DNAse and elastase. Moreover, multivariate analysis resulted in class-specific signatures, and ROC curves demonstrate the ability of these molecules in discriminating asymptomatic infection from uninfected controls.
   Conclusion: Molecules that are associated with NETs are differentially regulated between distinct states of infection with L. infantum, suggesting that NETs might have distinct roles depending on the clinical status of infection. Although unlikely to be exclusive for VL, these signatures can be useful to better characterize asymptomatic infections in endemic regions of this disease.
C1 [Gardinassi, Luiz Gustavo; Garcia, Gustavo R.; de Miranda Santos, Isabel K. F.] Univ Sao Paulo, Dept Bioquim & Imunol, Fac Med Ribeirao Preto, Ribeirao Preto, SP, Brazil.
   [DeSouza-Vieira, Thiago S.; da Silva, Naila O.; Saraiva, Elvira M.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Imunol, Rio De Janeiro, RJ, Brazil.
   [Borges, Valeria M.] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Campos, Roseane N. S.; de Almeida, Roque P.] Univ Fed Sergipe, Hosp Univ, Dept Med, Aracaju, SE, Brazil.
RP Gardinassi, LG; Santos, IKFD (corresponding author), Univ Sao Paulo, Dept Bioquim & Imunol, Fac Med Ribeirao Preto, Ribeirao Preto, SP, Brazil.; Saraiva, EM (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Imunol, Rio De Janeiro, RJ, Brazil.
EM luiz.gardinassi@emory.edu; imsantos@fmrp.usp.br; esaraiva@micro.ufrj.br
RI Borges, Valeria/G-2009-2014; Gardinassi, Luiz/V-2225-2019; Gardinassi,
   Luiz Gustavo Araujo/K-6276-2012; Borges, Val/N-6647-2019; Saraiva,
   Elvira M/L-2864-2017; de Miranda Santos, Isabel KF/B-7597-2012
OI Gardinassi, Luiz/0000-0002-9027-2688; Gardinassi, Luiz Gustavo
   Araujo/0000-0002-9027-2688; Borges, Val/0000-0002-2775-5409; Saraiva,
   Elvira M/0000-0002-6388-5286; de Miranda Santos, Isabel
   KF/0000-0002-0438-4430; Campos, Roseane/0000-0001-6217-9278
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES; Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo - FAPESPFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2011/23819-0, 2014/25856-8,
   2013/00382-0]
FX This work was supported by Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ), Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES). LGG and GRG were
   supported by scholarships from the Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo - FAPESP (2011/23819-0 and 2014/25856-8;
   2013/00382-0, respectively).
CR Sampaio MJAD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000877
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   de Oliveira FA, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-331
   Leoratti FMD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001710
   Gabriel C, 2010, J IMMUNOL, V185, P4319, DOI 10.4049/jimmunol.1000893
   Gardinassi LG, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005123
   Gardinassi LG, 2014, MBIO, V5, DOI 10.1128/mBio.01844-14
   Guimaraes-Costa AB, 2014, INFECT IMMUN, V82, P1732, DOI 10.1128/IAI.01232-13
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   Khandpur R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005580
   Lu LL, 2016, CELL, V167, P433, DOI 10.1016/j.cell.2016.08.072
   Morgado FN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133063
   O'Donoghue AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075141
   Singh OP, 2014, CLIN INFECT DIS, V58, P1424, DOI 10.1093/cid/ciu102
   Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639
   Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380
   Yizengaw E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00517
NR 19
TC 4
Z9 5
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-3305
J9 PARASITE VECTOR
JI Parasites Vectors
PD JUN 6
PY 2017
VL 10
AR 285
DI 10.1186/s13071-017-2222-5
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA EW7JK
UT WOS:000402685400002
PM 28583201
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Romero, GAS
   Costa, DL
   Costa, CHN
   de Almeida, RP
   de Melo, EV
   de Carvalho, SFG
   Rabello, A
   de Carvalho, AL
   Sousa, AD
   Leite, RD
   Lima, SS
   Amaral, TA
   Alves, FP
   Rode, J
AF Sierra Romero, Gustavo Adolfo
   Costa, Dorcas Lamounier
   Nery Costa, Carlos Henrique
   de Almeida, Roque Pacheco
   de Melo, Enaldo Viera
   Guimaraes de Carvalho, Silvio Fernando
   Rabello, Ana
   de Carvalho, Andrea Lucchesi
   Sousa, Anastacio de Queiroz
   Leite, Roberio Dias
   Lima, Simone Soares
   Amaral, Thais Alves
   Alves, Fabiana Piovesan
   Rode, Joelle
CA Collaborative LVBrasil Grp
TI Efficacy and safety of available treatments for visceral leishmaniasis
   in Brazil: A multicenter, randomized, open label trial
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID LIPOSOMAL AMPHOTERICIN-B; SODIUM STIBOGLUCONATE; SINGLE; ANTIMONIATE;
   AMBISOME; CHILDREN; AFRICA; INDIA
AB Background
   There is insufficient evidence to support visceral leishmaniasis (VL) treatment recommendations in Brazil and an urgent need to improve current treatments. Drug combinations may be an option.
   Methods
   A multicenter, randomized, open label, controlled trial was conducted in five sites in Brazil to evaluate efficacy and safety of (i) amphotericin B deoxycholate (AmphoB) (1 mg/kg/day for 14 days), (ii) liposomal amphotericin B (LAMB) (3 mg/kg/day for 7 days) and (iii) a combination of LAMB (10 mg/kg single dose) plus meglumine antimoniate (MA) (20 mg Sb+5 /kg/day for 10 days), compared to (iv) standard treatment with MA (20 mg Sb+5/kg/day for 20 days). Patients, aged 6 months to 50 years, with confirmed VL and without HIV infection were enrolled in the study. Primary efficacy endpoint was clinical cure at 6 months. A planned efficacy and safety interim analysis led to trial interruption.
   Results
   378 patients were randomized to the four treatment arms: MA (n = 112), AmphoB (n = 45), LAMB (n = 109), or LAMB plus MA (n = 112). A high toxicity of AmphoB prompted an unplanned interim safety analysis and this treatment arm was dropped. Per intention-totreat protocol final analyses of the remaining 332 patients show cure rates at 6 months of 77.5% for MA, 87.2% for LAMB, and 83.9% for LAMB plus MA, without statistically significant differences between the experimental arms and comparator (LAMB: 9.7%; CI95% -0.28 to 19.68, p = 0.06; LAMB plus MA: 6.4%; CI95% -3.93 to 16.73; p = 0.222). LAMB monotherapy was safer than MA regarding frequency of treatment-related adverse events (AE) (p = 0.045), proportion of patients presenting at least one severe AE (p = 0.029), and the proportion of AEs resulting in definitive treatment discontinuation (p = 0.003).
   Conclusions
   Due to lower toxicity and acceptable efficacy, LAMB would be a more suitable first line treatment for VL than standard treatment. ClinicalTrials.gov identification number: NCT01310738.
C1 [Sierra Romero, Gustavo Adolfo] Univ Brasilia, Nucleo Med Trop, Brasilia, DF, Brazil.
   [Costa, Dorcas Lamounier; Nery Costa, Carlos Henrique] Univ Fed Piaui, Hosp Doencas Trop Natan Portela, Teresina, Piaui, Brazil.
   [de Almeida, Roque Pacheco; de Melo, Enaldo Viera] Univ Fed Sergipe, Hosp Univ, Aracaju, Sergipe, Brazil.
   [Guimaraes de Carvalho, Silvio Fernando] Univ Estadual Montes Claros, Dept Doencast Infecciosas, Hosp Univ Clemente de Faria, Montes Claros, MG, Brazil.
   [Rabello, Ana] Fundacao Oswaldo Cruz, Lab Pesquisa Clin & Polit Publ Doencas Infecciosa, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
   [de Carvalho, Andrea Lucchesi] Fundacao Hosp Estado Minas Gerais, Hosp Infantil Joao Paulo 2, Belo Horizonte, MG, Brazil.
   [Sousa, Anastacio de Queiroz; Leite, Roberio Dias] Univ Fed Ceara, Hosp Sao Jose Doencas Infecciosas, Fortaleza, Ceara, Brazil.
   [Lima, Simone Soares] Univ Fed Piaui, Hosp Infantil Lucidio Portela, Teresina, Piaui, Brazil.
   [Amaral, Thais Alves] Fundacao Oswaldo Cruz, Plataforma Pesquisa Cl nica, Pesquisa & Lab Referencia, Rio De Janeiro, RJ, Brazil.
   [Alves, Fabiana Piovesan] DNDi, Geneva, Switzerland.
   [Rode, Joelle] DNDi, Rio De Janeiro, RJ, Brazil.
RP Romero, GAS (corresponding author), Univ Brasilia, Nucleo Med Trop, Brasilia, DF, Brazil.
EM gromero@unb.br
RI Romero, Gustavo A.S./F-7214-2012
OI Romero, Gustavo A.S./0000-0003-1425-926X; Amaral Carrilho,
   Thais/0000-0002-4092-1707
FU The Ministry of Health of Brazil (CT/FINEP/MS/SCTIE/DECITCT-SAUDE); The
   Ministry of Health of Brazil (FNS); The Ministry of Science and
   Technology of Brazil [CNPq 420580/2013-1, CNPq 520029/2009-7]; Drugs for
   Neglected Diseases initiative; Department for International Development
   (DFID), UK; Spanish Agency for International Development Cooperation
   (AECID), Spain
FX This project was funded by The Ministry of Health of Brazil
   (CT/FINEP/MS/SCTIE/DECITCT-SAUDE and FNS) -
   http://portalsaude.saude.gov.br/index.php/o-ministerio/principal/secreta
   rias/sctie - GR; The Ministry of Science and Technology of Brazil
   (grants: CNPq 420580/2013-1 and CNPq 520029/2009-7) -
   http://www.cnpq.br/ - GR; Drugs for Neglected Diseases initiative -
   http://www.dndi.org/ - GR; DNDi would like to thank the following donors
   for their support: Department for International Development (DFID), UK;
   Spanish Agency for International Development Cooperation (AECID), Spain;
   and private donor in Brazil. The funders had no role in study design,
   data collection, and analysis, decision to publish, or preparation of
   the manuscript.
CR Altman DG, 2000, STAT CONFIDENCE
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Balasegaram M, 2012, EXPERT OPIN EMERG DR, V17, P493, DOI 10.1517/14728214.2012.748036
   Belo VS, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002982
   Berman JD, 1998, B WORLD HEALTH ORGAN, V76, P25
   Bern C, 2006, CLIN INFECT DIS, V43, P917, DOI 10.1086/507530
   Borges MM, 2017, REV SOC BRAS MED TRO, V50, P67, DOI 10.1590/0037-8682-0455-2016
   Brasil, LEISHM VISC REC CLIN
   Brasil, 2015, MAN REC DIAGN TRAT A
   Brasil. Ministerio da Saude, 2006, MAN VIG CONTR LEISHM
   Brustoloni YM, 2010, INFECTION, V38, P261, DOI 10.1007/s15010-010-0022-3
   CHULAY JD, 1985, AM J TROP MED HYG, V34, P702, DOI 10.4269/ajtmh.1985.34.702
   Davidson RN, 1996, CLIN INFECT DIS, V22, P938, DOI 10.1093/clinids/22.6.938
   diMartino L, 1997, J PEDIATR-US, V131, P271, DOI 10.1016/S0022-3476(97)70165-3
   Silveira LJD, 2015, REV INST MED TROP SP, V57, P33, DOI 10.1590/S0036-46652015000100005
   Division of AIDS National Institute of Allergy Infectious Diseases National Institutes of Health, 2004, DIV AIDS TABL GRAD S
   GlaxoSmithKline UK Ltd, 2012, DIR HEALTHC PROF COM
   Khalil EAG, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002613
   Martins-Melo FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093770
   Ministerio da Saude, SECR VIG SAUD
   Musa A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001674
   NVBDCP, 2014, NAT ROAD MAP KAL AZ
   Organizacion Panamericana de la Salud, 2013, LEISHM AM REC TRAT
   Orsini M, 2012, T ROY SOC TROP MED H, V106, P283, DOI 10.1016/j.trstmh.2012.01.008
   Pan American Health Organisation, 2016, LEISHM EP REP AM
   Pan American Health Organization, 2015, LEISHM EP REP AM
   Romero GAS, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000584
   Sundar S, 2004, CLIN INFECT DIS, V38, P377, DOI 10.1086/380971
   Sundar S, 2003, CLIN INFECT DIS, V37, P800, DOI 10.1086/377542
   Sundar S, 2001, BRIT MED J, V323, P419, DOI 10.1136/bmj.323.7310.419
   Sundar S, 2008, CLIN INFECT DIS, V47, P1000, DOI 10.1086/591972
   Sundar S, 2011, LANCET, V377, P477, DOI 10.1016/S0140-6736(10)62050-8
   Sundar S, 2010, NEW ENGL J MED, V362, P504, DOI 10.1056/NEJMoa0903627
   Syriopoulou V, 2003, CLIN INFECT DIS, V36, P560, DOI 10.1086/367843
   WHO, 2013, SUSTAINING THE DRIVE TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES: SECOND WHO REPORT ON NEGLECTED TROPICAL DISEASES, P1
   World Health Organization, 2011, WHO DIAGN EV SER
   World Health Organization Food and Agriculture Organization of the United Nations Evaluation of Certain Food Additives, 2010, WHO TECHN REP SER
NR 37
TC 26
Z9 26
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2017
VL 11
IS 6
AR e0005706
DI 10.1371/journal.pntd.0005706
PG 25
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EZ9WL
UT WOS:000405080700066
PM 28662034
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Santos, MLB
   Nico, D
   de Oliveira, FA
   Barreto, AS
   Palatnik-De-Sousa, I
   Carrillo, E
   Moreno, J
   de Luca, PM
   Morrot, A
   Rosa, DS
   Palatnik, M
   Bani-Correa, C
   de Almeida, RP
   Palatnik-de-Sousa, CB
AF Barbosa Santos, Micheli Luize
   Nico, Dirlei
   de Oliveira, Fabricia Alvisi
   Barreto, Aline Silva
   Palatnik-de-Sousa, Iam
   Carrillo, Eugenia
   Moreno, Javier
   de Luca, Paula Mello
   Morrot, Alexandre
   Rosa, Daniela Santoro
   Palatnik, Marcos
   Bani-Correa, Cristiane
   de Almeida, Roque Pacheco
   Palatnik-de-Sousa, Clarisa Beatriz
TI Leishmania donovani nucleoside hydrolase (NH36) Domains induce T-cell
   cytokine responses in human Visceral leishmaniasis
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE human visceral leishmaniasis; nucleoside hydrolase; recombinant domains;
   T cell epitopes; epitope vaccine design; Leishmania donovani; Leishmania
   infantum chagasi
ID DELAYED-TYPE HYPERSENSITIVITY; DNA VACCINE; KALA-AZAR; DERMAL
   LEISHMANIASIS; SYNTHETIC VACCINE; TERMINAL DOMAINS; AMPHOTERICIN-B;
   CLINICAL FORMS; BALB/C MICE; FML-VACCINE
AB Development of immunoprotection against visceral leishmaniasis (VL) focused on the identification of antigens capable of inducing a Th1 immune response. Alternatively, antigens targeting the CD8 and T-regulatory responses are also relevant in VL pathogenesis and worthy of being included in a preventive human vaccine. We assessed in active and cured patients and VL asymptomatic subjects the clinical signs and cytokine responses to the Leishmania donovani nucleoside hydrolase NH36 antigen and its N-(F1), central (F2) and C-terminal (F3) domains. As markers of VL resistance, the F2 induced the highest levels of IFN-gamma, IL-1 beta, and TNF-a and, together with F1, the strongest secretion of IL-17, IL-6, and IL-10 in DTH+ and cured subjects. F2 also promoted the highest frequencies of CD3(+)CD4(+)IL-2(+)TNF-alpha-IFN-gamma(-), CD3(+)CD4(+)IL-2(+)TNF-alpha+IFN-gamma(-), CD3(+)CD4(+)IL-2(+)TNF-alpha-IFN-gamma(+), and CD3(+)CD4(+)IL-2(+)TNF-alpha+IFN-gamma(+) T cells in cured and asymptomatic subjects. Consistent with this, the IFN-gamma increase was correlated with decreased spleen (R = -0.428, P = 0.05) and liver sizes (R = -0.428, P = 0.05) and with increased hematocrit counts (R = 0.532, P = 0.015) in response to F1 domain, and with increased hematocrit (R = 0.512, P 0.02) and hemoglobin counts (R = 0.434, P = 0.05) in response to F2. Additionally, IL-17 increases were associated with decreased spleen and liver sizes in response to F1 (R = -0.595, P = 0.005) and F2 (R = -0.462, P = 0.04). Conversely, F1 and F3 increased the CD3(+)CD8(+)IL-2(+)TNF-alpha-IFN-gamma(-), CD3(+)CD8(+)IL-2(+)TNF-alpha+IFN-gamma(-), and CD3(+)CD8(+)IL-2(+)TNF-alpha+IFN-gamma(+) T cell frequencies of VL patients correlated with increased spleen and liver sizes and decreased hemoglobin and hematocrit values. Therefore, cure and acquired resistance to VL correlate with the CD4(+)-Th1 and Th-17 T-cell responses to F2 and F1 domains. Clinical VL outcomes, by contrast, correlate with CD8(+) T-cell responses against F3 and F1, potentially involved in control of the early infection. The in silico-predicted NH36 epitopes are conserved and bind to many HL-DR and HLA and B allotypes. No human vaccine against Leishmania is available thus far. In this investigation, we identified the NH36 domains and epitopes that induce CD4(+) and CD8(+) T cell responses, which could be used to potentiate a human universal T-epitope vaccine against leishmaniasis.
C1 [Barbosa Santos, Micheli Luize; de Oliveira, Fabricia Alvisi; Barreto, Aline Silva; de Almeida, Roque Pacheco] Univ Fed Sergipe HU UFS, Dept Med, Univ Hosp, Mol Biol Lab, Aracaju, Sergipe, Brazil.
   [Nico, Dirlei; Palatnik-de-Sousa, Clarisa Beatriz] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Microbiol Geral, Lab Biol Bioquim Leishmania, Rio De Janeiro, RJ, Brazil.
   [Palatnik-de-Sousa, Iam] Pontificia Univ Catolica Rio de Janeiro, Lab Biometrol, Programa Posgrad Metrol, Rio De Janeiro, RJ, Brazil.
   [Carrillo, Eugenia; Moreno, Javier] Inst Salud Carlos III, WHO Collaborating Ctr Leishmaniasis, Ctr Nacl Microbiol, Madrid, Comunidad De Ma, Spain.
   [de Luca, Paula Mello] Inst Oswaldo Cruz, Lab Imunoparasitol, Rio De Janeiro, RJ, Brazil.
   [Morrot, Alexandre] Univ Fed Rio de Janeiro, Inst Microbiologia Paulo de Goes, Dept Imunol, Lab Imunol Integrada, Rio De Janeiro, RJ, Brazil.
   [Rosa, Daniela Santoro; de Almeida, Roque Pacheco; Palatnik-de-Sousa, Clarisa Beatriz] Univ Sao Paulo, Fac Med, Inst Invest Imunol, Sao Paulo, Brazil.
   [Carrillo, Eugenia; Rosa, Daniela Santoro] Univ Fed Sao Paulo UNIFESP, Dept Microbiol Imunol & Parasitol, Lab Vacinas Expt, Sao Paulo, SP, Brazil.
   [Palatnik, Marcos] Univ Fed Rio de Janeiro, Fac Med, Lab Imunohematol, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, RJ, Brazil.
   [Bani-Correa, Cristiane] Univ Fed Sergipe HU UFS, Dept Morfol, Aracaju, Sergipe, Brazil.
RP Palatnik-de-Sousa, CB (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Microbiol Geral, Lab Biol Bioquim Leishmania, Rio De Janeiro, RJ, Brazil.; Palatnik-de-Sousa, CB (corresponding author), Univ Sao Paulo, Fac Med, Inst Invest Imunol, Sao Paulo, Brazil.
EM immgcpa@micro.ufrj.br
RI Rosa, Daniela S/D-2190-2012; Carrillo, Eugenia/F-2058-2018; Correa,
   Cristiane Bani/AAR-9384-2020
OI Rosa, Daniela S/0000-0003-4536-891X; Carrillo,
   Eugenia/0000-0002-7869-7915; Palatnik-de-Sousa, Clarisa
   B./0000-0002-6231-0608; Moreno, Javier/0000-0003-0087-4659
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPQ)National Council for Scientific and Technological Development
   (CNPq) [300639/2003-1, 310977/2014-2, 310797/2015-2, 404400/2012-4];
   Fundacao Carlos Chagas de Amparo a Pesquisa do Estado de Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E-26-201.583/2014, E-26-102957/2011,
   E-26/111.682/2013, E-26/102415/2010, E-26/201747/2015]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel SuperiorCAPES [23038.005304/2011-0];
   CNPQ-Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe-PRONEX [12/2009]; FAPITEC CNPq (PRONEX) [019.203.02712/2009-8];
   VII PN I+D+I; FEDER FundsEuropean Union (EU) [RICET RD12/0018/0003]
FX This work was supported by the following: Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPQ) (Fellowships
   300639/2003-1 to MP, 310977/2014-2 to CP-d-S, 310797/2015-2 to AM, and
   grant 404400/2012-4 to CP-d-S, MP, PL, RA, JM, EC, and AM); by Fundacao
   Carlos Chagas de Amparo a Pesquisa do Estado de Rio de Janeiro (FAPERJ)
   (grant E-26-201.583/2014, E-26-102957/2011, and E-26/111.682/2013 to
   CP-d-S, and fellowships E-26/102415/2010 and E-26/201747/2015 to DN); by
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (grant
   23038.005304/2011-0 to MS), by CNPQ-Fundacao de Apoio a Pesquisa e a
   Inovacao Tecnologica do Estado de Sergipe-PRONEX (12/2009); and by
   FAPITEC CNPq (PRONEX) (019.203.02712/2009-8) to RA. EC was supported by
   a research contract funded via VII PN I+D+I 2013-2016 and FEDER Funds
   (RICET RD12/0018/0003).
CR Aguilar-Be I, 2005, INFECT IMMUN, V73, P812, DOI 10.1128/IAI.73.2.812-819.2005
   Al-Wabel MA, 2007, AM J TROP MED HYG, V77, P1060, DOI 10.4269/ajtmh.2007.77.1060
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Costa ASA, 2012, MEM I OSWALDO CRUZ, V107, P735, DOI 10.1590/S0074-02762012000600005
   [Anonymous], 2014, BLAST BAS LOC AL SEA
   ANTUNES CM, 1986, INT J EPIDEMIOL, V15, P572, DOI 10.1093/ije/15.4.572
   Ato M, 2002, NAT IMMUNOL, V3, P1185, DOI 10.1038/ni861
   Basu R, 2007, J INFECT DIS, V195, P1373, DOI 10.1086/513439
   Bhattacharya P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004422
   Borja-Cabrera GP, 2009, PROCEDIA VACCINOL, V1, P104, DOI 10.1016/j.provac.2009.07.019
   CARVALHO EM, 1992, J INFECT DIS, V165, P535, DOI 10.1093/infdis/165.3.535
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   Chamakh-Ayari R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092708
   Chamizo C, 2005, VET IMMUNOL IMMUNOP, V103, P67, DOI 10.1016/j.vetimm.2004.08.010
   CHER DJ, 1987, J IMMUNOL, V138, P3688
   Coler RN, 2015, CLIN TRANSL IMMUNOL, V4, DOI 10.1038/cti.2015.6
   Costa DL, 2013, PATHOG GLOB HEALTH, V107, P78, DOI 10.1179/2047773213Y.0000000078
   Cui LW, 2001, GENE, V280, P153, DOI 10.1016/S0378-1119(01)00768-5
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   De Groot AS, 2008, CURR OPIN PHARMACOL, V8, P620, DOI 10.1016/j.coph.2008.08.002
   De Groot AS, 2002, IMMUNOL CELL BIOL, V80, P255, DOI 10.1046/j.1440-1711.2002.01092.x
   de Oliveira FA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141265
   de Souza EP, 2001, VACCINE, V19, P3104, DOI 10.1016/S0264-410X(01)00031-7
   Duarte A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124786
   Fernandes AP, 2012, CURR OPIN MICROBIOL, V15, P476, DOI 10.1016/j.mib.2012.05.002
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   Freitas EO, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004297
   Freitas EO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124183
   Gamboa-Leon R, 2006, VACCINE, V24, P4863, DOI 10.1016/j.vaccine.2006.03.005
   Gurunathan S, 2000, J IMMUNOL, V165, P915, DOI 10.4049/jimmunol.165.2.915
   HO M, 1982, T ROY SOC TROP MED H, V76, P741, DOI 10.1016/0035-9203(82)90095-5
   Jeronimo SMB, 2007, GENES IMMUN, V8, P539, DOI 10.1038/sj.gene.6364422
   Jeronimo SMB, 2007, J INFECT DIS, V196, P1261, DOI 10.1086/521682
   Jeronimo SMB, 2004, SCAND J INFECT DIS, V36, P443, DOI 10.1080/00365540410020451
   Kao DJ, 2009, CHEM BIOL DRUG DES, V74, P33, DOI 10.1111/j.1747-0285.2009.00825.x
   Kaye PM, 2011, CLIN MICROBIOL INFEC, V17, P1462, DOI 10.1111/j.1469-0691.2011.03610.x
   Kaye PM, 2004, IMMUNOL REV, V201, P239, DOI 10.1111/j.0105-2896.2004.00188.x
   Khadem F, 2014, FUTURE MICROBIOL, V9, P901, DOI [10.2217/FMB.14.43, 10.2217/fmb.14.43]
   Khalil EAG, 2000, LANCET, V356, P1565, DOI 10.1016/S0140-6736(00)03128-7
   Kolpe A, 2017, EXPERT REV VACCINES, V16, P123, DOI 10.1080/14760584.2017.1240041
   Kumar R, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00251
   Kurkjian KM, 2006, CYTOM PART A, V69A, P353, DOI 10.1002/cyto.a.20256
   Launois P, 2007, MICROBES INFECT, V9, P1260, DOI 10.1016/j.micinf.2007.05.017
   Lima DS, 2013, NAT MED, V19, P909, DOI 10.1038/nm.3221
   Liu H., 2015, BIOMED RES INT, V2015, DOI DOI 10.1155/2015/594109
   Lovane E, 2008, BIOCHEMISTRY-US, V47, P4418, DOI 10.1021/bi702448s
   Lucero E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003699
   Mauricio IL, 2006, INT J PARASITOL, V36, P757, DOI 10.1016/j.ijpara.2006.03.006
   MAYRINK W, 1979, T ROY SOC TROP MED H, V73, P385, DOI 10.1016/0035-9203(79)90159-7
   Mendez S, 2001, J IMMUNOL, V166, P5122, DOI 10.4049/jimmunol.166.8.5122
   Mondal D, 2014, LANCET GLOB HEALTH, V2, pE51, DOI 10.1016/S2214-109X(13)70118-9
   MULLER I, 1992, EUR J IMMUNOL, V22, P3063, DOI 10.1002/eji.1830221206
   Nico D, 2009, PROCEDIA VACCINOL, V1, P115, DOI 10.1016/j.provac.2009.07.021
   Nico D, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00273
   Nico D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00189
   Nico D, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000866
   Nogueira FS, 2005, VACCINE, V23, P4805, DOI 10.1016/j.vaccine.2005.05.011
   Nylen S, 2007, TRENDS IMMUNOL, V28, P378, DOI 10.1016/j.it.2007.07.004
   Okwor IB, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003300
   Palatnik de Sousa CB, 1996, REV SOC BRAS MED TRO, V29, P153
   Palatnik-de-Sousa CB, 2008, EXPERT REV VACCINES, V7, P833, DOI 10.1586/14760584.7.6.833
   Palatnik-de-Sousa CB, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-197
   Palatnik-De-Sousa CB, 2009, VACCINE, V27, P3505, DOI 10.1016/j.vaccine.2009.03.045
   Parra-Lopez C, 2006, J BIOL CHEM, V281, P14907, DOI 10.1074/jbc.M511571200
   Plassmeyer ML, 2009, J BIOL CHEM, V284, P26951, DOI 10.1074/jbc.M109.013706
   Potestio M, 2004, IMMUNOLOGY, V113, P260, DOI 10.1111/j.1365-2567.2004.01948.x
   Ramos PK, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6937980
   Rodriguesa MHC, 2005, INT J PARASITOL, V35, P185, DOI 10.1016/j.ijpara.2004.11.003
   SACKS DL, 1987, J IMMUNOL, V138, P908
   Saha S, 2007, J IMMUNOL, V179, P5592, DOI 10.4049/jimmunol.179.8.5592
   Saini DK, 2002, PROTEIN EXPRES PURIF, V25, P203, DOI 10.1006/prep.2002.1628
   Saraiva EM, 2006, VACCINE, V24, P2423, DOI 10.1016/j.vaccine.2005.11.061
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Seyed N, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00467
   Shi WX, 1999, J BIOL CHEM, V274, P21114, DOI 10.1074/jbc.274.30.21114
   Singh B, 2012, VACCINE, V30, P3834, DOI 10.1016/j.vaccine.2012.03.068
   Singh OP, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001874
   Stober CB, 2012, AM J TROP MED HYG, V87, P663, DOI 10.4269/ajtmh.2012.12-0180
   Sundar S, 1999, J Assoc Physicians India, V47, P186
   Uzonna JE, 2004, J EXP MED, V199, P1559, DOI 10.1084/jem.20040172
   Versees W, 2009, BBA-PROTEINS PROTEOM, V1794, P953, DOI 10.1016/j.bbapap.2009.02.011
   ZANDIEH M, 2015, J MICROB BIOCH TECHN, V7, P427, DOI DOI 10.4172/1948-5948.1000250
NR 82
TC 15
Z9 15
U1 0
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAR 7
PY 2017
VL 8
AR 227
DI 10.3389/fimmu.2017.00227
PG 19
WC Immunology
SC Immunology
GA EM8FV
UT WOS:000395547800001
PM 28321221
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Fonseca, ABD
   Simon, MD
   Cazzaniga, RA
   de Moura, TR
   de Almeida, RP
   Duthie, MS
   Reed, SG
   de Jesus, AR
AF de Lima Fonseca, Adriana Barbosa
   Simon, Marise do Vale
   Cazzaniga, Rodrigo Anselmo
   de Moura, Tatiana Rodrigues
   de Almeida, Roque Pacheco
   Duthie, Malcolm S.
   Reed, Steven G.
   de Jesus, Amelia Ribeiro
TI The influence of innate and adaptative immune responses on the
   differential clinical outcomes of leprosy
SO INFECTIOUS DISEASES OF POVERTY
LA English
DT Review
DE Leprosy; Clinical presentation; Immunology; Innate immunity; Immune
   pathogenesis
ID TUMOR-NECROSIS-FACTOR; PERIPHERAL-NERVE PREDILECTION; TOLL-LIKE
   RECEPTOR-2; MYCOBACTERIUM-LEPRAE; SCAVENGER RECEPTOR; CYTOKINE PROFILES;
   DENDRITIC CELLS; IN-VITRO; TYPE-1; EXPRESSION
AB Leprosy is a chronic infectious disease caused by Mycobacterium leprae. According to official reports from 121 countries across five WHO regions, there were 213 899 newly diagnosed cases in 2014. Although leprosy affects the skin and peripheral nerves, it can present across a spectrum of clinical and histopathological forms that are strongly influenced by the immune response of the infected individuals. These forms comprise the extremes of tuberculoid leprosy (TT), with a M. leprae-specific Th1, but also a Th17, response that limits M. leprae multiplication, through to lepromatous leprosy (LL), with M. leprae-specific Th2 and T regulatory responses that do not control M. leprae replication but rather allow bacterial dissemination. The interpolar borderline clinical forms present with similar, but less extreme, immune biases. Acute inflammatory episodes, known as leprosy reactions, are complications that may occur before, during or after treatment, and cause further neurological damages that can cause irreversible chronic disabilities. This review discusses the innate and adaptive immune responses, and their interactions, that are known to affect pathogenesis and influence the clinical outcome of leprosy.
C1 [de Lima Fonseca, Adriana Barbosa; Simon, Marise do Vale; Cazzaniga, Rodrigo Anselmo; de Moura, Tatiana Rodrigues; de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Dept Med, Sao Cristovao, Sergipe, Brazil.
   [Duthie, Malcolm S.; Reed, Steven G.] Infect Dis Res Inst, Seattle, WA USA.
   [de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] CNPq, Inst Nacionais Ciencia & Tecnol, Inst Invest Imunol, Sao Paulo, SP, Brazil.
RP de Jesus, AR (corresponding author), Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Dept Med, Sao Cristovao, Sergipe, Brazil.; de Jesus, AR (corresponding author), CNPq, Inst Nacionais Ciencia & Tecnol, Inst Invest Imunol, Sao Paulo, SP, Brazil.
EM ameliaribeirodejesus@gmail.com
RI , Tatiana/AAN-1194-2020; Cazzaniga, Rodrigo/AAV-6694-2020
OI , Tatiana/0000-0002-7442-4434; Duthie, Malcolm/0000-0002-8515-5516
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [Edital MCT/CNPq No 14/2009 - Universal]; Fundacao de Apoio a Pesquisa e
   a Inovacao Tecnologica do Estado de Sergipe - FAPITEC/SE/Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq; EDITAL
   FAPITEC/SE/FUNTEC/CNPq [12/2009, 019.203.02712/2009-8]; American Leprosy
   Missions; CAPESCAPES
FX This work was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPq, Edital MCT/CNPq No 14/2009 - Universal,
   the Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe - FAPITEC/SE/Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico - CNPq, EDITAL FAPITEC/SE/FUNTEC/CNPq No. 12/2009 (Programa
   de Nucleos de Excelencia - PRONEX), Process no. 019.203.02712/2009-8 and
   American Leprosy Missions. MS and RAC received a fellowship from CAPES.
   ARJ is a CNPq investigator.
CR Aiba Y, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/258164
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P461
   [Anonymous], 1994, World Health Organ Tech Rep Ser, V847, P1
   BARNES PF, 1992, INFECT IMMUN, V60, P1441, DOI 10.1128/IAI.60.4.1441-1446.1992
   Belgaumkar VA, 2007, LEPROSY REV, V78, P223
   Bhat Ramesh Marne, 2012, Interdiscip Perspect Infect Dis, V2012, P181089, DOI 10.1155/2012/181089
   Bleharski JR, 2003, SCIENCE, V301, P1527, DOI 10.1126/science.1087785
   Bratschi MW, 2015, LEPROSY REV, V86, P142
   Buhl T, 2015, J INVEST DERMATOL, V135, P2198, DOI 10.1038/jid.2015.141
   Cho SN, 2001, CLIN DIAGN LAB IMMUN, V8, P138, DOI 10.1128/CDLI.8.1.138-142.2001
   Cruz D, 2008, J CLIN INVEST, V118, P2917, DOI 10.1172/JCI34189
   de Mattos KA, 2012, MEM I OSWALDO CRUZ, V107, P156, DOI 10.1590/S0074-02762012000900023
   Fava VM, 2015, J INFECT DIS, V211, P968, DOI 10.1093/infdis/jiu566
   Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002
   Gaschignard J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004345
   Hagge DA, 2009, AM J PATHOL, V174, P1379, DOI 10.2353/ajpath.2009.080550
   Halvorsen B, 2005, J LIPID RES, V46, P211, DOI 10.1194/jlr.M400324-JLR200
   Hirai KE, 2016, MICROB PATHOGENESIS, V91, P18, DOI 10.1016/j.micpath.2015.11.013
   Jardim MR, 2007, ARQ NEURO-PSIQUIAT, V65, P969, DOI 10.1590/S0004-282X2007000600009
   JOB C K, 1971, International Journal of Leprosy and Other Mycobacterial Diseases, V39, P251
   JOB CK, 1970, ARCH PATHOL, V89, P195
   JOB CK, 1989, INT J LEPROSY, V57, P532
   Jullien D, 1997, J IMMUNOL, V158, P800
   Kahawita IP, 2008, T ROY SOC TROP MED H, V102, P329, DOI 10.1016/j.trstmh.2008.01.004
   KAPLAN G, 1991, J EXP MED, V173, P993, DOI 10.1084/jem.173.4.993
   Khadge S, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1128-0
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   Krutzik SR, 2005, NAT MED, V11, P653, DOI 10.1038/nm1246
   Krutzik SR, 2003, NAT MED, V9, P525, DOI 10.1038/nm864
   Lastoria JC, 2014, AN BRAS DERMATOL, V89, P205, DOI 10.1590/abd1806-4841.20142450
   LOCKWOOD DNJ, 1993, INT J LEPROSY, V61, P8
   Maeda Y, 2005, INFECT IMMUN, V73, P2744, DOI 10.1128/IAI.73.5.2744-2750.2005
   Massone C, 2011, BRIT J DERMATOL, V165, P321, DOI 10.1111/j.1365-2133.2011.10412.x
   Massone C, 2010, AM J DERMATOPATH, V32, P251, DOI 10.1097/DAD.0b013e3181b7fc56
   Misch EA, 2010, MICROBIOL MOL BIOL R, V74, P589, DOI 10.1128/MMBR.00025-10
   Modlin RL, 2002, SKIN PHARMACOL APPL, V15, P1, DOI 10.1159/000058177
   Modlin RL, 2010, CURR OPIN IMMUNOL, V22, P48, DOI 10.1016/j.coi.2009.12.001
   Moraes MO, 1999, SCAND J IMMUNOL, V50, P541
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Motta Ana Carolina F., 2010, Braz. Dent. J., V21, P158, DOI 10.1590/S0103-64402010000200012
   Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2
   Okada S, 2015, SCIENCE, V349, P606, DOI 10.1126/science.aaa4282
   Oliveira RB, 2003, INFECT IMMUN, V71, P1427, DOI 10.1128/IAI.71.3.1427-1433.2003
   Palermo ML, 2012, AM J TROP MED HYG, V86, P878, DOI 10.4269/ajtmh.2012.12-0088
   PARTHASARATHY S, 1987, P NATL ACAD SCI USA, V84, P537, DOI 10.1073/pnas.84.2.537
   Partida-Sanchez S, 1998, INT ARCH ALLERGY IMM, V116, P60, DOI 10.1159/000023926
   Penna GO, 2008, REV SOC BRAS MED TRO, V41, P575, DOI 10.1590/S0037-86822008000600006
   Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9
   Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456
   Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3
   Rambukkana A, 2001, CURR OPIN MICROBIOL, V4, P21, DOI 10.1016/S1369-5274(00)00159-4
   Ranque B, 2007, CLIN INFECT DIS, V44, P33, DOI 10.1086/509923
   Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881
   Richard AC, 2015, J LEUKOCYTE BIOL, V98, P333, DOI 10.1189/jlb.3RI0315-095R
   Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255
   RIDLEY DS, 1974, B WORLD HEALTH ORGAN, V51, P451
   RIENECK K, 1993, IMMUNOL LETT, V37, P131, DOI 10.1016/0165-2478(93)90022-T
   Rodrigues IA, 2016, INT J INFECT DIS, V45, P118, DOI 10.1016/j.ijid.2016.02.018
   Russell DG, 2009, NAT IMMUNOL, V10, P943, DOI 10.1038/ni.1781
   Sadhu S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004338
   Saini C, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004592
   SALGAME P, 1992, CHEM IMMUNOL, V54, P44
   SAMPAIO EP, 1993, J INFECT DIS, V168, P408, DOI 10.1093/infdis/168.2.408
   SARNO EN, 1991, CLIN EXP IMMUNOL, V84, P103
   Scollard DM, 2006, CLIN INFECT DIS, V43, pE19, DOI 10.1086/505222
   Scollard DM, 2015, CLIN DERMATOL, V33, P46, DOI 10.1016/j.clindermatol.2014.07.008
   Scollard DM, 2008, LEPROSY REV, V79, P242
   Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006
   Shen JP, 2009, LEPROSY REV, V80, P164
   Quaresma JAS, 2009, AM J DERMATOPATH, V31, P527, DOI 10.1097/DAD.0b013e31819f1997
   Smith WCS, 2004, BMJ-BRIT MED J, V328, P1459, DOI 10.1136/bmj.38107.645926.AE
   Stefani MM, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-75
   Stefani MMA, 2003, J INFECT DIS, V188, P1024, DOI 10.1086/378410
   Terpstra V, 1998, P NATL ACAD SCI USA, V95, P1806, DOI 10.1073/pnas.95.4.1806
   Towers TL, 1998, J BIOL CHEM, V273, P10338, DOI 10.1074/jbc.273.17.10338
   Triccas JA, 1998, INFECT IMMUN, V66, P2684, DOI 10.1128/IAI.66.6.2684-2690.1998
   TRIPP CS, 1995, J CLIN INVEST, V95, P1628, DOI 10.1172/JCI117837
   TUNG KSK, 1987, CLIN EXP IMMUNOL, V69, P10
   Van Veen NHJ, 2008, LEPROSY REV, V79, P361
   Vieira AP, 2016, AM J TROP MED HYG, V94, P721, DOI 10.4269/ajtmh.15-0673
   Wheat WH, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003405
   YAMAMURA M, 1992, J IMMUNOL, V149, P1470
   YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582
NR 83
TC 26
Z9 27
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-5162
EI 2049-9957
J9 INFECT DIS POVERTY
JI Infect. Dis. Poverty
PD FEB 6
PY 2017
VL 6
AR 5
DI 10.1186/s40249-016-0229-3
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EL0EA
UT WOS:000394294500001
PM 28162092
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Campos, R
   Santos, M
   Tunon, G
   Cunha, L
   Magalhaes, L
   Moraes, J
   Ramalho, D
   Lima, S
   Pacheco, JA
   Lipscomb, M
   de Jesus, AR
   de Almeida, RP
AF Campos, Roseane
   Santos, Marcio
   Tunon, Gabriel
   Cunha, Luana
   Magalhaes, Lucas
   Moraes, Juliana
   Ramalho, Danielle
   Lima, Sanmy
   Pacheco, Jose Antonio
   Lipscomb, Michael
   de Jesus, Amelia Ribeiro
   de Almeida, Roque Pacheco
TI Epidemiological aspects and spatial distribution of human and canine
   visceral leishmaniasis in an endemic area in northeastern Brazil
SO GEOSPATIAL HEALTH
LA English
DT Article
DE Leishmaniasis; Epidemiological monitoring; Dog diseases; Spatial
   distribution; Brazil
ID INFANTUM INFECTION; RURAL AREA; SAND FLIES; DOGS; TRANSMISSION;
   RESERVOIR
AB Visceral leishmaniasis (VL) is a systemic disease endemic in tropical countries and transmitted through sand flies. In particular, Canis familiaris (or domesticated dogs) are believed to be a major urban reservoir for the parasite causing the disease Leishmania. The average number of human VL cases was 58 per year in the state of Sergipe. The city of Aracaju, capital of Sergipe in Northeastern Brazil, had 159 cases of VL in humans. Correlatively, the percentage of serologically positive dogs for leishmaniasis increased from 4.73% in 2008 to 12.69% in 2014. Thus, these studies aimed to delineate the spatial distribution and epidemiological aspects of human and canine VL as mutually supportive for increased incidence. The number of human cases of VL and the frequency of canine positive serology for VL both increased between 2008 and 2014. Spatial distribution analyses mapped areas of the city with the highest concentration of human and canine VL cases. The neighbourhoods that showed the highest disease frequency were located on the outskirts of the city and in urbanised areas or subjected to development. Exponential increase in VL-positive dogs further suggests that the disease is expanding in urban areas, where it can serve as a reservoir for transmission of dogs to humans via the sand fly vector.
C1 [Campos, Roseane; Santos, Marcio; Tunon, Gabriel; Cunha, Luana; Magalhaes, Lucas; Moraes, Juliana; Ramalho, Danielle; de Jesus, Amelia Ribeiro; de Almeida, Roque Pacheco] Univ Fed Sergipe, Mol Biol Lab, Sergipe, Brazil.
   [Lima, Sanmy; Pacheco, Jose Antonio] Univ Fed Sergipe, Dept Geol, Sergipe, Brazil.
   [Lipscomb, Michael] Howard Univ, Dept Biol, Washington, DC 20059 USA.
   [de Jesus, Amelia Ribeiro; de Almeida, Roque Pacheco] Univ Fed Sergipe, Dept Med, Sergipe, Brazil.
   [de Jesus, Amelia Ribeiro; de Almeida, Roque Pacheco] Inst Nacl Ciencia & Tecnol, Inst Invest Imunol, Ave Doutor Eneas de Carvalho Aguiai 44, Sao Paulo, SP, Brazil.
RP de Almeida, RP (corresponding author), Inst Nacl Ciencia & Tecnol, Inst Invest Imunol, Ave Doutor Eneas de Carvalho Aguiai 44, Sao Paulo, SP, Brazil.
EM roquepachecoalmeida@gmail.com
OI Sousa Magalhaes, Lucas/0000-0002-2169-7463; Campos,
   Roseane/0000-0001-6217-9278
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [032/2010]; CNPqNational Council for Scientific and Technological
   Development (CNPq) [552721/2011-5]
FX this work was supported by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES), Edital No 032/2010 (ARJ); CNPq). Grants:
   PROCAD/CASADINHO- no 552721/2011-5 (RPA). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Amóra Sthenia Santos Albano, 2006, Cienc. Rural, V36, P1854, DOI 10.1590/S0103-84782006000600029
   Belo VS, 2013, VET PARASITOL, V195, P1, DOI 10.1016/j.vetpar.2013.03.010
   Bhunia GS, 2010, GEOSPATIAL HEALTH, V4, P155, DOI 10.4081/gh.2010.197
   Dantas-Torres F, 2014, ACTA TROP, V137, P67, DOI 10.1016/j.actatropica.2014.04.034
   Dantas-Torres F, 2012, TRENDS PARASITOL, V28, P531, DOI 10.1016/j.pt.2012.08.007
   de Almeida AS, 2011, AM J TROP MED HYG, V84, P681, DOI 10.4269/ajtmh.2011.10-0325
   de Alvarenga DG, 2010, REV SOC BRAS MED TRO, V43, P194, DOI 10.1590/S0037-86822010000200017
   de Oliveira AG, 2008, ACTA TROP, V107, P238, DOI 10.1016/j.actatropica.2008.06.002
   De Oliveira EF, 2013, J MED ENTOMOL, V50, P277, DOI 10.1603/ME12082
   Faye B, 2011, T ROY SOC TROP MED H, V105, P333, DOI 10.1016/j.trstmh.2011.02.009
   Felipe K, 2014, REV SOC BRAS MED TRO, V47, P607
   Fischer D, 2010, GEOSPATIAL HEALTH, V5, P59, DOI 10.4081/gh.2010.187
   Góes Marco Aurélio de Oliveira, 2012, Rev. bras. epidemiol., V15, P298, DOI 10.1590/S1415-790X2012000200007
   Gouvea MV, 2007, ACTA TROP, V104, P99, DOI 10.1016/j.actatropica.2007.07.010
   Gramiccia M, 2011, VET PARASITOL, V181, P23, DOI 10.1016/j.vetpar.2011.04.019
   Harhay MO, 2011, TRENDS PARASITOL, V27, P403, DOI 10.1016/j.pt.2011.04.001
   Lara-Silva FD, 2015, ACTA TROP, V148, P128, DOI 10.1016/j.actatropica.2015.04.002
   Lopes EGP, 2010, ARQ BRAS MED VET ZOO, V62, P1062, DOI 10.1590/S0102-09352010000500007
   Quinnell RJ, 2003, IMMUNOGENETICS, V55, P23, DOI 10.1007/s00251-003-0545-1
   Ribeiro VM, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-8
   Silva Alba Valéria Machado da, 2005, Cad. Saúde Pública, V21, P324, DOI 10.1590/S0102-311X2005000100036
   Travi BL, 2002, RES VET SCI, V72, P83, DOI 10.1053/rvsc.2001.0527
   Tsegaw T, 2013, GEOSPATIAL HEALTH, V7, P299, DOI 10.4081/gh.2013.88
   Werneck GL, 2014, REV SAUDE PUBL, V48, P851, DOI 10.1590/S0034-8910.2014048005615
   WHO, 2010, 1 WHO REP NEGL TROP
NR 25
TC 9
Z9 9
U1 0
U2 0
PU UNIV NAPLES FEDERICO II
PI NAPLES
PA FAC VET MED, DEP PATHOLOGY & ANIMAL HEALTH, VET PARASITOLOGY, VIA DELLA
   VETERINARIA 1, NAPLES, 80137, ITALY
SN 1827-1987
EI 1970-7096
J9 GEOSPATIAL HEALTH
JI Geospatial Health
PY 2017
VL 12
IS 1
BP 67
EP 73
AR 503
DI 10.4081/gh.2017.503
PG 7
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA EU6DL
UT WOS:000401124100008
PM 28555473
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Campos, VC
   Barrios, MR
   Salvatori, R
   de Almeida, RP
   de Melo, EV
   Nascimento, ACS
   de Jesus, AR
   Aguiar-Oliveira, MH
AF Campos, Viviane C.
   Barrios, Monica R.
   Salvatori, Roberto
   de Almeida, Roque Pacheco
   de Melo, Enaldo V.
   Nascimento, Ana C. S.
   de Jesus, Amelia Ribeiro
   Aguiar-Oliveira, Manuel H.
TI Infectious diseases and immunological responses in adult subjects with
   lifetime untreated, congenital GH deficiency
SO ENDOCRINE
LA English
DT Article
DE Cellular and humoral immune response; Isolated GH deficiency; Vaccines
   and skin tests; Infectious diseases
ID GROWTH-HORMONE DEFICIENCY; X-LINKED HYPOGAMMAGLOBULINEMIA; FACTOR-I;
   IMMUNE-SYSTEM; RECEPTOR GENE; HOMOZYGOUS MUTATION; BINDING-PROTEINS;
   CELL DEVELOPMENT; PROLACTIN; INSENSITIVITY
AB Growth hormone is important for the development and function of the immune system, but there is controversy on whether growth hormone deficiency is associated to immune disorders. A model of isolated growth hormone deficiency may clarify if the lack of growth hormone is associated with increased susceptibility to infections, or with an altered responsiveness of the immune system. We have studied the frequency of infectious diseases and the immune function in adults with congenital, untreated isolated growth hormone deficiency. In a cross-sectional study, 35 adults with isolated growth hormone deficiency due to a homozygous mutation in the growth hormone releasing hormone receptor gene and 31 controls were submitted to a clinical questionnaire, physical examination serology for tripanosomiasis, leishmaniasis, HIV, tetanus, hepatitis B and C, and serum total immunoglobulin G, M, E and A measurement. The immune response was evaluated in a subset of these subjects by skin tests and response to vaccination for hepatitis B, tetanus, and bacillus Calmette-Gu,rin. There was no difference between the groups in history of infectious diseases and baseline serology. Isolated growth hormone deficiency subjects had lower total IgG, but within normal range. There was no difference in the response to any of the vaccinations or in the positivity to protein Purified Derived, streptokinase or candidin. Adult untreated isolated growth hormone deficiency does not cause an increased frequency of infectious diseases, and does not alter serologic tests, but is associated with lower total IgG levels, without detectable clinical impact.
C1 [Campos, Viviane C.; de Melo, Enaldo V.; Nascimento, Ana C. S.; Aguiar-Oliveira, Manuel H.] Univ Fed Sergipe, Div Endocrinol, BR-49060100 Aracaju, Sergipe, Brazil.
   [Barrios, Monica R.; de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Div Immunol, BR-49060100 Aracaju, Sergipe, Brazil.
   [Barrios, Monica R.; de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Mol Biol Lab, BR-49060100 Aracaju, Sergipe, Brazil.
   [Salvatori, Roberto] Johns Hopkins Univ, Sch Med, Div Endocrinol Diabet & Metab, Baltimore, MD 21287 USA.
RP Salvatori, R (corresponding author), Johns Hopkins Univ, Sch Med, Div Endocrinol Diabet & Metab, Baltimore, MD 21287 USA.
EM salvator@jhmi.edu
FU Foundation Research and Technological Innovation of
   Sergipe-FAPITEC/SE/FUNTEC/CNPq [12/2009]
FX This work was supported by Foundation Research and Technological
   Innovation of Sergipe-FAPITEC/SE/FUNTEC/CNPq No. 12/2009 (to A.R.J.).
CR ABBASSI V, 1985, PEDIATR RES, V19, P299, DOI 10.1203/00006450-198503000-00009
   Aguiar-Oliveira MH, 2010, J CLIN ENDOCR METAB, V95, P714, DOI 10.1210/jc.2009-1879
   Aguiar-Oliveira MH, 1999, J CLIN ENDOCR METAB, V84, P4118, DOI 10.1210/jc.84.11.4118
   AHMED AR, 1983, ARCH DERMATOL, V119, P934, DOI 10.1001/archderm.119.11.934
   Alba M, 2005, GROWTH HORM IGF RES, V15, P275, DOI 10.1016/j.ghir.2005.05.001
   Auernhammer CJ, 1995, EUR J ENDOCRINOL, V133, P635, DOI 10.1530/eje.0.1330635
   Auernhammer CJ, 2002, HORM RES, V57, P15, DOI 10.1159/000057941
   BLUMING AZ, 1971, CLIN EXP IMMUNOL, V9, P713
   Casanova JL, 2012, IMMUNITY, V36, P515, DOI 10.1016/j.immuni.2012.03.016
   Clark R, 1997, ENDOCR REV, V18, P157, DOI 10.1210/er.18.2.157
   De Bellis Annamaria, 2005, Pituitary, V8, P25
   Dorshkind K, 2000, ENDOCR REV, V21, P292, DOI 10.1210/er.21.3.292
   FLEISHER TA, 1980, NEW ENGL J MED, V302, P1429, DOI 10.1056/NEJM198006263022601
   FU YK, 1992, J CLIN INVEST, V89, P451, DOI 10.1172/JCI115605
   Guevara-Aguirre J, 2007, HORM RES, V68, P175
   Hattori N, 2001, J CLIN ENDOCR METAB, V86, P4284, DOI 10.1210/jc.86.9.4284
   Hattori N, 2009, GROWTH HORM IGF RES, V19, P187, DOI 10.1016/j.ghir.2008.12.001
   Hwa V, 2016, GROWTH HORM IGF RES, V28, P16, DOI 10.1016/j.ghir.2015.12.006
   Jan CF, 2010, HEPATOLOGY, V51, P1547, DOI 10.1002/hep.23543
   KANARIOU M, 1995, PEDIATR ALLERGY IMMU, V6, P24, DOI 10.1111/j.1399-3038.1995.tb00253.x
   Kecha O, 2000, ENDOCRINOLOGY, V141, P1209, DOI 10.1210/en.141.3.1209
   Kelley KW, 2007, BRAIN BEHAV IMMUN, V21, P384, DOI 10.1016/j.bbi.2006.11.010
   Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926
   Laron Z, 2011, LARON SYNDROME - FROM MAN TO MOUSE: LESSONS FROM CLINICAL AND EXPERIEMENTAL EXPERIENCE, P341, DOI 10.1007/978-3-642-11183-9_41
   Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53
   LINDSAY R, 1994, J PEDIATR-US, V125, P29, DOI 10.1016/S0022-3476(94)70117-2
   Linehan E, 2015, EUR J MICROBIOL IMMU, V5, P14, DOI [10.1556/EUJMI-D-14-00035, 10.1556/EuJMI-D-14-00035]
   Lithgow D, 2015, BIOL RES NURS, V17, P49, DOI 10.1177/1099800414524619
   Matera L, 1996, LIFE SCI, V59, P599, DOI 10.1016/0024-3205(96)00225-1
   Menezes M, 2008, MENOPAUSE, V15, P743, DOI 10.1097/gme.0b013e31815b97d4
   Menezes M, 2013, ENDOCRINE, V44, P207, DOI 10.1007/s12020-013-9896-z
   Ministerio da Saude Secretaria de Vigilancia em Saude Departamento de Vigilancia das Doencas Transmissiveis (Brasil), 2014, TECN APL LEIT PROV T
   Mukherjee A, 2009, CLIN EXP IMMUNOL, V156, P271, DOI 10.1111/j.1365-2249.2009.03881.x
   Oberlin D, 2009, IMMUNOLOGY, V128, P342, DOI 10.1111/j.1365-2567.2009.03136.x
   Ogershok PR, 2006, ANN ALLERG ASTHMA IM, V97, P653, DOI 10.1016/S1081-1206(10)61096-4
   Oliveira CRP, 2008, CLIN ENDOCRINOL, V69, P153, DOI 10.1111/j.1365-2265.2007.03148.x
   Prakash Charu, 2000, Journal of Communicable Diseases, V32, P17
   ROSENFELD RG, 1994, ENDOCR REV, V15, P369, DOI 10.1210/er.15.3.369
   Salvatori R, 2006, J ENDOCRINOL INVEST, V29, P805, DOI 10.1007/BF03347374
   Salvatori R, 1999, J CLIN ENDOCR METAB, V84, P917, DOI 10.1210/jc.84.3.917
   Scalco RC, 2013, ARQ BRAS ENDOCRINOL, V57, P333, DOI 10.1590/S0004-27302013000500001
   Shohreh R, 2011, ENDOCRINOLOGY, V152, P3803, DOI 10.1210/en.2011-1317
   Smith PE, 1930, ANAT REC, V47, P119, DOI 10.1002/ar.1090470110
   SPADONI GL, 1991, ACTA PAEDIATR SCAND, V80, P75, DOI 10.1111/j.1651-2227.1991.tb11733.x
   Stewart DM, 2008, IMMUNOL RES, V40, P262, DOI 10.1007/s12026-007-0028-9
   Taguchi T, 2006, EXP HEMATOL, V34, P508, DOI 10.1016/j.exphem.2006.01.009
   Thomas RJ, 2015, INDIAN J MED MICROBI, V33, pS32, DOI 10.4103/0255-0857.150877
   van Bilsen K, 2008, NETH J MED, V66, P368
   Yang Y, 1999, HORM METAB RES, V31, P380, DOI 10.1055/s-2007-978759
   Zhao LT, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00645
   Zuckerman JN, 2006, J MED VIROL, V78, P169, DOI 10.1002/jmv.20524
NR 51
TC 11
Z9 12
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-008X
EI 1559-0100
J9 ENDOCRINE
JI Endocrine
PD OCT
PY 2016
VL 54
IS 1
BP 182
EP 190
DI 10.1007/s12020-016-1061-z
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EA4WL
UT WOS:000386616300021
PM 27484773
DA 2020-12-08
ER

PT J
AU Ribeiro, LS
   Marques, RE
   de Jesus, AMR
   de Almeida, RP
   Teixeira, MM
AF Ribeiro, Lucas Secchim
   Marques, Rafael Elias
   Ribeiro de Jesus, Amelia Maria
   de Almeida, Roque Pacheco
   Teixeira, Mauro Martins
TI Zika crisis in Brazil: challenges in research and development
SO CURRENT OPINION IN VIROLOGY
LA English
DT Article
ID VIRUS-INFECTION; DENGUE VIRUS; TRANSMISSION; REPLICATION; MICRONESIA;
   INHIBITORS; PREGNANCY; EPIDEMIC; MODEL; MICE
AB Infection with the Zika virus (ZIKV) usually causes a mild acute illness, but two major severe syndromes have been described during the epidemic in Brazil: microcephaly and the Guillain-Barre Syndrome. There is now much evidence to show that ZIKV can infect and damage neuronal cells in vitro. In experimental animals, ZIKV has significant neurotropism and can cause brain damage. At present, diagnosis is still a challenge in the field and there is no treatment available. Another major challenge is that one must devise therapies for pregnant women, at all stages of pregnancy. Devising adequate treatment for ZIKV infections represents a challenge that will only be met by the joint effort of the research community.
C1 [Ribeiro, Lucas Secchim] Univ Fed Minas Gerais, Dept Microbiol, Belo Horizonte, MG, Brazil.
   [Ribeiro, Lucas Secchim; Marques, Rafael Elias; Teixeira, Mauro Martins] Univ Fed Minas Gerais, Immunopharmacol, Belo Horizonte, MG, Brazil.
   [Ribeiro de Jesus, Amelia Maria; de Almeida, Roque Pacheco] Univ Fed Sergipe, Lab Biol Mol, Univ Hosp, Aracaju, Brazil.
   [Ribeiro de Jesus, Amelia Maria; de Almeida, Roque Pacheco] Univ Fed Sergipe, Programa Pos Grad Ciencias Saude, Univ Hosp, Aracaju, Brazil.
RP Teixeira, MM (corresponding author), Univ Fed Minas Gerais, Immunopharmacol, Belo Horizonte, MG, Brazil.
EM mmtex@icb.ufmg.br
RI Marques, Rafael Elias/R-4890-2016; amsalu, ribka/G-8780-2019; Teixeira,
   Mauro M/A-4587-2008
OI Marques, Rafael Elias/0000-0002-6949-0947; Teixeira, Mauro
   M/0000-0002-6944-3008; Secchim Ribeiro, Lucas/0000-0001-8876-3827
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPEMIGMinas Gerais State Research Foundation (FAPEMIG)
FX We would like to thank CNPq and FAPEMIG for their financial support.
CR [Anonymous], 2016, LANCET INFECT DIS, V16, P265
   Balm MND, 2012, J MED VIROL, V84, P1501, DOI 10.1002/jmv.23241
   Barreto ML, 2016, LANCET, V387, P919, DOI 10.1016/S0140-6736(16)00545-6
   BELL TM, 1971, ARCH GES VIRUSFORSCH, V35, P183, DOI 10.1007/BF01249709
   Brasil P, 2016, N ENGL J MED
   Brazilian Health Ministry BR, 2015, MIN SAUD DIV B EP
   Brazilian Health Ministry BR, 2016, EPIDEMIOL WEEK, V2016, P5
   Brazilian Health Ministry BR, 2016, MON MICR CAS BRAZ
   Calvert C, 2014, NEW ENGL J MED, V371, P1075, DOI 10.1056/NEJMc1408436
   Calvet G, 2016, LANCET INFECT DIS
   Campos RD, 2016, J CLIN VIROL, V77, P69, DOI 10.1016/j.jcv.2016.02.009
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Cauchemez S, 2016, LANCET
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   DARWISH MA, 1983, T ROY SOC TROP MED H, V77, P442, DOI 10.1016/0035-9203(83)90106-2
   Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058
   Diallo D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109442
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Eyer L, 2015, ANTIMICROB AGENTS CH, V59, P5483, DOI 10.1128/AAC.00807-15
   Faria N.R., 2016, SCIENCE
   Freitas BP, 2016, JAMA OPHTHALMOL
   Garcez PPLE, 2016, PEERJ PREPRINTS, V4
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   Jouannic JM, 2016, LANCET, V387, P1051, DOI 10.1016/S0140-6736(16)00625-5
   Julander JG, 2009, ANTIMICROB AGENTS CH, V53, P202, DOI 10.1128/AAC.01074-08
   Kuno G, 2007, ARCH VIROL, V152, P687, DOI 10.1007/s00705-006-0903-z
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lazear H M, 2016, JAMA
   Lazear H. M., 2016, J VIROL
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Morrison Juliet, 2014, JAKSTAT, V3, pe27715, DOI 10.4161/jkst.27715
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Oehler E., 2014, Eurosurveillance, V19, P20720
   Paixao ES, 2016, AM J PUBLIC HEALTH, V106, P606, DOI 10.2105/AJPH.2016.303112
   Roberts SS, 2010, BIRTH DEFECTS RES A, V88, P551, DOI 10.1002/bdra.20682
   Rossi SL, 2016, AM J TROP MED HYG
   Roze B, 2016, EUROSURVEILLANCE, P21, DOI DOI 10.28707/1560-7917.ES.2016.21.9.30154
   Rudolph KE, 2014, AM J TROP MED HYG, V90, P882, DOI 10.4269/ajtmh.13-0403
   Schul W, 2007, J INFECT DIS, V195, P665, DOI 10.1086/511310
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316
   Tang H, 2016, CELL STEM CELL
   Thorne C, 2007, DRUG SAFETY, V30, P203, DOI 10.2165/00002018-200730030-00004
   Villamil-Gomez WE, 2016, J INFECT PUBLIC HLTH
   Vogel G, 2016, SCIENCE, V351, P1377, DOI 10.1126/science.351.6280.1377
   Wang QY, 2015, J VIROL, V89, P8233, DOI 10.1128/JVI.00855-15
   Yuki N, 2012, NEW ENGL J MED, V366, P2294, DOI 10.1056/NEJMra1114525
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 52
TC 24
Z9 24
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1879-6257
J9 CURR OPIN VIROL
JI Curr. Opin. Virol.
PD JUN
PY 2016
VL 18
BP 76
EP 81
DI 10.1016/j.coviro.2016.04.002
PG 6
WC Virology
SC Virology
GA DU5TC
UT WOS:000382273200014
PM 27179929
DA 2020-12-08
ER

PT J
AU Farias, MD
   Matos, FD
   Carvalho, NC
   de Almeida, RP
   de Mendonca, AAM
   de Albuquerque, RLC
   Ribeiro, MAG
AF Farias, Michelle de Paula
   Matos, Felipe de Souza
   Carvalho, Nayane Chagas
   de Almeida, Roque Pacheco
   Melo de Mendonca, Adriano Augusto
   Cavalcanti de Albuquerque Junior, Ricardo Luiz
   Gonzaga Ribeiro, Maria Amalia
TI ASSESSMENT OF INTRACANAL MEDICATIONS CYTOTOXICITY ON L929 FIBROBLAST
   CELLS
SO BIOSCIENCE JOURNAL
LA English
DT Article
DE Cytotoxicity tests; Immunologic; Endodontics; Calcium hydroxide;
   Iodoform; Fibroblasts
ID MINERAL TRIOXIDE AGGREGATE; DENTINAL TUBULE DISINFECTION; CALCIUM
   HYDROXIDE; IN-VITRO; CONNECTIVE-TISSUE; UP-REGULATION; REPAIR;
   GENOTOXICITY; GELATINASES; TEETH
AB This study aimed to evaluate the cytotoxicity of intracanal medications on L929 fibroblast cells at different periods of observation. The following experimental groups were studied: calcium hydroxide with camphorated paramonochlorophenol and glycerin (CPG); iodoform with glycerin (IG); calcium hydroxide with iodoform and distilled water (CIW); iodoform with distilled water (IW); calcium hydroxide with distilled water (CW); Otosporin (R) (OT); and a control group composed of cells and culture medium. Eluates were prepared from each group and placed in contact with 1 x 10(5) cells/well for periods of 30 minutes, 12, 24, 48 and 72 hours, 5 and 7 days. After each experimental period, a cytotoxicity test was performed using methyltetrazolium (MTT) and a spectrophotometer at an optical density of 570 nm to analyze cell viability. The ANOVA and Tukey test with a significance level of 5% was used to analyze the data. At 30 minutes and at 12 hours, all groups were equal to the control group. At 24 hours, there was greater cytotoxicity in the IG group than in the control group (P<0.001). At 48 hours, only the OT group was cytotoxic (P<0.001). At 72 hours and at 5 days, the most cytotoxic groups were CW and OT. At 7 days, the IW and CPG groups were the least cytotoxic (P<0.001). With respect to experimental time, significant differences between 24 hours and 7 days were observed in all groups. Otosporin (R) was the most cytotoxic medication, followed by calcium hydroxide with distilled water.
C1 [Farias, Michelle de Paula; Matos, Felipe de Souza; Carvalho, Nayane Chagas] Univ Fed Sergipe, Postgrad Program Dent, Aracaju, SE, Brazil.
   [de Almeida, Roque Pacheco] Univ Fed Sergipe, Dept Med, Aracaju, SE, Brazil.
   [Melo de Mendonca, Adriano Augusto; Gonzaga Ribeiro, Maria Amalia] Univ Fed Sergipe, Dept Dent, Aracaju, SE, Brazil.
   [Cavalcanti de Albuquerque Junior, Ricardo Luiz] Univ Tiradentes, Dept Dent, Aracaju, SE, Brazil.
RP Farias, MD (corresponding author), Univ Fed Sergipe, Postgrad Program Dent, Aracaju, SE, Brazil.
EM felipe_smatos@hotmail.com
RI Albuquerque-Junior, Ricardo/ABC-5165-2020; Albuquerque-Junior, Ricardo
   LC/J-7316-2015; de Souza Matos, Felipe/A-3138-2015
OI Albuquerque-Junior, Ricardo/0000-0003-4444-7632; de Souza Matos,
   Felipe/0000-0001-5619-3831
CR Camargo SEA, 2010, J APPL ORAL SCI, V18, P273, DOI 10.1590/S1678-77572010000300014
   ANTHONY DR, 1982, ORAL SURG ORAL MED O, V54, P560, DOI 10.1016/0030-4220(82)90195-5
   Camargo SEA, 2009, INT ENDOD J, V42, P227, DOI 10.1111/j.1365-2591.2008.01506.x
   Chang YC, 1998, J ENDODONT, V24, P604, DOI 10.1016/S0099-2399(98)80119-2
   Cwikla SJ, 2005, J ENDODONT, V31, P50, DOI 10.1097/01.DON.0000134291.03828.D1
   Neiva LBD, 2013, ACTA PAUL ENFERM, V26, P57, DOI 10.1590/S0103-21002013000100010
   Estrela C, 1996, Braz Dent J, V7, P41
   Estrela Carlos, 2005, J Appl Oral Sci, V13, P152, DOI 10.1590/S1678-77572005000200011
   Gahyva Sérgio Márcio Motta, 2005, J. Appl. Oral Sci., V13, P387, DOI 10.1590/S1678-77572005000400014
   Gomes JE, 2009, J ENDODONT, V35, P1577, DOI 10.1016/j.joen.2009.07.022
   Grecca FS, 2001, J ENDODONT, V27, P610
   Guigand M, 1999, J ENDODONT, V25, P419, DOI 10.1016/S0099-2399(99)80270-2
   Heward S, 2011, J ENDODONT, V37, P40, DOI 10.1016/j.joen.2010.09.003
   Hirschman WR, 2012, J ENDODONT, V38, P385, DOI 10.1016/j.joen.2011.11.012
   Holland R, 1999, J ENDODONT, V25, P161, DOI 10.1016/S0099-2399(99)80134-4
   Huang TH, 2009, J DENT SCI, V4, P18, DOI 10.1016/S1991-7902(09)60004-0
   Kandaswamy D, 2010, INT ENDOD J, V43, P419, DOI 10.1111/j.1365-2591.2010.01696.x
   Lana Patricia Elaine Panicali, 2009, Braz. Dent. J., V20, P32, DOI 10.1590/S0103-64402009000100005
   MATOS Felipe de Souza, 2014, Rev. odontol. UNESP, V43, P343, DOI 10.1590/rou.2014.055
   MIURA C. A. S., 2010, REV ODONTOL BRAS CEN, V19, P192
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nelson P, 1999, INT ENDOD J, V32, P303
   Pallotta Raul Capp, 2010, Rev. odonto ciênc., V25, P59, DOI 10.1590/S1980-65232010000100012
   Sepet E, 2009, QUINTESSENCE INT, V40, pE55
   Silva EJNL, 2012, INT ENDOD J, V45, P815, DOI 10.1111/j.1365-2591.2012.02038.x
   Silva EJNL, 2012, INT ENDOD J, V45, P49, DOI 10.1111/j.1365-2591.2011.01946.x
   Silva EJNL, 2013, J ENDODONT, V39, P274, DOI 10.1016/j.joen.2012.06.030
   Tomaz Pablicia Juliana Santos, 2013, American Journal of Applied Sciences, V10, P81, DOI 10.3844/ajassp.2013.81.88
   Vianna Morgana Eli, 2009, Braz. Dent. J., V20, P382, DOI 10.1590/S0103-64402009000500005
   Yasuda Y, 2010, J ENDODONT, V36, P260, DOI 10.1016/j.joen.2009.11.002
   Yoshino Patrícia, 2013, Braz. Dent. J., V24, P111, DOI 10.1590/0103-6440201302115
NR 31
TC 2
Z9 2
U1 0
U2 3
PU UNIV FEDERAL UBERLANDIA
PI UBERLANDIA
PA AV PARA, 1720 CAMPUS UMUARAMA, UBERLANDIA, 38400-902, BRAZIL
SN 1981-3163
J9 BIOSCI J
JI Biosci. J.
PD MAR-APR
PY 2016
VL 32
IS 2
BP 566
EP 574
PG 9
WC Agriculture, Multidisciplinary; Agronomy; Biology
SC Agriculture; Life Sciences & Biomedicine - Other Topics
GA DI7QU
UT WOS:000373697500033
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU de Moura, TR
   Santos, MLB
   Braz, JM
   Santos, LFVC
   Aragao, MT
   de Oliveira, FA
   Santos, PL
   da Silva, AM
   de Jesus, AR
   de Almeida, RP
AF de Moura, Tatiana R.
   Barbosa Santos, Micheli Luize
   Braz, Juciene M.
   Santos, Luis Felipe V. C.
   Aragao, Matheus T.
   de Oliveira, Fabricia A.
   Santos, Priscila L.
   da Silva, Angela Maria
   de Jesus, Amelia Ribeiro
   de Almeida, Roque P.
TI Cross-resistance of Leishmania infantum isolates to nitric oxide from
   patients refractory to antimony treatment, and greater tolerance to
   antileishmanial responses by macrophages
SO PARASITOLOGY RESEARCH
LA English
DT Article
DE Visceral leishmaniasis; Leishmania infantum; Antimony resistance; Nitric
   oxide; Clinical isolate; Antileishmanial responses
ID VISCERAL LEISHMANIASIS; AMPHOTERICIN-B; MEGLUMINE ANTIMONIATE;
   PENTAVALENT ANTIMONY; VIANNIA BRAZILIENSIS; DRUG-RESISTANCE; IN-VITRO;
   SODIUM STIBOGLUCONATE; TRIVALENT ANTIMONY; DONOVANI
AB Visceral leishmaniasis is a life-threatening disease characterized by intense parasitism of the spleen, liver, and bone marrow. Antimonials have served as front-line antileishmanial therapeutics for decades, but the increasing failure rates under antimonial treatment have challenged the continued use of these drugs. Pentavalent antimonials are known to reinforce the killing mechanisms of macrophages, although the associated mechanism remains unclear. Here, for the first time, we determined whether Leishmania infantum strains isolated from patients refractory to antimony treatment (relapse cases) were cross-resistant to antimonials, liposomal amphotericin B, and/or nitric oxide, and also whether these strains modulate macrophage infection. We selected four clinical isolates from relapse cases and two clinical isolates from antimony-responsive patients (control group) for the present study. The L. infantum promastigotes from all four relapse cases were resistant to trivalent antimonial treatment and nitric oxide, while only one isolate was resistant to liposomal amphotericin B. We evaluated whether the resistant strains from relapse cases showed enhanced infectivity and amastigote survival in macrophages, or macrophage-killing mechanisms in macrophages activated by lipopolysaccharide plus interferon gamma. Infection indexes calculated using macrophages infected with isolates from relapse were higher than those observed with control strains that were stimulated independently. Macrophage infection was higher with L. infantum isolates from relapse cases and correlated with enhanced interleukin 1-beta production but showed similar nitrite production. Our results demonstrate that L. infantum field isolates from relapse cases were resistant to antimonials and nitric oxide and that these parasites stimulated inflammatory cytokines and were resistant to macrophage-killing mechanisms, factors that may contribute to disease severity.
C1 [de Moura, Tatiana R.; Barbosa Santos, Micheli Luize; Braz, Juciene M.; Santos, Luis Felipe V. C.; Aragao, Matheus T.; de Oliveira, Fabricia A.; Santos, Priscila L.; da Silva, Angela Maria; de Jesus, Amelia Ribeiro; de Almeida, Roque P.] Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, BR-4906010 Aracaju, Brazil.
   [de Jesus, Amelia Ribeiro; de Almeida, Roque P.] Inst Invest Imunol, BR-01246903 Sao Paulo, Brazil.
RP de Moura, TR (corresponding author), Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, BR-4906010 Aracaju, Brazil.
EM tmoura.ufs@gmail.com
RI , Tatiana/AAN-1194-2020
OI , Tatiana/0000-0002-7442-4434
CR Ait-Oudhia K, 2011, PARASITOL RES, V109, P1225, DOI 10.1007/s00436-011-2555-5
   ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   Carrio J, 2001, ACTA TROP, V79, P179, DOI 10.1016/S0001-706X(01)00125-5
   Carrio Jaume, 2002, BMC Pharmacol, V2, P11, DOI 10.1186/1471-2210-2-11
   Carter KC, 2006, ANTIMICROB AGENTS CH, V50, P88, DOI 10.1128/AAC.50.1.88-95.2006
   Carter KC, 2003, ANTIMICROB AGENTS CH, V47, P1529, DOI 10.1128/AAC.47.5.1529-1535.2003
   Chandra D, 2008, CLIN EXP IMMUNOL, V154, P224, DOI 10.1111/j.1365-2249.2008.03741.x
   COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050
   Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]
   de Azevedo AF, 2014, PARASITOL RES, V113, P19, DOI 10.1007/s00436-013-3621-y
   de Melo EC, 2013, J TROP MED-US, V2013, DOI 10.1155/2013/319234
   Decuypere S, 2005, ANTIMICROB AGENTS CH, V49, P4616, DOI 10.1128/AAC.49.11.4616-4621.2005
   Decuypere S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001514
   Di Giorgio C, 1999, J ANTIMICROB CHEMOTH, V44, P71, DOI 10.1093/jac/44.1.71
   Erfan MBK, 2013, IRAN J PARASITOL, V8, P359
   Escobar P, 2002, ACTA TROP, V81, P151, DOI 10.1016/S0001-706X(01)00197-8
   FarautGambarelli F, 1997, ANTIMICROB AGENTS CH, V41, P827, DOI 10.1128/AAC.41.4.827
   Feng GJ, 1999, J IMMUNOL, V163, P6403
   Genestra M, 2006, ARCH MED RES, V37, P328, DOI 10.1016/j.arcmed.2005.07.011
   Giudice A, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-7
   Goyeneche-Patino DA, 2008, ANTIMICROB AGENTS CH, V52, P4503, DOI 10.1128/AAC.01075-08
   GRAMICCIA M, 1992, ANN TROP MED PARASIT, V86, P613, DOI 10.1080/00034983.1992.11812717
   Holzmuller P, 2005, ANTIMICROB AGENTS CH, V49, P4406, DOI 10.1128/AAC.49.10.4406-4409.2005
   Jeddi F, 2014, ANTIMICROB AGENTS CH, V58, P4866, DOI 10.1128/AAC.02521-13
   Kothari H, 2007, PARASITOL INT, V56, P77, DOI 10.1016/j.parint.2006.10.005
   Lachaud L, 2002, J CLIN MICROBIOL, V40, P210, DOI 10.1128/JCM.40.1.210-215.2002
   Lima DS, 2013, NAT MED, V19, P909, DOI 10.1038/nm.3221
   Lonardoni MVC, 2000, INFECT IMMUN, V68, P6355, DOI 10.1128/IAI.68.11.6355-6361.2000
   MAUEL J, 1987, EUR J IMMUNOL, V17, P203, DOI 10.1002/eji.1830170209
   Mikus Judith, 2000, Parasitology International, V48, P265, DOI 10.1016/S1383-5769(99)00020-3
   MISHRA M, 1992, LANCET, V340, P1256, DOI 10.1016/0140-6736(92)92952-C
   Mittal MK, 2007, AM J TROP MED HYG, V76, P681, DOI 10.4269/ajtmh.2007.76.681
   Mukherjee B, 2013, P NATL ACAD SCI USA, V110, pE575, DOI [10.1073/pnas.1213839110, 10.]
   Ouellette M, 2004, DRUG RESIST UPDATE, V7, P257, DOI 10.1016/j.drup.2004.07.002
   Purkait B, 2012, ANTIMICROB AGENTS CH, V56, P1031, DOI 10.1128/AAC.00030-11
   RALPH P, 1975, NATURE, V257, P393, DOI 10.1038/257393a0
   Romero GAS, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000584
   Santos PL, 2012, NITRIC OXIDE-BIOL CH, V27, P67, DOI 10.1016/j.niox.2012.04.004
   Souza AS, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-209
   Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121
   Sundar S, 2007, CLIN INFECT DIS, V45, P556, DOI 10.1086/520665
   Sundar S, 2013, EXPERT OPIN PHARMACO, V14, P53, DOI 10.1517/14656566.2013.755515
   t'Kindt R, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000904
   Teixeira AC, 2008, REV INST MED TROP SP, V50, P157, DOI 10.1590/S0036-46652008000300005
   Vanaerschot M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023120
   Zauli-Nascimento RC, 2010, TROP MED INT HEALTH, V15, P68, DOI 10.1111/j.1365-3156.2009.02414.x
NR 47
TC 12
Z9 12
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0932-0113
EI 1432-1955
J9 PARASITOL RES
JI Parasitol. Res.
PD FEB
PY 2016
VL 115
IS 2
BP 713
EP 721
DI 10.1007/s00436-015-4793-4
PG 9
WC Parasitology
SC Parasitology
GA DE8EO
UT WOS:000370868800030
PM 26481489
DA 2020-12-08
ER

PT J
AU dos Santos, PL
   de Oliveira, FA
   Santos, MLB
   Cunha, LCS
   Lino, MTB
   de Oliveira, MFS
   Bomfim, MOM
   Silva, AM
   de Moura, TR
   de Jesus, AR
   Duthie, MS
   Reed, SG
   de Almeida, RP
AF dos Santos, Priscila L.
   de Oliveira, Fabricia A.
   Santos, Micheli Luize B.
   Cunha, Luana Celina S.
   Lino, Michelle T. B.
   de Oliveira, Michelle F. S.
   Bomfim, Manuela O. M.
   Silva, Angela Maria
   de Moura, Tatiana R.
   de Jesus, Amelia R.
   Duthie, Malcolm S.
   Reed, Steven G.
   de Almeida, Roque P.
TI The Severity of Visceral Leishmaniasis Correlates with Elevated Levels
   of Serum IL-6, IL-27 and sCD14
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID INTERFERON-GAMMA; IFN-GAMMA; CLINICAL EVOLUTION; CYTOKINE PROFILE;
   IMMUNE-RESPONSE; PLASMA-LEVELS; SOLUBLE CD14; RISK-FACTORS; KALA-AZAR;
   PATHOGENESIS
AB Background
   Visceral leishmaniasis (VL) is a severe disease caused by infection with protozoa of the genus Leishmania. Classic VL is characterized by a systemic infection of phagocytic cells and an intense activation of the inflammatory response. It is unclear why 90% of infected individuals do not develop the disease while a minority develop the classical form. Furthermore, among those that develop disease, a small group progresses to more severe form that is unresponsive to treatment. The presence of inflammatory mediators in serum could theoretically help to control the infection. However, there is also a release of anti-inflammatory mediators that could interfere with the control of parasite multiplication. In this study, we took advantage of the spectrum of outcomes to test the hypothesis that the immune profile of individuals infected with Leishmania (L.) infantum is associated with the development and severity of disease.
   Methodology/Principal Findings
   Sera from patients with confirmed diagnosis of VL were evaluated for the presence of numerous molecules, and levels compared with healthy control and asymptomatic infected individuals.
   Conclusions/Principal Findings
   Although differences were not observed in LPS levels, higher levels of sCD14 were detected in VL patients. Our data suggest that L. infantum may activate the inflammatory response via CD14, stimulating a generalized inflammatory response with production of several cytokines and soluble molecules, including IFN-., IL-27, IL-10, IL-6 and sCD14. These molecules were strongly associated with hepatosplenomegaly, neutropenia and thrombocytopenia. We also observed that IL-6 levels greater than 200 pg/ml were strongly associated with death. Together our data reinforce the close relationship of IFN-gamma, IL-10, IL-6, TNF-alpha and IL-27 in the immune dynamics of VL and suggest the direct participation of sCD14 in the activation of the immune response against L. infantum.
C1 [dos Santos, Priscila L.; de Oliveira, Fabricia A.; Santos, Micheli Luize B.; Cunha, Luana Celina S.; Lino, Michelle T. B.; de Oliveira, Michelle F. S.; Bomfim, Manuela O. M.; Silva, Angela Maria; de Moura, Tatiana R.; de Jesus, Amelia R.; de Almeida, Roque P.] Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Aracaju, Brazil.
   [de Jesus, Amelia R.; de Almeida, Roque P.] Univ Fed Sergipe, Programa Posgrad Ciencias Saude, Aracaju, Brazil.
   [de Jesus, Amelia R.; de Almeida, Roque P.] Inst Invest Imunol, Sao Paulo, Brazil.
   [Duthie, Malcolm S.; Reed, Steven G.] IDRI, Washington, DC USA.
RP de Almeida, RP (corresponding author), Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Aracaju, Brazil.; de Almeida, RP (corresponding author), Univ Fed Sergipe, Programa Posgrad Ciencias Saude, Aracaju, Brazil.; de Almeida, RP (corresponding author), Inst Invest Imunol, Sao Paulo, Brazil.
EM roquepachecoalmeida@gmail.com
RI , Tatiana/AAN-1194-2020
OI , Tatiana/0000-0002-7442-4434; Duthie, Malcolm/0000-0002-8515-5516
FU Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico [019.203.02712/2009-8, 019.203.01157/2011-9];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Programa Nacional de Incentivo a Pesquisa em Parasitologia
   Basica [032/2010]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) PROCAD/CASADINHO [552721/2011-5]; Edital/Chamada:
   Universal [483540/2011-0]
FX This work was supported by: Fundacao de Apoio a Pesquisa e a Inovacao
   Tecnologica do Estado de Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico, Grants: CNPq no 12/2009
   Processo no 019.203.02712/2009-8 (ARJ); CNPq no 04/2011 Processo n.
   019.203.01157/2011-9 (TRdM). Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES), Grant: Programa Nacional de Incentivo a
   Pesquisa em Parasitologia Basica, Edital No 032/2010 (ARdJ). Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Grants:
   PROCAD/CASADINHO- no 552721/2011-5 (RPdA); Edital/Chamada: Universal
   14/2011 Processo n. 483540/2011-0 (TRdM). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ADERKA D, 1989, J IMMUNOL, V143, P3517
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Sampaio MJAD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000877
   Gama MEA, 2013, REV SOC BRAS MED TRO, V46, P741, DOI 10.1590/0037-8682-0203-2013
   Costa ASA, 2012, MEM I OSWALDO CRUZ, V107, P735, DOI 10.1590/S0074-02762012000600005
   ANDRADE TM, 1990, J INFECT DIS, V162, P1354, DOI 10.1093/infdis/162.6.1354
   Ansari NA, 2011, J IMMUNOL, V186, P3977, DOI 10.4049/jimmunol.1003588
   Bacellar O, 1996, J INFECT DIS, V173, P1515, DOI 10.1093/infdis/173.6.1515
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   Bacellar O, 2005, GAZETA MED BAHIA, P75
   BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003
   BARRALNETTO M, 1991, J INFECT DIS, V163, P853, DOI 10.1093/infdis/163.4.853
   Belkhelfa M, 2014, J INTERFERON CYTOKIN
   Belo VS, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002982
   Belo VS, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002182
   Caldas A, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-113
   CARVALHO EM, 1994, J IMMUNOL, V152, P5949
   Clark IA, 2004, CLIN MICROBIOL REV, V17, P509, DOI 10.1128/CMR.17.3.509-539.2004
   COSTA CHN, 1990, REV SAUDE PUBL, V24, P361, DOI 10.1590/S0034-89101990000500003
   Costa DL, 2013, PATHOG GLOB HEALTH, V107, P78, DOI 10.1179/2047773213Y.0000000078
   de Oliveira FA, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-331
   Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9
   Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9
   Diro E, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002869
   Duthie MS, 2014, EUR J CLIN MICROBIOL, V33, P639, DOI 10.1007/s10096-013-1999-1
   Gautam S, 2011, J INFECT DIS, V204, P1134, DOI 10.1093/infdis/jir461
   Gluck T, 2001, EUR J MED RES, V6, P351
   Goto H, 2009, REV I MED TROP, V51, P241, DOI 10.1590/S0036-46652009000500002
   Hailu A, 2004, AM J TROP MED HYG, V71, P561, DOI 10.4269/ajtmh.2004.71.561
   Hunter CA, 2012, IMMUNITY, V37, P960, DOI 10.1016/j.immuni.2012.11.003
   JANEWAY CA, 1988, CURR TOP MICROBIOL, V137, P171
   Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0
   Khoshdel A, 2009, BRAZ J INFECT DIS, V13, P44, DOI 10.1590/S1413-86702009000100010
   Kinra P, 2013, TROP BIOMED, V30, P645
   Landmann R, 1996, J INFECT DIS, V173, P661, DOI 10.1093/infdis/173.3.661
   Landmann R, 1996, INFECT IMMUN, V64, P1762, DOI 10.1128/IAI.64.5.1762-1769.1996
   Leite Alexandro Iris, 2013, Revista de Patologia Tropical, V42, P301, DOI 10.5216/rpt.v42i3.26928
   Liu LM, 2006, PARASITOL RES, V99, P189, DOI 10.1007/s00436-006-0168-1
   MAEGRAITH B, 1948, T ROY SOC TROP MED H, V41, P687, DOI 10.1016/S0035-9203(48)90678-6
   de Araujo VEM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001511
   Costa CHN, 2010, REV SOC BRAS MED TRO, V43, P386, DOI 10.1590/S0037-86822010000400010
   Nylen S, 2007, TRENDS IMMUNOL, V28, P378, DOI 10.1016/j.it.2007.07.004
   Peruhype-Magalhaes V, 2006, CLIN EXP IMMUNOL, V146, P124, DOI 10.1111/j.1365-2249.2006.03171.x
   Peruhype-Magalhaes V, 2005, SCAND J IMMUNOL, V62, P487, DOI 10.1111/j.1365-3083.2005.01686.x
   Ramachandran G, 2014, VIRULENCE, V5, P213, DOI 10.4161/viru.27024
   Sabat R, 2010, CYTOKINE GROWTH F R, V21, P331, DOI 10.1016/j.cytogfr.2010.09.002
   Santos-Oliveira JR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001198
   Saude BMd, 2006, MAN VIG CONTR LEISHM
   Silva JM, 2014, AM J TROP MED HYG, V90, P621, DOI 10.4269/ajtmh.13-0376
   Skraba CM, 2015, REV SOC BRAS MED TRO, V48, P437, DOI 10.1590/0037-8682-0067-2015
   Travi BL, 2002, INFECT IMMUN, V70, P2288, DOI 10.1128/IAI.70.5.2288-2296.2002
   Tuon FF, 2012, REV INST MED TROP SP, V54, P159, DOI 10.1590/S0036-46652012000300008
   Verma S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010107
   Wang SM, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/195453
   WHO, 2010, WHO TECH REP SER, V949, P1
   Wynick C, 2014, J INTERFERON CYTOKIN
   Xu C, 2014, KIDNEY INT, V85, P72, DOI 10.1038/ki.2013.286
NR 57
TC 31
Z9 33
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JAN
PY 2016
VL 10
IS 1
AR e0004375
DI 10.1371/journal.pntd.0004375
PG 16
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DH1SR
UT WOS:000372565700069
PM 26814478
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Oliveira, FA
   Barreto, AS
   Bomfim, LGS
   Leite, TRS
   dos Santos, PL
   de Almeida, RP
   da Silva, AM
   Duthie, MS
   Reed, SG
   de Moura, TR
   de Jesus, AR
AF de Oliveira, Fabricia Alvisi
   Barreto, Aline Silva
   Bomfim, Lays G. S.
   Leite, Talita Rebeca S.
   dos Santos, Priscila Lima
   de Almeida, Roque Pacheco
   da Silva, Angela Maria
   Duthie, Malcolm S.
   Reed, Steven G.
   de Moura, Tatiana Rodrigues
   de Jesus, Amelia Ribeiro
TI Soluble CD40 Ligand in Sera of Subjects Exposed to Leishmania infantum
   Infection Reduces the Parasite Load in Macrophages
SO PLOS ONE
LA English
DT Article
ID ACUTE CORONARY SYNDROMES; EXPERIMENTAL VISCERAL LEISHMANIASIS;
   NITRIC-OXIDE PRODUCTION; CELL-MEDIATED-IMMUNITY; NF-KAPPA-B; CD40-CD40
   LIGAND; DENDRITIC CELLS; HUMAN MONOCYTES; T-CELLS; DONOVANI INFECTIONS
AB Background
   While CD40L is typically a membrane glycoprotein expressed on activated T cells and platelets that binds and activates CD40 on the surface on antigen presenting cells, a soluble derivative (sCD40L) that appears to retain its biological activity after cleavage from cell membrane also exists. We recently reported that sCD40L is associated with clinical resolution of visceral leishmaniasis and protection against the disease. In the present study we investigated if this sCD40L is functional and exerts anti-parasitic effect in L. infantum-infected macrophages.
   Methodology/Principal Findings
   Macrophages from normal human donors were infected with L. infantum promastigotes and incubated with either sera from subjects exposed to L. infantum infection, monoclonal antibodies against human CD40L, or an isotype control antibody. We then evaluated infection by counting the number of infected cells and the number of parasites in each cell. We also measured a variety of immune modulatory cytokines in these macrophage culture supernatants by Luminex assay. The addition of sCD40L, either recombinant or from infected individuals' serum, decreased both the number of infected macrophages and number of intracellular parasites. Moreover, this treatment increased the production of IL-12, IL-23, IL27, IL-15, and IL1 beta such that negative correlations between the levels of these cytokines with both the infection ratio and number of intracellular parasites were observed.
   Conclusions/Significance
   sCD40L from sera of subjects exposed to L. infantum is functional and improves both the control of parasite and production of inflamatory cytokines of infected macrophages. Although the mechanisms involved in parasite killing are still unclear and require further exploration, these findings indicate a protective role of sCD40L in visceral leishmaniasis.
C1 [de Oliveira, Fabricia Alvisi; Barreto, Aline Silva; Bomfim, Lays G. S.; Leite, Talita Rebeca S.; dos Santos, Priscila Lima; de Almeida, Roque Pacheco; da Silva, Angela Maria; de Moura, Tatiana Rodrigues; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Univ Hosp, Lab Biol Mol, Aracaju, Brazil.
   [de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Inst Invest Imunol, Sao Paulo, Brazil.
   [Duthie, Malcolm S.; Reed, Steven G.] IDRI, Seattle, WA USA.
RP de Jesus, AR (corresponding author), Univ Fed Sergipe, Univ Hosp, Lab Biol Mol, Aracaju, Brazil.
EM ameliaribeirodejesus@gmail.com
RI , Tatiana/AAN-1194-2020
OI , Tatiana/0000-0002-7442-4434; Santos Bomfim, Lays
   Gisele/0000-0002-4773-6889; Duthie, Malcolm/0000-0002-8515-5516
FU Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico [12/2009, 019.203.02712/2009-8]; CNPqNational
   Council for Scientific and Technological Development (CNPq) [04/2011,
   019.203.01157/2011-9]; Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES), Grant: Programa Nacional de Incentivo a Pesquisa
   em Parasitologia Basica [032/2010]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)National Council for Scientific and
   Technological Development (CNPq) [552721/2011-5]; Edital/Chamada:
   Universal [483540/2011-0]
FX This work was supported by: Fundacao de Apoio a Pesquisa e a Inovacao
   Tecnologica do Estado de Sergipe (FAPITEC)/SE/FUNTEC/Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico, Grants: CNPq no 12/2009
   Processo no 019.203.02712/2009-8 (ARJ); CNPq no 04/2011 Processo n.
   019.203.01157/2011-9 (TRM). Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES), Grant: Programa Nacional de Incentivo a Pesquisa
   em Parasitologia Basica, Edital No 032/2010 (ARJ). Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Grants:
   PROCAD/CASADINHO- no552721/2011-5 (RPA); Edital/Chamada: Universal
   14/2011 Processo n. 483540/2011-0 (TRM). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Andrade RM, 2005, J IMMUNOL, V175, P6014, DOI 10.4049/jimmunol.175.9.6014
   Ansari NA, 2011, J IMMUNOL, V186, P3977, DOI 10.4049/jimmunol.1003588
   Bacellar O, 1996, J INFECT DIS, V173, P1515, DOI 10.1093/infdis/173.6.1515
   Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7
   CARVALHO EM, 1988, BRAZ J MED BIOL RES, V21, P85
   Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747
   Chen G, 2001, INFECT IMMUN, V69, P3255, DOI 10.1128/IAI.69.5.3255-3263.2001
   D'Aversa TG, 2002, AM J PATHOL, V160, P559, DOI 10.1016/S0002-9440(10)64875-4
   de Oliveira FA, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-331
   Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004
   GHALIB HW, 1995, J IMMUNOL, V154, P4623
   GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570
   GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639
   Grewal IS, 1997, CURR OPIN IMMUNOL, V9, P491, DOI 10.1016/S0952-7915(97)80100-8
   Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111
   Gurunathan S, 1998, J IMMUNOL, V161, P4563
   Guzzo C, 2010, J BIOL CHEM, V285, P24404, DOI 10.1074/jbc.M110.112599
   Heeschen C, 2003, NEW ENGL J MED, V348, P1104, DOI 10.1056/NEJMoa022600
   Heinzel FP, 1998, CELL IMMUNOL, V184, P129, DOI 10.1006/cimm.1998.1267
   HO JL, 1992, J INFECT DIS, V165, P1094, DOI 10.1093/infdis/165.6.1094
   Indramohan M, 2012, INFECT IMMUN, V80, P4099, DOI 10.1128/IAI.00589-12
   Jana M, 2001, J BIOL CHEM, V276, P44527, DOI 10.1074/jbc.M106771200
   Kalliolias GD, 2008, J IMMUNOL, V180, P6325, DOI 10.4049/jimmunol.180.9.6325
   Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105-2896.2004.00214.x
   Lieberman LA, 2004, J IMMUNOL, V173, P1887, DOI 10.4049/jimmunol.173.3.1887
   LIEW FY, 1990, IMMUNOLOGY, V71, P556
   Lima DS, 2013, NAT MED, V19, P909, DOI 10.1038/nm.3221
   Liu JG, 2007, J EXP MED, V204, P141, DOI 10.1084/jem.20061440
   Lorente L, 2011, CRIT CARE, V15, DOI 10.1186/cc10104
   Ludewig B, 1996, EUR J IMMUNOL, V26, P3137, DOI 10.1002/eji.1830261246
   Malik N, 1996, J IMMUNOL, V156, P3952
   Mathur RK, 2006, TRENDS PARASITOL, V22, P117, DOI 10.1016/j.pt.2006.01.003
   Mathur RK, 2004, NAT MED, V10, P540, DOI 10.1038/nm1045
   McDowell MA, 2002, INFECT IMMUN, V70, P3994, DOI 10.1128/IAI.70.8.3994-4001.2002
   McMahon-Pratt D, 2004, IMMUNOL REV, V201, P206, DOI 10.1111/j.0105-2896.2004.00190.x
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Murray HW, 2005, J IMMUNOL, V174, P4916, DOI 10.4049/jimmunol.174.8.4916
   Murray HW, 2003, INFECT IMMUN, V71, P6453, DOI 10.1128/IAI.71.11.6453-6462.2003
   Nylen S, 2007, TRENDS IMMUNOL, V28, P378, DOI 10.1016/j.it.2007.07.004
   Reinhard K, 2011, EUR J IMMUNOL, V41, P1388, DOI 10.1002/eji.201041056
   Ribbens C, 2000, IMMUNOLOGY, V99, P279, DOI 10.1046/j.1365-2567.2000.00948.x
   Shimizu M, 2013, IMMUNOBIOLOGY, V218, P628, DOI 10.1016/j.imbio.2012.07.028
   Sipsas NV, 2002, CLIN DIAGN LAB IMMUN, V9, P558, DOI 10.1128/CDLI.9.3.558-561.2002
   Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3
   Stager S, 2006, EUR J IMMUNOL, V36, P1764, DOI 10.1002/eji.200635937
   Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I
   Subauste CS, 2009, SEMIN IMMUNOL, V21, P273, DOI 10.1016/j.smim.2009.06.003
   Suttles J, 2009, SEMIN IMMUNOL, V21, P257, DOI 10.1016/j.smim.2009.05.011
   Tan ZY, 2009, INT J BIOCHEM CELL B, V41, P733, DOI 10.1016/j.biocel.2008.04.027
   TIAN LC, 1995, EUR J IMMUNOL, V25, P306, DOI 10.1002/eji.1830250152
   Tousoulis D, 2010, TRENDS CARDIOVAS MED, V20, P153, DOI 10.1016/j.tcm.2010.12.004
   Van Assche T, 2011, FREE RADICAL BIO MED, V51, P337, DOI 10.1016/j.freeradbiomed.2011.05.011
   van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2
   Verma S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010107
   Watford WT, 2004, IMMUNOL REV, V202, P139, DOI 10.1111/j.0105-2896.2004.00211.x
   Wesa Amy, 2002, BMC Immunol, V3, P14, DOI 10.1186/1471-2172-3-14
   Xie P, 2006, J IMMUNOL, V176, P5388, DOI 10.4049/jimmunol.176.9.5388
   Yan JC, 2004, CLIN CHIM ACTA, V343, P155, DOI 10.1016/j.cccn.2004.01.012
NR 58
TC 10
Z9 10
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 21
PY 2015
VL 10
IS 10
AR e0141265
DI 10.1371/journal.pone.0141265
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CU0ZM
UT WOS:000363248400118
PM 26488744
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Tunon, GIL
   de Moura, TR
   de Jesus, AR
   de Almeida, RP
AF Lee Tunon, Gabriel Isaias
   de Moura, Tatiana Rodrigues
   de Jesus, Amelia Ribeiro
   de Almeida, Roque Pacheco
TI In vitro infection by Leishmania infantum in the peripheral blood
   mononuclear cell-derived macrophages from crab-eating foxes (Cerdocyon
   thous)
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Epidemiology; Peripheral blood mononuclear cell-derived macrophage;
   Visceral leishmaniasis; Wild canids
ID CANINE VISCERAL LEISHMANIASIS; WILD CANIDS; BRAZIL; DOGS; CHAGASI;
   TRANSMISSION; ACTIVATION; STATE; SPP.
AB Wild canids are natural reservoirs of visceral leishmaniais (VL). In Brazil, only the crab-eating fox (Cerdocyon thous) is a natural reservoir of this zoonotic disease, but there is still a lack of understanding regarding the sylvatic transmission of the Leishmania infantum infection. This is the first study on the isolation, cultivation and infection with L. infantum in the peripheral blood mononuclear cell-derived macrophages from crab-eating foxes. It is also the first to compare macrophages from crab-eating foxes to other canine macrophages under the same conditions. Blood samples collected from crab-eating foxes held at the local zoo were processed to obtain macrophages that were subsequently infected with stationary phase L. infantum promastigotes. The percentage of infected macrophages and intracellular amastigotes per 100 macrophages were similar in both fox and dog blood samples at 2 h after infection. Unlike dog macrophages, in fox macrophages there was a significant reduction in the number of infected macrophages after 24 and 48 h. At 72 h after infection, the intracellular amastigotes were practically undetectable. These results indicate that crab-eating foxes have cellular mechanisms of infection control as efficient as the domestic dog. Further study is required to discern the potential epidemiologic role of crab-eating foxes in the visceral leishmaniasis transmission cycle. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Lee Tunon, Gabriel Isaias] Univ Fed Sergipe, Dept Med Vet, BR-49100000 Sao Cristovao, SE, Brazil.
   [de Moura, Tatiana Rodrigues] Univ Fed Sergipe, Dept Morfol, BR-49100000 Sao Cristovao, SE, Brazil.
   [de Jesus, Amelia Ribeiro; de Almeida, Roque Pacheco] Univ Fed Sergipe, Univ Hosp, Dept Med, BR-49060100 Aracaju, SE, Brazil.
RP Tunon, GIL (corresponding author), Univ Fed Sergipe, Dept Med Vet, Cidade Univ Jose Aloisio de Campos, BR-49100000 Sao Cristovao, SE, Brazil.
EM glee@ufs.br
RI , Tatiana/AAN-1194-2020
OI , Tatiana/0000-0002-7442-4434
FU Edital CNPq/Universal [477935/2009-5]; Pronex Edital
   FAPITEC/SE/FUNTEC/CNPq [12/2009, 019.203.02712/2009-8]
FX This research project was funded by Edital CNPq/Universal, 2009, Process
   number 477935/2009-5 and by Pronex Edital FAPITEC/SE/FUNTEC/CNPq number
   12/2009, Process 019.203.02712/2009-8.
CR Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Coura-Vital W, 2013, VET PARASITOL, V197, P411, DOI 10.1016/j.vetpar.2013.07.031
   Courtenay O, 2002, PARASITOLOGY, V125, P407, DOI 10.1017/S0031182002002238
   Courtenay O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002583
   Dantas-Torres F, 2007, VET PARASITOL, V149, P139, DOI 10.1016/j.vetpar.2007.07.007
   Dantas-Torres Filipe, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P151, DOI 10.1590/S0036-46652006000300007
   Dawit G, 2013, J BACTERIOL PARASITO, V4, P2, DOI DOI 10.4172/2155-9597.10001
   Leal GGD, 2014, VET PARASITOL, V205, P472, DOI 10.1016/j.vetpar.2014.08.022
   Diaz S, 2012, VET PARASITOL, V189, P137, DOI 10.1016/j.vetpar.2012.05.004
   Jusi MMG, 2011, REV BRAS PARASITOL V, V20, P219, DOI 10.1590/S1984-29612011000300008
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Khuls K., 2011, PLOS NEGLECT TROP D, V5, pe1155
   Luppi MM, 2008, VET PARASITOL, V155, P146, DOI 10.1016/j.vetpar.2008.04.024
   Madeira MF, 1999, MEM I OSWALDO CRUZ, V94, P645, DOI 10.1590/S0074-02761999000500015
   Marcondes M., 2013, Brazilian Journal of Veterinary Research and Animal Science, V50, P341, DOI 10.11606/issn.2318-3659.v50i5p341-352
   Melo LM, 2014, INT IMMUNOPHARMACOL, V18, P373, DOI 10.1016/j.intimp.2013.12.012
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Loria-Cervera EN, 2014, REV INST MED TROP SP, V56, P1, DOI 10.1590/S0036-46652014000100001
   Quinnell RJ, 2009, PARASITOLOGY, V136, P1915, DOI 10.1017/S0031182009991156
   Richini-Pereira VB, 2014, J VENOM ANIM TOXINS, V20, DOI 10.1186/1678-9199-20-27
   Sampaio Weverton M, 2007, BMC Vet Res, V3, P11, DOI 10.1186/1746-6148-3-11
   Santos PL, 2012, NITRIC OXIDE-BIOL CH, V27, P67, DOI 10.1016/j.niox.2012.04.004
   Souza NP, 2010, REV SOC BRAS MED TRO, V43, P333, DOI 10.1590/S0037-86822010000300024
   Rodrigues CAT, 2009, VET IMMUNOL IMMUNOP, V127, P382, DOI 10.1016/j.vetimm.2008.10.324
   Viana KF, 2013, VET PARASITOL, V198, P62, DOI 10.1016/j.vetpar.2013.08.014
   Vouldoukis I, 2006, VET PARASITOL, V135, P137, DOI 10.1016/j.vetpar.2005.09.003
NR 26
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP 15
PY 2015
VL 212
IS 3-4
BP 417
EP 421
DI 10.1016/j.vetpar.2015.06.027
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA CU2LQ
UT WOS:000363355400055
PM 26194430
DA 2020-12-08
ER

PT J
AU Nascimento, MSL
   Carregaro, V
   Lima, DS
   Costa, DL
   Ryffel, B
   Duthie, MS
   de Jesus, A
   de Almeida, RP
   da Silva, JS
AF Lima Nascimento, Manuela Sales
   Carregaro, Vanessa
   Lima-Junior, Djalma Souza
   Costa, Diego Luis
   Ryffel, Bernhard
   Duthie, Malcolm S.
   de Jesus, Amelia
   de Almeida, Roque Pacheco
   da Silva, Joao Santana
TI Interleukin 17A Acts Synergistically With Interferon gamma to Promote
   Protection Against Leishmania infantum Infection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Leishmania infantum; visceral leishmaniasis; IL-17; nitric oxide
ID CHEMOKINE RECEPTOR EXPRESSION; HUMAN VISCERAL LEISHMANIASIS;
   IL-17-PRODUCING T-CELLS; DONOVANI INFECTIONS; HOST-DEFENSE; MICE;
   RESPONSES; IL-17; LYMPHOCYTES; DISEASE
AB Interleukin 17 (IL-17) is an inflammatory cytokine that plays a protective role against intracellular parasites. The role of IL-17 during Leishmania infection remains controversial and poorly defined. We evaluated whether IL-17 participates in the host immune response to Leishmania infantum. IL-17A is present in sera from patients with visceral leishmaniasis and decreases after successful treatment. In C57BL/6 infected mice, higher production of IL-17A coincided with the peak of parasitism gamma Il17ra(-/-) mice were more susceptible to infection and also exhibited reduced inflammatory infiltration and interferon gamma (IFN-gamma)-expressing CD4(+) T-cell frequencies than wild-type mice. The frequencies of FoxP3(+)CD4(+) T cells and interleukin 10 (IL-10)-expressing CD4(+) T cells were increased in Il17ra(-/-) mice. We also demonstrated that IL-17A acts synergistically with IFN-gamma to potentiate NO production and leishmanicidal activity in infected macrophages. Therefore, our results indicate that L. infantum induces IL-17A production, which promotes the control of parasite replication by strengthening T-helper type 1 responses and NO production and prevents regulatory T-cell and IL-10-expressing T-cell expansion.
C1 [Lima Nascimento, Manuela Sales; Carregaro, Vanessa; Lima-Junior, Djalma Souza; Costa, Diego Luis; da Silva, Joao Santana] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Aracaju, Brazil.
   [de Jesus, Amelia; de Almeida, Roque Pacheco] Univ Fed Sergipe, Ctr Biol & Hlth Sci, Aracaju, Brazil.
   [Ryffel, Bernhard] Univ Orleans, UMR6218, Orleans, France.
   [Ryffel, Bernhard] CNRS, F-45071 Orleans, France.
   [Duthie, Malcolm S.] Infect Dis Res Inst, Seattle, WA USA.
RP da Silva, JS (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Av Bandeirantes 3900, BR-14049900 Sao Paulo, Brazil.
EM jsdsilva@fmrp.usp.br
RI Costa, Diego Luis/F-7168-2019; Carregaro, Vanessa/D-2913-2012;
   nascimento, manuela/C-8628-2018; Silva, Joao S/A-4484-2008; Souza Lima
   Junior, Djalma/H-4833-2013
OI Costa, Diego Luis/0000-0002-9440-2814; Silva, Joao
   S/0000-0002-3410-3927; nascimento, manuela/0000-0002-6887-8931;
   Carregaro, Vanessa/0000-0002-8435-0766; Souza Lima Junior,
   Djalma/0000-0002-2092-8047; Duthie, Malcolm/0000-0002-8515-5516
FU Nucleo de Apoio a Pesquisa em Doencas Inflamatorias [11.1.21625.01.0];
   Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2013/01967-2, 2012/14524-9]
FX This work was supported by Nucleo de Apoio a Pesquisa em Doencas
   Inflamatorias (grant 11.1.21625.01.0) and Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (grants 2013/01967-2 and 2012/14524-9).
CR Ayres JS, 2012, ANNU REV IMMUNOL, V30, P271, DOI 10.1146/annurev-immunol-020711-075030
   Bermejo DA, 2013, NAT IMMUNOL, V14, P514, DOI 10.1038/ni.2569
   BIRON CA, 1995, CURR OPIN IMMUNOL, V7, P485, DOI 10.1016/0952-7915(95)80093-X
   Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213
   BUFFET PA, 1995, ANTIMICROB AGENTS CH, V39, P2167, DOI 10.1128/AAC.39.9.2167
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   CARVALHO EM, 1994, J IMMUNOL, V152, P5949
   Guedes PMD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000604
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   ENGLEN MD, 1995, J IMMUNOL METHODS, V184, P281, DOI 10.1016/0022-1759(95)00136-X
   Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106
   Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586
   Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893
   Gardener P J, 1977, Trop Dis Bull, V74, P1069
   Gautam S, 2011, J INFECT DIS, V204, P1134, DOI 10.1093/infdis/jir461
   GHALIB HW, 1995, J IMMUNOL, V154, P4623
   GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570
   Ghosh K, 2013, J INFECT DIS, V207, P1016, DOI 10.1093/infdis/jis771
   Gonzalez-Lombana C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003243
   Higgins SC, 2006, J IMMUNOL, V177, P7980, DOI 10.4049/jimmunol.177.11.7980
   Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329
   Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009
   Kedzierski L, 2008, EUR J IMMUNOL, V38, P3090, DOI 10.1002/eji.200838423
   Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018
   Kopf M, 1996, J EXP MED, V184, P1127, DOI 10.1084/jem.184.3.1127
   Kostka SL, 2009, J IMMUNOL, V182, P3039, DOI 10.4049/jimmunol.0713598
   Kryczek I, 2009, BLOOD, V114, P1141, DOI 10.1182/blood-2009-03-208249
   Kurasawa K, 2000, ARTHRITIS RHEUM-US, V43, P2455, DOI 10.1002/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K
   Lin YY, 2009, IMMUNITY, V31, P799, DOI 10.1016/j.immuni.2009.08.025
   Guedes PMM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001630
   Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173
   Novoa R, 2011, PARASITE IMMUNOL, V33, P132, DOI 10.1111/j.1365-3024.2010.01256.x
   Nylen S, 2007, TRENDS IMMUNOL, V28, P378, DOI 10.1016/j.it.2007.07.004
   Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141
   Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x
   Pitta MGR, 2009, J CLIN INVEST, V119, P2379, DOI 10.1172/JCI38813
   Qiu Z, 2009, IMMUNOBIOLOGY, V214, P835, DOI 10.1016/j.imbio.2009.06.007
   Rodrigues OR, 2009, IMMUNOBIOLOGY, V214, P101, DOI 10.1016/j.imbio.2008.07.001
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875
   Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2
   Sebastiani S, 2001, J IMMUNOL, V166, P996, DOI 10.4049/jimmunol.166.2.996
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   Vargas-Inchaustegui DA, 2008, J IMMUNOL, V180, P7537, DOI 10.4049/jimmunol.180.11.7537
   Yang Zheng-Sheng, 2011, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V27, P959
NR 45
TC 55
Z9 55
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR 15
PY 2015
VL 211
IS 6
BP 1015
EP 1026
DI 10.1093/infdis/jiu531
PG 12
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CC3CX
UT WOS:000350223300020
PM 25274569
OA Bronze
DA 2020-12-08
ER

PT J
AU Gardinassi, LG
   Dotz, V
   Ederveen, AH
   de Almeida, RP
   Costa, CHN
   Costa, DL
   de Jesus, AR
   Mayboroda, OA
   Garcia, GR
   Wuhrer, M
   Santosa, IKFD
AF Gardinassi, Luiz Gustavo
   Dotz, Viktoria
   Ederveen, Agnes Hipgrave
   de Almeida, Roque Pacheco
   Nery Costa, Carlos Henrique
   Costa, Dorcas Lamounier
   de Jesus, Amelia Ribeiro
   Mayboroda, Oleg A.
   Garcia, Gustavo Rocha
   Wuhrer, Manfred
   Ferreira de Miranda Santosa, Isabel Kinney
TI Clinical Severity of Visceral Leishmaniasis Is Associated with Changes
   in Immunoglobulin G Fc N-Glycosylation
SO MBIO
LA English
DT Article
ID CIRCULATING IMMUNE-COMPLEXES; B-CELL ACTIVATION; ANTIINFLAMMATORY
   ACTIVITY; RHEUMATOID-ARTHRITIS; DONOVANI INFECTION; STRUCTURAL-CHANGES;
   IGG GLYCOSYLATION; GAMMA RECEPTORS; ANTIBODY; BINDING
AB Visceral leishmaniasis (VL) has a high fatality rate if not treated; nevertheless, the majority of human infections with the causative agent, Leishmania infantum chagasi, are asymptomatic. Although VL patients often present with increased levels of serum immunoglobulins, the contribution of antibodies to resistance or progression to disease remains unknown. Effector and regulatory functions of antibodies rely on their interactions with type I and II Fc receptors, and these interactions are tuned by the patterns of antibody Fc N-glycosylation. In view of these facts, we applied a robust method of IgG Fc N-glycopeptide profiling of serum samples from 187 patients with VL, 177 asymptomatic individuals, 116 endemic controls (individuals residing in areas where VL is endemic) and 43 nonendemic controls (individuals living in an area where VL is not endemic). We show that, in comparison to the overall IgG Fc N-glycan profiles of asymptomatic or uninfected healthy individuals, those of patients with VL are profoundly altered. These changes correlate with levels of serum cytokines and the inflammation marker C-reactive protein. We also fitted univariate and multivariate ordinal logistic regression models to demonstrate the ability of IgG Fc N-glycosylation features and immunity regulators present in serum to predict disease severity in VL patients. Importantly, we show that Fc N-glycosylation profiles change after treatment of VL. This study introduces important concepts contributing to the understanding of antibody responses in infections with Leishmania parasites and provides new insights into the pathology of human VL.
   IMPORTANCE Immunoglobulins (Ig) have been shown to present pro-and anti-inflammatory functions according to the profile of carbohydrates attached to their Fc region. Glycosylation features of serum IgG have been examined in relation to several autoimmune and infectious diseases and provide a mechanistic basis for the protective or pathogenic role of antibodies. Leishmania infantum chagasi is the causative agent of visceral leishmaniasis (VL) in South America, and we show that VL patients produce IgG with patterns of Fc glycans similar to those found in other inflammatory conditions. Specific Fc N-glycosylation features and levels of serum cytokines and C-reactive protein are significantly associated with the development of severe clinical symptoms and, notably, Fc glycosylation changes after treatment. The modifications detected in the N-glycosylation features of IgG Fc from VL patients raise new perspectives on the effector or regulatory role of antibodies in immune responses elicited by infection with Leishmania parasites.
C1 [Gardinassi, Luiz Gustavo; Garcia, Gustavo Rocha; Ferreira de Miranda Santosa, Isabel Kinney] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Bioquim Imunol, BR-14049 Ribeirao Preto, Brazil.
   [Dotz, Viktoria; Wuhrer, Manfred] Vrije Univ Amsterdam, Div Bioanalyt Chem, Amsterdam, Netherlands.
   [Ederveen, Agnes Hipgrave; Mayboroda, Oleg A.; Wuhrer, Manfred] Leiden Univ, Med Ctr, Ctr Prote & Metabol, Leiden, Netherlands.
   [de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Med, Aracaju, Brazil.
   [Nery Costa, Carlos Henrique; Costa, Dorcas Lamounier] Univ Fed Piaui, Inst Doencas Tropicais Natan Portela, Dept Med Comunitaria, Teresina, Brazil.
   [Wuhrer, Manfred] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands.
RP Wuhrer, M (corresponding author), Vrije Univ Amsterdam, Div Bioanalyt Chem, Amsterdam, Netherlands.
EM m.wuhrer@lumc.nl; imsantos@fmrp.usp.br
RI Mayboroda, Oleg/B-5634-2008; Mayboroda, Oleg/N-4850-2019; Gardinassi,
   Luiz Gustavo Araujo/K-6276-2012; de Miranda Santos, Isabel K.
   F./D-5261-2016; Gardinassi, Luiz/V-2225-2019; Wuhrer,
   Manfred/ABE-9168-2020; de Miranda Santos, Isabel KF/B-7597-2012
OI Mayboroda, Oleg/0000-0001-8739-9875; Mayboroda,
   Oleg/0000-0001-8739-9875; Gardinassi, Luiz Gustavo
   Araujo/0000-0002-9027-2688; Gardinassi, Luiz/0000-0002-9027-2688;
   Wuhrer, Manfred/0000-0002-0814-4995; de Miranda Santos, Isabel
   KF/0000-0002-0438-4430; Hipgrave Ederveen, Agnes/0000-0003-1689-0442;
   Dotz, Viktoria/0000-0002-9888-7409
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq)
   [559603/2009-6]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/53645-3, 2012/06708-2]; European UnionEuropean Union (EU)
   [278535]; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2011/23819-0, 2013/00382-0]
FX This work was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (grant 559603/2009-6), the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP; grants 2009/53645-3,
   2012/06708-2, and 2012/06708-2), and by the European Union's Seventh
   Framework Program (FP7-Health-F5-2011) under grant agreement 278535
   (HighGlycan). L.G.G. and G.R.G. were supported by FAPESP (scholarships
   2011/23819-0 and 2013/00382-0, respectively).
CR Ackerman ME, 2013, J CLIN INVEST, V123, P2183, DOI 10.1172/JCI65708
   Ahmed AA, 2014, J MOL BIOL, V426, P3166, DOI 10.1016/j.jmb.2014.07.006
   Alonso DP, 2007, J INFECT DIS, V195, P1212, DOI 10.1086/512683
   Ansar W, 2009, GLYCOCONJUGATE J, V26, P1151, DOI 10.1007/s10719-009-9236-y
   Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134
   BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639
   Bakovic MP, 2013, J PROTEOME RES, V12, P821, DOI 10.1021/pr300887z
   Biburger M, 2011, IMMUNITY, V35, P932, DOI 10.1016/j.immuni.2011.11.009
   Brasil Ministerio da Saude . Secretaria de Vigilancia em Saude. Departamento de Vigilancia Epidemiologica, 2006, MAN VIG CONTR LEISHM
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   Chu NS, 2010, J IMMUNOL, V185, P6939, DOI 10.4049/jimmunol.1002484
   Collins ES, 2013, RHEUMATOLOGY, V52, P1572, DOI 10.1093/rheumatology/ket189
   Costa DL, 2013, PATHOG GLOB HEALTH, V107, P78, DOI 10.1179/2047773213Y.0000000078
   Deak E, 2010, EUR J IMMUNOL, V40, P1355, DOI 10.1002/eji.200939455
   Duthie MS, 2014, EUR J CLIN MICROBIOL, V33, P639, DOI 10.1007/s10096-013-1999-1
   Elshafie AI, 2007, J IMMUNOL, V178, P5383, DOI 10.4049/jimmunol.178.8.5383
   EVANS TG, 1989, MEM I OSWALDO CRUZ, V84, P157, DOI 10.1590/S0074-02761989000200003
   GALVAOCASTRO B, 1984, CLIN EXP IMMUNOL, V56, P58
   Gautam S, 2011, J INFECT DIS, V204, P1134, DOI 10.1093/infdis/jir461
   Gibson-Corley KN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106426
   Hess C, 2013, J CLIN INVEST, V123, P3788, DOI 10.1172/JCI65938
   Ho CH, 2014, J INFECT DIS
   Huffman JE, 2014, MOL CELL PROTEOMICS, V13, P1598, DOI 10.1074/mcp.M113.037465
   Imafuku Y, 2003, CLIN CHIM ACTA, V334, P217, DOI 10.1016/S0009-8981(03)00245-6
   Jeddi P, 1999, IMMUNOLOGY, V98, P475, DOI 10.1046/j.1365-2567.1999.00896.x
   Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594
   Karsten CM, 2012, NAT MED, V18, P1401, DOI 10.1038/nm.2862
   Lauc G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003225
   MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237
   Mauer J, 2014, NAT IMMUNOL, V15, P423, DOI 10.1038/ni.2865
   McCall LI, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003053
   Mehta AS, 2008, J VIROL, V82, P1259, DOI 10.1128/JVI.01600-07
   Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470
   Costa CHN, 2010, REV SOC BRAS MED TRO, V43, P386, DOI 10.1590/S0037-86822010000400010
   Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948
   Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206
   Nimmerjahn F, 2007, P NATL ACAD SCI USA, V104, P8433, DOI 10.1073/pnas.0702936104
   Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141
   O'Regan NL, 2014, PARASITE IMMUNOL
   Osorio EY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002417
   Owens BMJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002827
   PAREKH R, 1989, J AUTOIMMUN, V2, P101, DOI 10.1016/0896-8411(89)90148-0
   PEARSON RD, 1983, J INFECT DIS, V147, P1102, DOI 10.1093/infdis/147.6.1102
   Peruhype-Magalhaes V, 2006, CLIN EXP IMMUNOL, V146, P124, DOI 10.1111/j.1365-2249.2006.03171.x
   Pincetic A, 2014, NAT IMMUNOL, V15, P707, DOI 10.1038/ni.2939
   Rombouts Y., 2013, ANN RHEUM DIS
   ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890
   Ryan JR, 2002, J CLIN MICROBIOL, V40, P1037, DOI 10.1128/JCM.40.3.1037-1043.2002
   Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484
   Santos IKFD, 2001, INFECT IMMUN, V69, P5212
   Sela-Culang I, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00302
   Selman MHJ, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014563
   Selman MHJ, 2011, J PROTEOME RES, V10, P143, DOI 10.1021/pr1004373
   Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200
   Shikata K, 1998, GLYCOCONJUGATE J, V15, P683, DOI 10.1023/A:1006936431276
   Siberil S, 2006, CLIN IMMUNOL, V118, P170, DOI 10.1016/j.clim.2005.10.008
   Smelt SC, 2000, J IMMUNOL, V164, P3681, DOI 10.4049/jimmunol.164.7.3681
   Stadlmann J, 2008, PROTEOMICS, V8, P2858, DOI 10.1002/pmic.200700968
   Stadlmann J, 2009, PROTEOMICS, V9, P4143, DOI 10.1002/pmic.200800931
   Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0
   Troelsen LN, 2012, J RHEUMATOL, V39, P463, DOI 10.3899/jrheum.110584
   Tudor D, 2012, P NATL ACAD SCI USA, V109, P12680, DOI 10.1073/pnas.1200024109
   VANZEBEN D, 1994, BRIT J RHEUMATOL, V33, P36
   VELGE P, 1991, EUR J IMMUNOL, V21, P2145, DOI 10.1002/eji.1830210924
   Wang J, 2011, MOL CELL PROTEOMICS, V10, DOI [10.1074/mcp.M111.010017-1, 10.1074/mcp.M111.010017]
   WHITE AC, 1992, AM J TROP MED HYG, V46, P123, DOI 10.4269/ajtmh.1992.46.123
   Woelbing F, 2006, J EXP MED, V203, P177, DOI 10.1084/jem.20052288
   Wuhrer M, 2007, PROTEOMICS, V7, P4070, DOI 10.1002/pmic.200700289
   Xia YM, 2013, MOL IMMUNOL, V56, P28, DOI 10.1016/j.molimm.2013.04.004
   Yamada E, 1997, GLYCOCONJUGATE J, V14, P401, DOI 10.1023/A:1018582930906
   Zauner G, 2013, MOL CELL PROTEOMICS, V12, P856, DOI 10.1074/mcp.R112.026005
   ZIJLSTRA EE, 1994, AM J TROP MED HYG, V51, P826, DOI 10.4269/ajtmh.1994.51.826
   Zou GZ, 2011, J AM CHEM SOC, V133, P18975, DOI 10.1021/ja208390n
NR 73
TC 23
Z9 24
U1 0
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD NOV-DEC
PY 2014
VL 5
IS 6
AR e01844
DI 10.1128/mBio.01844-14
PG 12
WC Microbiology
SC Microbiology
GA AX7CE
UT WOS:000347073600010
PM 25467439
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Sacramento, LA
   Cunha, FQ
   de Almeida, RP
   da Silva, JS
   Carregaro, V
AF Sacramento, Lais Amorim
   Cunha, Fernando Q.
   de Almeida, Roque Pacheco
   da Silva, Joao Santana
   Carregaro, Vanessa
TI Protective Role of 5-Lipoxigenase during Leishmania infantum Infection
   Is Associated with Th17 Subset
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID HUMAN POLYMORPHONUCLEAR LEUKOCYTES; INDUCED NEUTROPHIL MIGRATION;
   ARACHIDONIC-ACID METABOLISM; LEUKOTRIENE B-4 RECEPTOR; PULMONARY
   HOST-DEFENSE; DENDRITIC CELLS; 5-LIPOXYGENASE EXPRESSION; AMAZONENSIS
   INFECTION; SYNOVIAL-FLUID; PRODUCE IL-12
AB Visceral leishmaniasis (VL) is a chronic and fatal disease caused by Leishmania infantum in Brazil. Leukocyte recruitment to infected tissue is a crucial event for the control of infections such as VL. Leucotriens are lipid mediators synthesized by 5-lipoxygenase (5-LO) and they display a protective role against protozoan parasites by inducing several functions in leucocytes. We determined the role of 5-LO activity in parasite control, focusing on the inflammatory immune response against Leishmania infantum infection. LTB4 is released during in vitro infection. The genetic ablation of 5-LO promoted susceptibility in highly resistant mice strains, harboring more parasites into target organs. The susceptibility was related to the failure of neutrophil migration to the infectious foci. Investigating the neutrophil failure, there was a reduction of proinflammatory cytokines involved in the related Th17 axis released into the organs. Genetic ablation of 5-LO reduced the CD4(+)T cells producing IL-17, without interfering in Th1 subset. L. infantum failed to activate DC from 5-LO-/-, showing reduced surface costimulatory molecule expression and proinflammatory cytokines involved in Th17 differentiation. BLT1 blockage with selective antagonist interferes with DC maturation and proinflammatory cytokines release. Thus, 5-LO activation coordinates the inflammatory immune response involved in the control of VL.
C1 [Sacramento, Lais Amorim; Cunha, Fernando Q.; da Silva, Joao Santana; Carregaro, Vanessa] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Cunha, Fernando Q.; de Almeida, Roque Pacheco] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pharmacol, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Carregaro, V (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM vcarregaro@usp.br
RI Carregaro, Vanessa/D-2913-2012; Silva, Joao S/A-4484-2008; Cunha,
   Fernando Q/M-3090-2014; Moreira-Silva, Joana/J-6443-2015
OI Silva, Joao S/0000-0002-3410-3927; Moreira-Silva,
   Joana/0000-0003-1087-6009; Carregaro, Vanessa/0000-0002-8435-0766;
   Cunha, Fernando Queiroz/0000-0003-4755-1670
FU CAPES-PRODOCCAPES; Sao Paulo Research Foundation (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/14524-9,
   2013/08216-2]; University of Sao Paulo NAP-DIN [11.1.21625.01.0]
FX The authors are grateful to Giuliana Bertozi for helping with the
   LTB<INF>4</INF> measurement. The research leading to these results
   received funding from the CAPES-PRODOC, Sao Paulo Research Foundation
   (FAPESP) under Grant Agreements nos. 2012/14524-9 (Thematic Project) and
   2013/08216-2 (Center for Research in Inflammatory Disease) and from the
   University of Sao Paulo NAP-DIN under Grant Agreement no.
   11.1.21625.01.0.
CR Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200
   Antoniazi S, 2004, INFECT IMMUN, V72, P5168, DOI 10.1128/IAI.72.9.5168-5174.2004
   Balamayooran G, 2011, INFECT IMMUN, V79, P2567, DOI 10.1128/IAI.00067-11
   Balderramas HA, 2014, CYTOKINE, V67, P36, DOI 10.1016/j.cyto.2014.02.004
   BEIL WJ, 1992, J LEUKOCYTE BIOL, V52, P135
   Carregaro V, 2008, J LEUKOCYTE BIOL, V84, P104, DOI 10.1189/jlb.1107797
   Chaves MM, 2014, J IMMUNOL, V192, P4765, DOI 10.4049/jimmunol.1301058
   Chen HY, 2009, PROSTAG LEUKOTR ESS, V80, P195, DOI 10.1016/j.plefa.2009.01.006
   CONTI P, 1990, Cytokine, V2, P142, DOI 10.1016/1043-4666(90)90008-H
   De Trez C, 2004, INFECT IMMUN, V72, P824, DOI 10.1128/IAI.72.2.824-832.2004
   Del Prete A, 2007, BLOOD, V109, P626, DOI 10.1182/blood-2006-02-003665
   Engwerda CR, 2000, IMMUNOL TODAY, V21, P73, DOI 10.1016/S0167-5699(99)01549-2
   Fan J, 2003, NAT MED, V9, P315, DOI 10.1038/nm832
   Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008
   Faurschou M, 2002, BBA-MOL CELL RES, V1591, P29, DOI 10.1016/S0167-4889(02)00243-4
   Flamand L, 2004, J INFECT DIS, V189, P2001, DOI 10.1086/386374
   FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0
   Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593
   Gaudreault E, 2007, VIRAL IMMUNOL, V20, P407, DOI 10.1089/vim.2006.0099
   Gelfand EW, 2006, J ALLERGY CLIN IMMUN, V117, P577, DOI 10.1016/j.jaci.2005.12.1340
   Ghosh K, 2013, J INFECT DIS, V207, P1016, DOI 10.1093/infdis/jis771
   GOETZL EJ, 1981, BIOCHEM BIOPH RES CO, V101, P344, DOI 10.1016/0006-291X(81)91266-3
   GOODWIN JS, 1986, J CLIN INVEST, V77, P1244, DOI 10.1172/JCI112427
   Gorak PMA, 1998, EUR J IMMUNOL, V28, P687, DOI 10.1002/(SICI)1521-4141(199802)28:02&lt;687::AID-IMMU687&gt;3.0.CO;2-N
   Haeggstrom J. Z., 2011, TRANSDUCTION MECH CE, P349
   Harizi H, 2002, PROSTAG LEUKOTR ESS, V66, P459, DOI 10.1054/plef.2002.0383
   Hashimoto A, 2003, J RHEUMATOL, V30, P1712
   Ito S, 2008, SHOCK, V30, P87, DOI 10.1097/SHK.0b013e31815d06a1
   Kihara Y, 2010, BIOCHEM BIOPH RES CO, V394, P673, DOI 10.1016/j.bbrc.2010.03.049
   KLICKSTEIN LB, 1980, J CLIN INVEST, V66, P1166, DOI 10.1172/JCI109947
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Kumar NS, 1996, ALLERGY ASTHMA PROC, V17, P93, DOI 10.2500/108854196778645047
   Laan M, 1999, J IMMUNOL, V162, P2347
   Lefevre L, 2013, IMMUNITY, V38, P1038, DOI 10.1016/j.immuni.2013.04.010
   Leon B, 2007, IMMUNITY, V26, P519, DOI 10.1016/j.immuni.2007.01.017
   Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870
   Mancuso P, 2001, INFECT IMMUN, V69, P2011, DOI 10.1128/IAI.69.4.2011-2016.2001
   Mancuso P, 2010, INFECT IMMUN, V78, P2264, DOI 10.1128/IAI.01323-09
   Tristao FSM, 2013, INFECT IMMUN, V81, P1256, DOI 10.1128/IAI.01209-12
   Medoff BD, 2009, J IMMUNOL, V182, P623, DOI 10.4049/jimmunol.182.1.623
   Muraille E, 2003, J IMMUNOL, V170, P4237, DOI 10.4049/jimmunol.170.8.4237
   Nauseef WM, 2007, IMMUNOL REV, V219, P88, DOI 10.1111/j.1600-065X.2007.00550.x
   Patnode ML, 2014, J EXP MED, V211, P1281, DOI 10.1084/jem.20132336
   Pavanelli WR, 2010, MICROBES INFECT, V12, P587, DOI 10.1016/j.micinf.2010.03.016
   Peres CM, 2007, MICROBES INFECT, V9, P483, DOI 10.1016/j.micinf.2007.01.006
   Peters-Golden M, 2001, FEBS LETT, V487, P323, DOI 10.1016/S0014-5793(00)02374-7
   RAE SA, 1981, J PHARM PHARMACOL, V33, P616, DOI 10.1111/j.2042-7158.1981.tb13884.x
   REINER NE, 1985, J IMMUNOL, V134, P556
   REINER NE, 1984, CELL IMMUNOL, V88, P501, DOI 10.1016/0008-8749(84)90181-3
   Rinaldo-Matthis A, 2010, BIOCHIMIE, V92, P676, DOI 10.1016/j.biochi.2010.01.010
   Ritter U, 2002, PARASITE IMMUNOL, V24, P295, DOI 10.1046/j.1365-3024.2002.00467.x
   ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P7505, DOI 10.1073/pnas.82.22.7505
   Sabroe I, 2003, J IMMUNOL, V171, P1630, DOI 10.4049/jimmunol.171.4.1630
   SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011
   Santos PC, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002390
   Secatto A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031701
   Serezani CH, 2006, J IMMUNOL, V177, P3201, DOI 10.4049/jimmunol.177.5.3201
   Serezani CH, 2011, J CLIN INVEST, V121, P671, DOI 10.1172/JCI43302
   SMITH MJH, 1980, J PHARM PHARMACOL, V32, P517, DOI 10.1111/j.2042-7158.1980.tb12985.x
   Spanbroek R, 2000, BLOOD, V96, P3857, DOI 10.1182/blood.V96.12.3857.h8003857_3857_3865
   Spanbroek R, 1998, P NATL ACAD SCI USA, V95, P663, DOI 10.1073/pnas.95.2.663
   Stockinger B, 2007, CURR OPIN IMMUNOL, V19, P281, DOI 10.1016/j.coi.2007.04.005
   SUMIMOTO H, 1984, BIOCHIM BIOPHYS ACTA, V803, P271, DOI 10.1016/0167-4889(84)90117-4
   Tavares NM, 2014, J INFECT DIS, V210, P656, DOI 10.1093/infdis/jiu158
   Thalhofer CJ, 2011, INFECT IMMUN, V79, P108, DOI 10.1128/IAI.00338-10
   vanPelt JPA, 1997, BIOCHEM PHARMACOL, V53, P1005, DOI 10.1016/S0006-2952(96)00884-2
   von Stebut E, 1998, J EXP MED, V188, P1547, DOI 10.1084/jem.188.8.1547
   YONG EC, 1994, J EXP MED, V180, P1637, DOI 10.1084/jem.180.5.1637
NR 68
TC 14
Z9 14
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 264270
DI 10.1155/2014/264270
PG 12
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AX1LA
UT WOS:000346707400001
PM 25309905
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Vazquez, CMP
   Netto, RSM
   Barbosa, KBF
   de Moura, TR
   de Almeida, RP
   Duthie, MS
   de Jesus, AR
AF Passos Vazquez, Cecilia Maria
   Mendes Netto, Raquel Simoes
   Ferreira Barbosa, Kiriaque Barra
   Rodrigues de Moura, Tatiana
   Pacheco de Almeida, Roque
   Duthie, Malcolm S.
   Ribeiro de Jesus, Amelia
TI Micronutrients influencing the immune response in leprosy
SO NUTRICION HOSPITALARIA
LA English
DT Review
DE Nutrition; Leprosy; Oxidative stress and antioxidants
ID PULMONARY TUBERCULOSIS PATIENTS; D-RECEPTOR GENE; CD4(+) T-CELLS;
   VITAMIN-D; CATHELICIDIN LL-37; OXIDATIVE STRESS; HANSENS-DISEASE;
   GREATER VITORIA; ESPIRITO-SANTO; TRACE-ELEMENTS
AB Leprosy is a chronic infectious disease caused by Mycobacterium leprae, an intracellular bacillus of airborne transmission. The disease affects the skin and peripheral nerves and can cause neurological sequelae. The bacillus multiplies slowly in the host and the disease probably occurs due to malfunctioning in host immune response. This review addresses the role of some specific micronutrients in the immune response, such as Vitamins A, D, E, C, Zinc and Selenium, detailing their mechanisms of actions in infectious diseases, and in leprosy. The immune response to pathogens releases harmful substances, which lead to tissue damage. This review discusses how a decreased level of antioxidants may contribute to an increased oxidative stress and complications of infectious diseases and leprosy. As the nutrients have a regulatory effect in the innate and adaptative immune responses, a perfect balance in their concentrations is important to improve the immune response against the pathogens.
C1 [Passos Vazquez, Cecilia Maria; Rodrigues de Moura, Tatiana; Pacheco de Almeida, Roque; Ribeiro de Jesus, Amelia] Univ Fed Sergipe, Dept Med, Univ Hosp, Mol Biol Lab, Aracaju, Brazil.
   [Mendes Netto, Raquel Simoes; Ferreira Barbosa, Kiriaque Barra] Univ Fed Sergipe, Dept Nutr, Aracaju, Brazil.
   [Pacheco de Almeida, Roque; Ribeiro de Jesus, Amelia] CNPq, Inst Nacionais Ciencia & Tecnol, Inst Invest Imunol, Brasilia, DF, Brazil.
   [Duthie, Malcolm S.] IDRI, Seattle, WA 98014 USA.
RP de Jesus, AR (corresponding author), Univ Fed Sergipe, Dept Med, Univ Hosp, Mol Biol Lab, Aracaju, Brazil.
EM jesus-amelia@uol.com.br
RI Barbosa, Kiriaque/E-4269-2014; Mendes-Netto, Raquel/W-8120-2019
OI Duthie, Malcolm/0000-0002-8515-5516
FU Coordination of Improvement of Education Personnel (CAPES); Brazilian
   Council for Scientific and Technological Development (CNPq)/ Universal
   [477935/2009-5]; PRONEX, FAPITEC/SE/FUNTEC/CNPq [12/2009,
   019.203.02712/2009-8]
FX The research group is funded by Coordination of Improvement of Education
   Personnel (CAPES) and the Brazilian Council for Scientific and
   Technological Development (CNPq)/ Universal, 2009, Grant No.
   477935/2009-5 and by PRONEX, FAPITEC/SE/FUNTEC/CNPq, 12/2009, Grant No.
   019.203.02712/2009-8. ARJ and RPA are scientists from CNPq.
CR Afridi HI, 2011, CLIN LAB, V57, P171
   Albert B., 2004, BIOL MOL CELULA
   Alter A, 2008, HUM GENET, V123, P227, DOI 10.1007/s00439-008-0474-z
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   [Anonymous], 2010, NOT SDIDAD
   Aranha F. Q., 2000, Revista de Nutricao, V13, P89
   Azzini E, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-125
   Bakaev VV, 2004, INT J TUBERC LUNG D, V8, P263
   Barbosa E, 2007, REV NUTR, V20, P693, DOI 10.1590/S1415-52732007000600011
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Bogdan C, 1998, BERL MUNCH TIERARZTL, V111, P409
   Britton WJ, 2004, LANCET, V363, P1209, DOI 10.1016/S0140-6736(04)15952-7
   Calder PC, 2000, NUTR RES REV, V13, P3, DOI 10.1079/095442200108728981
   Calder PC, 2002, BRIT J NUTR, V88, pS165, DOI 10.1079/BJN2002682
   CHANDRA RK, 1994, J NUTR, V124, pS1433, DOI 10.1093/jn/124.suppl_8.1433S
   Chocano-Bedoya P, 2009, NUTR REV, V67, P289, DOI 10.1111/j.1753-4887.2009.00195.x
   Coura J. R., 2005, DINAMICA DOENCAS INF
   Dawson HD, 1999, J NUTR, V129, P1510
   Fairweather-Tait SJ, 2011, ANTIOXID REDOX SIGN, V14, P1337, DOI 10.1089/ars.2010.3275
   Fujio K, 2010, ADV IMMUNOL, V105, P99, DOI 10.1016/S0065-2776(10)05004-2
   Gibney KB, 2008, CLIN INFECT DIS, V46, P443, DOI 10.1086/525268
   Jyothi P, 2008, Indian J Dermatol Venereol Leprol, V74, P80
   Kerr-Pontes LRS, 2006, INT J EPIDEMIOL, V35, P994, DOI 10.1093/ije/dyl072
   Koury Josely Correa, 2003, Rev. Nutr., V16, P433, DOI 10.1590/S1415-52732003000400007
   Kowalski Jan, 2004, Pol Merkur Lekarski, V16, P119
   Larnsal Madhab, 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P695
   Leite H, 2003, REV BRAS NUTR CLIN, V18, P87
   Lima Emerson S., 2007, Rev. Inst. Med. trop. S. Paulo, V49, P211, DOI 10.1590/S0036-46652007000400003
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   Luz K G, 2001, Rev Soc Bras Med Trop, V34, P381, DOI 10.1590/S0037-86822001000400013
   Maggini S, 2007, BRIT J NUTR, V98, pS29, DOI 10.1017/S0007114507832971
   Maret W, 2000, J NUTR, V130, p1455S, DOI 10.1093/jn/130.5.1455S
   Martineau AR, 2007, J IMMUNOL, V178, P7190, DOI 10.4049/jimmunol.178.11.7190
   Matzner M, 2011, ACTA TROP, V117, P56, DOI 10.1016/j.actatropica.2010.09.007
   Meydani M, 1998, NUTR REV, V56, pS177
   Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378
   Moulin CM, 2009, ARQ BRAS ENDOCRINOL, V53, P183, DOI 10.1590/S0004-27302009000200010
   MURRAY R. K, 2002, HARPER BIOQUIMICA
   Montenegro RMN, 2012, CAD SAUDE PUBLICA, V28, P31, DOI 10.1590/S0102-311X2012000100004
   Montenegro RMN, 2011, REV SOC BRAS MED TRO, V44, P228, DOI [10.1590/S0037-86822011005000016, 10.1590/s0037-86822011005000016]
   Neve J., 1997, PR MED BIOL A, V8, P985
   Nnoaham KE, 2008, INT J EPIDEMIOL, V37, P113, DOI 10.1093/ije/dym247
   Nogueira Carla, 2010, Rev. paul. pediatr., V28, P381, DOI 10.1590/S0103-05822010000400015
   Oh SY, 1998, INT J LEPROSY, V66, P34
   Palace VP, 1999, FREE RADICAL BIO MED, V26, P746, DOI 10.1016/S0891-5849(98)00266-4
   Palermo ML, 2012, AM J TROP MED HYG, V86, P878, DOI 10.4269/ajtmh.2012.12-0088
   Plit ML, 1998, INT J TUBERC LUNG D, V2, P590
   Prasad AS, 2000, J INFECT DIS, V182, pS62, DOI 10.1086/315916
   Ramakrishnan K, 2012, CLIN LAB, V58, P165
   Rivas-Santiago B, 2008, INFECT IMMUN, V76, P935, DOI 10.1128/IAI.01218-07
   Roy S, 1999, J INFECT DIS, V179, P187, DOI 10.1086/314536
   Scollard DM, 2008, SOUTH MED J, V101, P583, DOI 10.1097/SMJ.0b013e318172e077
   Scollard DM, 2008, LEPROSY REV, V79, P242
   Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006
   Selvaraj P, 2004, J CLIN IMMUNOL, V24, P523, DOI 10.1023/B:JOCI.0000040923.07879.31
   Seyedrezazadeh E, 2008, RESPIROLOGY, V13, P294, DOI 10.1111/j.1440-1843.2007.01200.x
   Shaik-Dasthagirisaheb YB, 2013, J BIOL REG HOMEOS AG, V27, P291
   Shapira Y, 2010, CLIN REV ALLERG IMMU, V38, P169, DOI 10.1007/s12016-009-8150-1
   SIES H, 1995, AM J CLIN NUTR, V62, P1315
   Siest G, 2008, DRUG METAB DISPOS, V36, P182, DOI 10.1124/dmd.107.017228
   Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167
   Ueda N, 2009, J NEUROL SCI, V287, P216, DOI 10.1016/j.jns.2009.07.020
   van Lettow M, 2005, EUR J CLIN NUTR, V59, P526, DOI 10.1038/sj.ejcn.1602116
   Vannucchi Helio, 1998, Medicina (Ribeirao Preto), V31, P31
   Vijayaraghavan R, 2005, EUR J CLIN NUTR, V59, P1121, DOI 10.1038/sj.ejcn.1602221
   Villamor E, 2005, CLIN MICROBIOL REV, V18, P446, DOI 10.1128/CMR.18.3.446-464.2005
   Waitzbertg D, 2006, NUTR ORAL ENTERAL PA
   Wanasen N, 2007, INFECT IMMUN, V75, P2802, DOI 10.1128/IAI.00026-07
   Wang QZ, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-104
   Wang XC, 2007, J CLIN IMMUNOL, V27, P193, DOI 10.1007/s10875-006-9068-5
   WHO, 2011, LEPR TOD
   Wintergerst ES, 2006, ANN NUTR METAB, V50, P85, DOI 10.1159/000090495
   Wintergerst ES, 2007, ANN NUTR METAB, V51, P301, DOI 10.1159/000107673
   Wood RJ, 2000, J NUTR, V130, p1350S, DOI 10.1093/jn/130.5.1350S
   World Health Organization, 2011, WEEKLY EPIDEMIOLOGIC
   Zaccone P, 2011, EUR J IMMUNOL, V41, P2709, DOI 10.1002/eji.201141429
   Zasloff M, 2006, NAT MED, V12, P388, DOI 10.1038/nm0406-388
NR 77
TC 5
Z9 6
U1 0
U2 7
PU ARAN EDICIONES, S L
PI MADRID
PA C/ CASTELLO, 128, 1O, MADRID, 28006, SPAIN
SN 0212-1611
EI 1699-5198
J9 NUTR HOSP
JI Nutr. Hosp.
PD JAN
PY 2014
VL 29
IS 1
BP 26
EP 36
DI 10.3305/nh.2014.29.1.6988
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AA8IV
UT WOS:000331340100005
PM 24483959
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU de Azevedo, AF
   Dutra, JLD
   Santos, MLB
   Santos, DD
   Alves, PB
   de Moura, TR
   de Almeida, RP
   Fernandes, MF
   Scher, R
   Fernandes, RPM
AF de Azevedo, Alana Freire
   de Lisboa Dutra, Jorge Luis
   Barbosa Santos, Micheli Luize
   Santos, Darlisson de Alexandria
   Alves, Pericles Barreto
   de Moura, Tatiana Rodrigues
   de Almeida, Roque Pacheco
   Fernandes, Marcelo Ferreira
   Scher, Ricardo
   Miranda Fernandes, Roberta Pereira
TI Fatty acid profiles in Leishmania spp. isolates with natural resistance
   to nitric oxide and trivalent antimony
SO PARASITOLOGY RESEARCH
LA English
DT Article
ID AMASTIGOTES; METABOLISM; PARASITE
AB Fatty acids, especially those from phospholipids (PLFA), are essential membrane components that are present in relatively constant proportions in biological membranes under natural conditions. However, under harmful growth conditions, such as diseases, environmental changes, and chemical exposure, the fatty acid proportions might vary. If such changes could be identified and revealed to be specific for adverse situations, they could be used as biomarkers. Such biomarkers could facilitate the identification of virulence and resistance mechanisms to particular chemotherapeutic agents. Therefore, specific biomarkers could lead to better therapeutic decisions that would, in turn, enhance treatment effectiveness. The objective of this study was to compare the fatty acid profiles of trivalent antimony and nitric oxide (NO)-resistant and -sensitive Leishmania chagasi and Leishmania amazonensis isolates. Fatty acid methyl esters (FAMEs) were obtained from total lipids (MIDI), ester-linked lipids (ELFA), and ester-linked phospholipids (PLFA). FAMEs were analyzed by chromatography and mass spectrometry. Species- or resistance-associated differences in FAME profiles were assessed by nonmetric multidimensional scaling, multiresponse permutation procedures, and indicator species analyses. The isolate groups had different MIDI-FAME profiles. However, neither the ELFA nor PLFA profiles differed between the sensitive and resistant isolates. Levels of the fatty acid 18:1 Delta 9c were increased in sensitive isolates (p < 0,001), whereas the fatty acid 20:4 Delta 5,8,11,14 showed the opposite trend (p < 0.01). We conclude that these two fatty acids are potential biomarkers for NO and antimony resistance in L. chagasi and L. amazonensis and that they could be helpful in therapeutic diagnoses.
C1 [de Azevedo, Alana Freire; de Lisboa Dutra, Jorge Luis; Miranda Fernandes, Roberta Pereira] Univ Fed Sergipe, Dept Fisiol, BR-49100000 Sao Cristovao, Sergipe, Brazil.
   [Barbosa Santos, Micheli Luize; de Almeida, Roque Pacheco] UFS, Dept Med, BR-49060100 Aracaju, Sergipe, Brazil.
   [Santos, Darlisson de Alexandria; Alves, Pericles Barreto] Univ Fed Sergipe, Dept Quim, BR-49100000 Sao Cristovao, Sergipe, Brazil.
   [Fernandes, Marcelo Ferreira] Embrapa Tabuleiros Costeiros, BR-49025040 Aracaju, Sergipe, Brazil.
   [de Moura, Tatiana Rodrigues; Scher, Ricardo] Univ Fed Sergipe, Dept Morfol, BR-49100000 Sao Cristovao, Sergipe, Brazil.
RP Fernandes, RPM (corresponding author), Univ Fed Sergipe, Dept Fisiol, Av Marechal Rondon S-N, BR-49100000 Sao Cristovao, Sergipe, Brazil.
EM robertafernandes@ufs.br
RI Alves, Pericles/S-8768-2019; Santos, Darlisson A/E-2970-2016; Fernandes,
   Roberta/J-4301-2014; de Alexandria Santos, Darlisson/AAV-8587-2020; ,
   Tatiana/AAN-1194-2020; Fernandes, Marcelo F/F-9360-2012
OI Alves, Pericles/0000-0002-8955-9614; Santos, Darlisson
   A/0000-0001-5817-5792; Fernandes, Roberta/0000-0003-1467-3946; de
   Alexandria Santos, Darlisson/0000-0001-5817-5792; ,
   Tatiana/0000-0002-7442-4434; 
FU Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe (FAPITEC)/Brazilian Research National Council (CNPq)/Ministerio
   da Saude ( [08/2009]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES; Brazilian Research National Council
   (CNPq)National Council for Scientific and Technological Development
   (CNPq)
FX This work was supported by Fundacao de Apoio a Pesquisa e a Inovacao
   Tecnologica do Estado de Sergipe (FAPITEC)/Brazilian Research National
   Council (CNPq)/Ministerio da Saude (Programa de Apoio a Projetos para o
   Sistema Unico de Saude - PPSUS Edital 08/2009. We thank Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and Brazilian
   Research National Council (CNPq) for the graduate and undergraduate
   students scholarship. RPA and MFF are scientists from the Brazilian
   Research National Council (CNPq).
CR ADOSRAKU RK, 1993, MOL BIOCHEM PARASIT, V62, P251, DOI 10.1016/0166-6851(93)90114-D
   Alloatti A, 2011, MOL BIOCHEM PARASIT, V175, P126, DOI 10.1016/j.molbiopara.2010.10.006
   Basselin M, 1998, PARASITOL RES, V84, P78, DOI 10.1007/s004360050361
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Butler JL, 2003, APPL ENVIRON MICROB, V69, P6793, DOI 10.1128/AEM.69.11.6793-6800.2003
   Cauchetier E, 2002, INT J PARASITOL, V32, P1043, DOI 10.1016/S0020-7519(02)00065-6
   CAVIGELLI MA, 1995, PLANT SOIL, V170, P99, DOI 10.1007/BF02183058
   Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]
   Dufrene M, 1997, ECOL MONOGR, V67, P345, DOI 10.1890/0012-9615(1997)067[0345:SAAIST]2.0.CO;2
   Giudice A, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-7
   GUCKERT JB, 1986, APPL ENVIRON MICROB, V52, P794, DOI 10.1128/AEM.52.4.794-801.1986
   Holzmuller P, 2005, ANTIMICROB AGENTS CH, V49, P4406, DOI 10.1128/AAC.49.10.4406-4409.2005
   Holzmuller P, 2006, INFECT GENET EVOL, V6, P187, DOI 10.1016/j.meegid.2005.03.003
   Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142
   HSUCHEN CC, 1973, BIOCHEM BIOPH RES CO, V51, P972, DOI 10.1016/0006-291X(73)90022-3
   Kates M, 1986, TECHNIQUES LIPIDOLOG
   Lanoiselet VM, 2005, MYCOLOGIA, V97, P77, DOI 10.3852/mycologia.97.1.77
   Mauel J, 1997, EXP PARASITOL, V87, P98, DOI 10.1006/expr.1997.4205
   Mbongo N, 1998, ANTIMICROB AGENTS CH, V42, P352
   McCune B., 2002, ANAL ECOLOGICAL COMM
   Mielke P.W., 2000, PERMUTATION METHODS
   Monhanty BP, 2012, APPL BIOCHEM BIOTECH, V169, P192
   Ouellette M, 2004, DRUG RESIST UPDATE, V7, P257, DOI 10.1016/j.drup.2004.07.002
   Piotrowska-Seget Z, 2003, POL J ENVIRON STUD, V12, P669
   Rakotomanga M, 2005, ANTIMICROB AGENTS CH, V49, P2677, DOI 10.1128/AAC.49.7.2677-2686.2005
   Rath S, 2003, QUIM NOVA, V26, P550, DOI 10.1590/S0100-40422003000400018
   Santos PL, 2012, NITRIC OXIDE-BIOL CH, V27, P67, DOI 10.1016/j.niox.2012.04.004
   Sasser M., 1990, 101 MICR ID
   Scheltema RA, 2010, PARASITOLOGY, V137, P1291, DOI 10.1017/S0031182009992022
   Schutter ME, 2000, SOIL SCI SOC AM J, V64, P1659, DOI 10.2136/sssaj2000.6451659x
   Sudhandiran G, 2003, J BIOL CHEM, V278, P25120, DOI 10.1074/jbc.M301975200
   t'Kindt R, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000904
   WHO, 2010, M WHO EXP COMM CONTR
   Zhang K, 2010, ADV EXP MED BIOL, V688, P238
   Zhang K, 2010, MOL BIOCHEM PARASIT, V170, P55, DOI 10.1016/j.molbiopara.2009.12.004
   Zhang O, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000692
NR 36
TC 12
Z9 12
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0932-0113
EI 1432-1955
J9 PARASITOL RES
JI Parasitol. Res.
PD JAN
PY 2014
VL 113
IS 1
BP 19
EP 27
DI 10.1007/s00436-013-3621-y
PG 9
WC Parasitology
SC Parasitology
GA 281MU
UT WOS:000329106500003
PM 24096610
OA Green Published
DA 2020-12-08
ER

PT J
AU de Oliveira, FA
   Silva, CVO
   Damascena, NP
   Passos, RO
   Duthie, MS
   Guderian, JA
   Bhatia, A
   de Moura, TR
   Reed, SG
   de Almeida, RP
   de Jesus, AR
AF de Oliveira, Fabricia Alvisi
   Oliveira Silva, Carla Vanessa
   Damascena, Nayra Prata
   Passos, Rodrigo Oliveira
   Duthie, Malcolm S.
   Guderian, Jeffrey A.
   Bhatia, Ajay
   de Moura, Tatiana Rodrigues
   Reed, Steven G.
   de Almeida, Roque Pacheco
   de Jesus, Amelia Ribeiro
TI High levels of soluble CD40 ligand and matrix metalloproteinase-9 in
   serum are associated with favorable clinical evolution in human visceral
   leishmaniasis
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Visceral leishmaniasis; Soluble CD40 ligand; Matrix metalloproteinase-9;
   Biomarkers; Clinical outcome
ID TRYPANOSOMA-CRUZI INFECTION; ACUTE CORONARY SYNDROMES;
   CELL-MEDIATED-IMMUNITY; MATRIX METALLOPROTEINASES; ASYMPTOMATIC
   INFECTION; CD40-CD40 LIGAND; IFN-GAMMA; CHAGASI; ACTIVATION;
   INTERLEUKIN-10
AB Background: Soluble CD40 ligand (sCD40L) and matrix metalloproteinase 9 (MMP-9) are inflammation markers and have been poorly described in infectious disease. In this prospective study, we describe the sera kinetics of these two molecules in the course of treatment follow up in human visceral leishmaniasis (VL).
   Methods: Sera from VL patients were collected before and during follow up of regular Antimony treatment. sCD40L and MMP-9 were measured by Luminex assay. Paired analysis by Wilcoxon signed test was used for comparison of values of the same subjects before and after initiation of treatment. Correlations between clinical data and parasite load with the serum levels of sCD40L and MMP-9 were performed by Spearman test. Tests were considered statistically significant if the probability of a type I error was less than 5% (p-value <0.05).
   Results: While sCD40L and MMP-9 were not observed in sera from non endemic controls which are at low risk of Leishmania chagasi infection, elevated levels were observed in sera from VL patients, and an increase in sCD40L and MMP-9 levels were detectable during the follow-up of VL patients undergoing antimony treatment. sCD40L levels were also high in individuals living in endemic settings at high risk of infection (endemic controls). Additionally, negative correlations were found between spleen sizes and MMP-9 before treatment and sCD40L at day 15 of treatment. Negative correlations were also found between parasite load with both sCD40L and MMP-9.
   Conclusion: Serum sCD40L and MMP-9 are identified as new and simple biomarkers in two situations: (i) monitoring the success of therapy and (ii) predicting favorable clinical outcome of human VL.
C1 [de Oliveira, Fabricia Alvisi; Oliveira Silva, Carla Vanessa; Damascena, Nayra Prata; Passos, Rodrigo Oliveira; de Moura, Tatiana Rodrigues; de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, BR-4906010 Aracaju, Sergipe, Brazil.
   [Duthie, Malcolm S.; Guderian, Jeffrey A.; Bhatia, Ajay; Reed, Steven G.] IDRI Infect Dis Res Inst, Seattle, WA 98102 USA.
   [de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] CNPq, Inst Nacionais Ciencia & Tecnol, Inst Invest Imunol, Sao Paulo, Brazil.
RP de Jesus, AR (corresponding author), Univ Fed Sergipe, Univ Hosp, Mol Biol Lab, Rua Claudio Batista S-N, BR-4906010 Aracaju, Sergipe, Brazil.
EM jesus-amelia@uol.com.br
RI , Tatiana/AAN-1194-2020
OI , Tatiana/0000-0002-7442-4434; Duthie, Malcolm/0000-0002-8515-5516
FU Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do Estado de
   Sergipe (FAPITEC)/Brazilian Research National Council (CNPq)/Ministerio
   da Saude [019.203.02712/2009-8]; Bill & Melinda Gates Foundation,
   Seattle, USA [42387]; Programa Nacional de Incentivo a Pesquisa em
   Parasitologia Basica [032/2010]; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES
FX We thank to the Pediatric and Infectious Disease Clinic Group from the
   University Hospital, Universidade Federal de Sergipe. This work was
   supported by: Fundacao de Apoio a Pesquisa e a Inovacao Tecnologica do
   Estado de Sergipe (FAPITEC)/Brazilian Research National Council
   (CNPq)/Ministerio da Saude (Programa de Apoio a Projetos para o Sistema
   Unico de Saude - PPSUS Edital 08/2009 and Programas de Nucleos de
   Excelencia - PRONEX, Processo no 019.203.02712/2009-8); Bill & Melinda
   Gates Foundation [grant number 42387], Seattle, USA. Programa Nacional
   de Incentivo a Pesquisa em Parasitologia Basica, Edital No 032/2010,
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES). ARJ
   and RPA are scientists from the Brazilian Research National Council
   (CNPq).
CR Bacellar O, 2000, CYTOKINE, V12, P1228, DOI 10.1006/cyto.2000.0694
   BARRALNETTO M, 1989, BRAZ J MED BIOL RES, V22, P1485
   Caldas AJM, 2002, T ROY SOC TROP MED H, V96, P21, DOI 10.1016/S0035-9203(02)90227-0
   Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7
   CARVALHO EM, 1988, BRAZ J MED BIOL RES, V21, P85
   CARVALHO EM, 1992, J INFECT DIS, V165, P535, DOI 10.1093/infdis/165.3.535
   CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209
   Costa JD, 2008, ACTA TROP, V106, P175, DOI 10.1016/j.actatropica.2008.03.006
   Donhauser N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033925
   Elmetwali T, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-52
   Geurts N, 2012, PHARMACOL THERAPEUT, V133, P257, DOI 10.1016/j.pharmthera.2011.11.008
   Gong YQ, 2008, J CLIN INVEST, V118, P3012, DOI 10.1172/JCI32750
   Goto H, 2009, REV I MED TROP, V51, P241, DOI 10.1590/S0036-46652009000500002
   GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639
   Haanen JBAG, 2007, NAT MED, V13, P248, DOI 10.1038/nm0307-248
   Habib M, 2007, J IMMUNOL, V178, P6700, DOI 10.4049/jimmunol.178.11.6700
   Heeschen C, 2003, NEW ENGL J MED, V348, P1104, DOI 10.1056/NEJMoa022600
   Heymans S, 1999, NAT MED, V5, P1135
   HOLADAY BJ, 1993, J CLIN INVEST, V92, P2626, DOI 10.1172/JCI116878
   Hsu YM, 1997, J BIOL CHEM, V272, P911, DOI 10.1074/jbc.272.2.911
   Lima ID, 2012, AM J TROP MED HYG, V86, P99, DOI 10.4269/ajtmh.2012.10-0492
   Lorente L, 2011, CRIT CARE, V15, DOI 10.1186/cc10104
   Malik N, 1996, J IMMUNOL, V156, P3952
   Mathur RK, 2006, TRENDS PARASITOL, V22, P117, DOI 10.1016/j.pt.2006.01.003
   Mathur RK, 2004, NAT MED, V10, P540, DOI 10.1038/nm1045
   McDyer JF, 1998, J IMMUNOL, V160, P1701
   Melo GD, 2011, VET J, V188, P243, DOI 10.1016/j.tvjl.2010.03.017
   Murray HW, 2000, J INFECT DIS, V182, P1497, DOI 10.1086/315890
   Murray HW, 2003, INFECT IMMUN, V71, P6453, DOI 10.1128/IAI.71.11.6453-6462.2003
   Murray HW, 2003, J INFECT DIS, V188, P458, DOI 10.1086/376510
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Olmo M, 2012, HIV MED, V13, P488, DOI 10.1111/j.1468-1293.2012.01000.x
   Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851
   Palombo D, 1999, J CARDIOVASC SURG, V40, P257
   Portillo JAC, 2007, IMMUNOBIOLOGY
   Rai AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031551
   Reichel CA, 2008, J LEUKOCYTE BIOL, V83, P864, DOI 10.1189/jlb.1007666
   Gutierrez FRS, 2008, J INFECT DIS, V197, P1468, DOI 10.1086/587487
   Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776
   Schulz A, 2003, J CLIN MICROBIOL, V41, P1529, DOI 10.1128/JCM.41.4.1529-1535.2003
   Sipsas NV, 2002, CLIN DIAGN LAB IMMUN, V9, P558, DOI 10.1128/CDLI.9.3.558-561.2002
   Subauste CS, 2009, SEMIN IMMUNOL, V21, P273, DOI 10.1016/j.smim.2009.06.003
   Subauste CS, 1999, J IMMUNOL, V162, P6690
   Sui Z, 2007, J IMMUNOL, V178, P3226, DOI 10.4049/jimmunol.178.5.3226
   Taylor JL, 2006, INFECT IMMUN, V74, P6135, DOI 10.1128/IAI.02048-05
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   Tousoulis D, 2010, TRENDS CARDIOVAS MED, V20, P153, DOI 10.1016/j.tcm.2010.12.004
   van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2
   Verma S, 2010, PLOS ONE, V5
NR 49
TC 14
Z9 14
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUL 19
PY 2013
VL 13
AR 331
DI 10.1186/1471-2334-13-331
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 194YN
UT WOS:000322668700001
PM 23870715
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Rollemberg, CVV
   Santos, CMB
   Silva, MMBL
   Souza, AMB
   da Silva, AM
   de Almeida, JAP
   de Almeida, RP
   de Jesus, AR
AF Vieira Rollemberg, Carla Virginia
   Bomfim Santos, Cybele Maria
   Bezerra Lemos Silva, Marilia Matos
   Barros Souza, Acacia Maria
   da Silva, Angela Maria
   Pacheco de Almeida, Jose Antonio
   de Almeida, Roque Pacheco
   de Jesus, Amelia Ribeiro
TI Epidemiological characteristics and geographical distribution of
   schistosomiasis and geohelminths, in the State of Sergipe, according to
   data from the Schistosomiasis Control Program in Sergipe
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA Portuguese
DT Article
DE Schistosomiasis; Schistosoma mansoni; Epidemiology; Morbidity;
   Geoprocessing
ID MANSONI; NORTHEAST
AB Introduction: Schistosomiasis is endemic in Brazil, with high prevalence in the State of Sergipe, despite the existence of the Schistosomiasis Control Program (PCE). Methods: The data from Sergipe's PCE between 2005 and 2008 were surveyed. From the raw information, a database was created on a spreadsheet using the Access software. The frequency and geographic distribution of infections due to Schistosoma mansoni and other intestinal parasites were analyzed. These data were exported to the Spring 5.0.5 software for georeferencing and preparation of thematic maps of the spatial and temporal distribution according to year of evaluation. Results: In 2005, 13.6% (14,471/106,287) of the tests were positive for S. mansoni, 11.2% (16,196/145,069) in 2006, 11.8% (10,220/86,824) in 2007 and 10.6% (8,329/78,859) in 2008. Analysis on the maps showed that there was high prevalence of the disease in Sergipe, and particularly in the municipalities of Ilha das Flores, Santa Rosa de Lima, Santa Luzia do Itanhi and Sao Cristovao. Furthermore, we evaluated the association between the frequencies of these parasitic diseases and social and developmental indicators in the different municipalities, according to data from the Brazilian Institute for Geography and Statistics (IBGE) and the Department of Water Resources (SRH). We found that municipalities with schistosomiasis prevalence higher than 15% had lower coverage of sewage systems (hygiene index) (p = 0.05). Additionally, municipalities with hookworm prevalence higher than 10% had lower educational HDI (p = 0.04). Conclusions: The importance of greater control over environmental risk and educational factors needs to be emphasized in attempts to reduce the prevalence of these parasitic diseases.
C1 [Vieira Rollemberg, Carla Virginia; Bomfim Santos, Cybele Maria; da Silva, Angela Maria; de Almeida, Roque Pacheco; de Jesus, Amelia Ribeiro] Univ Fed Sergipe, Dept Med, Aracaju, SE, Brazil.
   [Bezerra Lemos Silva, Marilia Matos; Barros Souza, Acacia Maria; Pacheco de Almeida, Jose Antonio] Univ Fed Sergipe, Dept Geog, Aracaju, SE, Brazil.
   Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Invest Imunol, Inst Nacionais Ciencia Tecnol, Sao Paulo, Brazil.
RP de Jesus, AR (corresponding author), Hosp Univ, Lab Biol Mol, DME, UFS, Rua Claudio Batista S-N, BR-49060100 Aracaju, SE, Brazil.
EM jesus-amelia@uol.com.br
RI almeida, roque/F-5609-2012
CR BUTTERWORTH AE, 1988, PHILOS T ROY SOC B, V321, P495, DOI 10.1098/rstb.1988.0105
   Campos MR, 2002, REV SAUDE PUBL, V36, P69, DOI 10.1590/s0034-89102002000100011
   CHEEVER AW, 1992, MEM I OSWALDO CRUZ, V87, P337, DOI 10.1590/S0074-02761992000800054
   Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4
   COURA JR, 1992, MEM I OSWALDO CRUZ, V87, P175, DOI 10.1590/S0074-02761992000800027
   Coura JR, 2004, MEM I OSWALDO CRUZ, V99, P13, DOI 10.1590/S0074-02762004000900003
   Coura-Filho, 1997, Cad Saude Publica, V13, P245, DOI 10.1590/S0102-311X1997000200014
   Coutinho A. D., 1992, Cadernos de Saude Publica, V8, P302, DOI 10.1590/S0102-311X1992000300009
   DEJESUS AMR, 1993, EUR J IMMUNOL, V23, P152, DOI 10.1002/eji.1830230125
   do Amaral RS, 2006, MEM I OSWALDO CRUZ, V101, P79, DOI 10.1590/S0074-02762006000900012
   Drummond SC, 2006, MEM I OSWALDO CRUZ, V101, P37, DOI 10.1590/S0074-02762006000900007
   Geiger SM, 2008, ACTA TROP, V108, P118, DOI 10.1016/j.actatropica.2008.05.012
   Guimaraes ICS, 2006, REV SOC BRAS MED TRO, V39, P451, DOI 10.1590/S0037-86822006000500006
   Instituto Brasileiro de Geografia e Estatistica, 2010, IBGE CID
   JESUS AR, 2004, INFECT IMMUN, V72, P3391
   Katz N, 2000, Rev Soc Bras Med Trop, V33, P303, DOI 10.1590/S0037-86822000000300009
   Lambertucci J, 2005, DINAMICA DOENCAS INF, P931
   *MIN SAUD, 1998, CONTR ESQ BRAS DIR T
   PROGRAMA DAS NACOES UNIDAS PARA O DESENVOLVIMENTO-PNUD, 2000, ATL DES HUM
   RIHET P, 1991, EUR J IMMUNOL, V21, P2679, DOI 10.1002/eji.1830211106
   Rollemberg CVV, 2008, REV FAPESE, V4, P63
   SLEIGH AC, 1985, LANCET, V2, P63
   WALDMAN EA, 2000, VELHOS NOVOS MALES S, P195
   World Health Organization, 1985, CONTR SCHIST
NR 24
TC 3
Z9 3
U1 1
U2 1
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD JAN-FEB
PY 2011
VL 44
IS 1
PG 6
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 723VT
UT WOS:000287536100020
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU de Jesus, AR
   Luna, T
   de Almeida, RP
   Machado, PRL
   Carvalho, EM
AF de Jesus, Amelia Ribeiro
   Luna, Tania
   de Almeida, Roque Pacheco
   Machado, Paulo Roberto Lima
   Carvalho, Edgar M.
TI Pentoxifylline down modulate in vitro T cell responses and attenuate
   pathology in Leishmania and HTLV-1 infections
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article; Proceedings Paper
CT 13th International Congress of Immunology
CY AUG 21-25, 2007
CL Rio de Janeiro, BRAZIL
DE pentoxifylline; HTLV-1; leishmaniasis; cutaneous leishmaniasis; mucosal
   leishmaniasis; immunotherapy
ID VIRUS TYPE-I; COLONY-STIMULATING FACTOR; AMERICAN CUTANEOUS
   LEISHMANIASIS; NF-KAPPA-B; GRANULOCYTE-MACROPHAGE; DOUBLE-BLIND; MUCOSAL
   LEISHMANIASIS; INTERFERON-ALPHA; VISCERAL LEISHMANIASIS; PENTAVALENT
   ANTIMONY
AB Tumor necrosis factor-alpha (TNF-alpha) is known to have numerous biological properties relating to inflammation. This cytokine participates in the tissue damage of chronic inflammatory, autoimmune and infectious diseases. Pentoxifylline is a methylxanthine that inhibits phosphodiesterase IV, which inhibits the degradation of the cAMP and prostanoids. The increased intracellular concentration of the cAMP leads to a negative regulation of NF-kappa B and NF-AT transcription factors and suppresses TNF-alpha production. This review describes studies that support evidences that TNF-alpha is involved in the pathogenesis of HTLV-1 associated myelopathy and of cutaneous and mucosal leishmaniasis. Additionally, it demonstrates the effect of pentoxifylline in vitro in inhibiting TNF-alpha. and IFN-gamma spontaneous production in PBMC from HTLV-1-infected patients, as well as its in vivo effect in inhibiting TNF-a in sera from mucosal leishmaniasis patients. Moreover, we review the results of clinical studies from the last 10 years using pentoxifylline to treat HTLV-1 associated myelopathy and cutaneous and mucosal leishmaniasis. (c) 2008 Elsevier B.V. All rights reserved.
C1 [de Jesus, Amelia Ribeiro; Luna, Tania; de Almeida, Roque Pacheco; Machado, Paulo Roberto Lima; Carvalho, Edgar M.] Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, BR-40110160 Salvador, BA, Brazil.
   [de Jesus, Amelia Ribeiro; de Almeida, Roque Pacheco] Univ Fed Sergipe, Dept Med, Aracaju, SE, Brazil.
RP Carvalho, EM (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, 5 Andar,Rua Joao Botas S-No, BR-40110160 Salvador, BA, Brazil.
EM edgar@ufba.br
RI MACHADO, PAULO ROBERTO LIMA/AAP-2642-2020; KALIL, JORGE/C-8029-2012;
   almeida, roque/F-5609-2012
OI MACHADO, PAULO ROBERTO LIMA/0000-0003-1894-6171; KALIL,
   JORGE/0000-0001-8415-4274; 
CR Almeida R, 1999, J INFECT DIS, V180, P1735, DOI 10.1086/315082
   Almeida RP, 1996, AM J TROP MED HYG, V54, P178, DOI 10.4269/ajtmh.1996.54.178
   Almeida RP, 2005, AM J TROP MED HYG, V73, P79, DOI 10.4269/ajtmh.2005.73.79
   AMVROSIEVA TV, 1993, VOP VIRUSOL+, V38, P230
   ANTONELLI LR, 2005, IMMUNOL LETT, V2
   Antonelli LRV, 2004, CLIN EXP IMMUNOL, V136, P341, DOI 10.1111/j.1365-2249.2004.02426.x
   Araujo A. Q.-C., 1993, Acta Neurologica Scandinavica, V88, P59
   ARAUJO AD, 1995, J NEUROL SCI, V129, P147
   ARDIZZOIA A, 1993, SUPPORT CARE CANCER, V1, P331, DOI 10.1007/BF00364972
   Azimi N, 2001, P NATL ACAD SCI USA, V98, P14559, DOI 10.1073/pnas.251540598
   Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
   BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104
   Bafica A, 2003, INT J DERMATOL, V42, P203, DOI 10.1046/j.1365-4362.2003.01868.x
   Becker I, 1999, PARASITOL RES, V85, P165, DOI 10.1007/s004360050529
   Ben Salah A, 2005, J INFECT DIS, V192, P1981, DOI 10.1086/498042
   BISWAS DK, 1993, J ACQ IMMUN DEF SYND, V6, P778
   BITTENCOURT AL, 1991, MEM I OSWALDO CRUZ, V86, P51, DOI 10.1590/S0074-02761991000100009
   Blackwell JM, 1997, PHILOS T R SOC B, V352, P1331, DOI 10.1098/rstb.1997.0118
   Blam ME, 2001, AM J GASTROENTEROL, V96, P1977, DOI 10.1016/S0002-9270(01)02494-7
   Bomfim G, 1996, EXP PARASITOL, V84, P188, DOI 10.1006/expr.1996.0104
   CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259
   Cabrera-Gomez JA, 1999, REV NEUROLOGIA, V29, P1225, DOI 10.33588/rn.2912.98318
   Carod-Artal FJ, 2000, REV NEUROLOGIA, V31, P32, DOI 10.33588/rn.3101.2000004
   CARVALHO EM, 1985, J IMMUNOL, V135, P4144
   Carvalho LP, 2007, PARASITE IMMUNOL, V29, P251, DOI 10.1111/j.1365-3024.2007.00940.x
   Castellucci L, 2006, J INFECT DIS, V194, P519, DOI 10.1086/505504
   Castes Marianella, 1998, Acta Cientifica Venezolana, V49, P42
   Castro Neviton M., 2007, Int. braz j urol., V33, P238, DOI 10.1590/S1677-55382007000200016
   Castro NM, 2007, UROLOGY, V69, P813, DOI 10.1016/j.urology.2007.01.052
   Clerici M, 1997, J INFECT DIS, V175, P1210, DOI 10.1086/593570
   Cupolillo E, 1997, ANN TROP MED PARASIT, V91, P617, DOI 10.1080/00034989760716
   daCosta RM, 1997, AM J SURG, V173, P165, DOI 10.1016/S0002-9610(97)89589-X
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   Desjeux P., 1992, World Health Statistics Quarterly, V45, P267
   Edlich Richard F, 2003, J Long Term Eff Med Implants, V13, P127, DOI 10.1615/JLongTermEffMedImplants.v13.i2.70
   Eigler A, 1997, IMMUNOL TODAY, V18, P487, DOI 10.1016/S0167-5699(97)01118-3
   Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Follador I, 1999, Rev Soc Bras Med Trop, V32, P497, DOI 10.1590/S0037-86821999000500005
   Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
   FRANKE ED, 1990, ANN INTERN MED, V113, P934, DOI 10.7326/0003-4819-113-12-934
   Fujimoto T, 1999, INTERNAL MED, V38, P717, DOI 10.2169/internalmedicine.38.717
   GESSAIN A, 1985, LANCET, V2, P407
   GRIMALDI G, 1993, CLIN MICROBIOL REV, V6, P230, DOI 10.1128/CMR.6.3.230-250.1993
   Guerreiro JB, 2006, CLIN EXP IMMUNOL, V145, P296, DOI 10.1111/j.1365-2249.2006.03150.x
   HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213
   HO JL, 1990, J INFECT DIS, V162, P224, DOI 10.1093/infdis/162.1.224
   Izumo S, 1996, NEUROLOGY, V46, P1016, DOI 10.1212/WNL.46.4.1016
   Jacobson S, 2002, J INFECT DIS, V186, pS187, DOI 10.1086/344269
   JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73
   KAPLAN G, 1992, J EXP MED, V175, P1717, DOI 10.1084/jem.175.6.1717
   Karplus TM, 2002, INFECT IMMUN, V70, P6919, DOI 10.1128/IAI.70.12.6919-6925.2002
   Kassiotis G, 2001, J EXP MED, V193, P427, DOI 10.1084/jem.193.4.427
   Kollias G, 1999, ANN RHEUM DIS, V58, P32, DOI 10.1136/ard.58.2008.i32
   Kunkel S L, 1988, Methods Achiev Exp Pathol, V13, P240
   KURODA Y, 1992, ACTA NEUROL SCAND, V86, P82, DOI 10.1111/j.1600-0404.1992.tb08059.x
   LAINSON R, 1983, T ROY SOC TROP MED H, V77, P569, DOI 10.1016/0035-9203(83)90185-2
   Lessa HA, 2001, AM J TROP MED HYG, V65, P87, DOI 10.4269/ajtmh.2001.65.87
   Machado P, 2002, CLIN INFECT DIS, V34, pE69, DOI 10.1086/340526
   Machado P, 2002, EUR J DERMATOL, V12, P449
   Machado PRL, 2007, CLIN INFECT DIS, V44, P788, DOI 10.1086/511643
   Machuca A, 2001, VIRUS RES, V78, P93, DOI 10.1016/S0168-1702(01)00287-8
   Martin JA, 2003, AEROSPACE AM, V41, P6
   Nagai M, 2003, J NEUROVIROL, V9, P228, DOI 10.1080/13550280390194028
   Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225
   Nagai M, 2001, J INFECT DIS, V183, P197, DOI 10.1086/317932
   Nakagawa M, 1996, J NEUROVIROL, V2, P345, DOI 10.3109/13550289609146899
   Narikawa K, 2005, J NEUROIMMUNOL, V159, P177, DOI 10.1016/j.jneuroim.2004.10.011
   Navarro J, 1996, AIDS, V10, P469, DOI 10.1097/00002030-199605000-00004
   Navarro J, 1998, J VIROL, V72, P4712, DOI 10.1128/JVI.72.6.4712-4720.1998
   Neuner P, 1997, IMMUNOLOGY, V90, P435, DOI 10.1111/j.1365-2567.1997.00435.x
   Osame M, 2002, J NEUROVIROL, V8, P359, DOI 10.1080/13550280260422668
   OSAME M, 1986, LANCET, V1, P1031
   Papadakis KA, 2000, GASTROENTEROLOGY, V119, P1148, DOI 10.1053/gast.2000.18160
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Reilly MP, 2007, J INVEST MED, V55, P26, DOI 10.2310/6650.2007.06013
   Ribeiro-de-Jesus A, 1998, BRAZ J MED BIOL RES, V31, P143, DOI 10.1590/S0100-879X1998000100020
   ROBSON M, 1994, EUR J CLIN MICROBIOL, V13, pS41, DOI 10.1007/BF01973601
   Rozieres A, 2006, ANN DERMATOL VENER, V133, P174, DOI 10.1016/S0151-9638(06)70873-0
   RYFFEL B, 1991, IMMUNOLOGY, V74, P446
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Sadeghian G, 2006, INT J DERMATOL, V45, P819, DOI 10.1111/j.1365-4632.2006.02867.x
   Saito M, 2004, J INFECT DIS, V189, P29, DOI 10.1086/380101
   Sandborn WJ, 2002, GASTROENTEROLOGY, V122, P1592, DOI 10.1053/gast.2002.33426
   Santos JB, 2004, J INFECT DIS, V190, P1793, DOI 10.1086/424848
   Santos SB, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-7
   Santos SB, 2006, NEUROIMMUNOMODULAT, V13, P145, DOI 10.1159/000097259
   Schriefer A, 2004, INFECT IMMUN, V72, P508, DOI 10.1128/IAI.72.1.508-514.2004
   SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x
   Shirabe S, 1997, J NEUROL SCI, V151, P97, DOI 10.1016/S0022-510X(97)00074-9
   Staak K, 1997, BLOOD, V89, P3682, DOI 10.1182/blood.V89.10.3682.3682_3682_3690
   Suryaprasad AG, 2003, AUTOIMMUN REV, V2, P346, DOI 10.1016/S1568-9972(03)00048-X
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Turetz ML, 2002, J INFECT DIS, V186, P1829, DOI 10.1086/345772
   WEISER WY, 1987, J EXP MED, V166, P1436, DOI 10.1084/jem.166.5.1436
   Witkamp R, 2000, VET QUART, V22, P11, DOI 10.1080/01652176.2000.9695016
NR 96
TC 16
Z9 16
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD OCT
PY 2008
VL 8
IS 10
SI SI
BP 1344
EP 1353
DI 10.1016/j.intimp.2008.03.020
PG 10
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA 350XC
UT WOS:000259385900007
DA 2020-12-08
ER

PT J
AU de Jesus, AR
   Silva, A
   Santana, LB
   Magalhaes, A
   de Jesus, AA
   de Almeida, RP
   Rego, MAV
   Burattini, MN
   Pearce, EJ
   Carvalho, EM
AF de Jesus, AR
   Silva, A
   Santana, LB
   Magalhaes, A
   de Jesus, AA
   de Almeida, RP
   Rego, MAV
   Burattini, MN
   Pearce, EJ
   Carvalho, EM
TI Clinical and immunologic evaluation of 31 patients with acute
   schistosomiasis mansoni
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 49th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY OCT 29-NOV 02, 2000
CL HOUSTON, TEXAS
SP Amer Soc Trop Med & Hyg
ID CIRCULATING IMMUNE-COMPLEXES; MURINE SCHISTOSOMIASIS; CYTOKINE
   PRODUCTION; RESPONSES; ANTIGENS; INFECTION; DISEASE; GAMMA; TYPE-1;
   IL-10
AB Thirty-one patients with acute schistosomiasis were evaluated clinically and immunologically. Cytokine levels were determined in peripheral blood mononuclear cell (PBMC) supernatants. Levels of total and antigen-specific IgE, tumor necrosis factor (TNF)-alpha, and immune complexes were measured in serum samples. Clinical findings included general symptoms, liver damage, pulmonary involvement, and pericarditis. All patients had eosinophilia. Immune complexes were detected in 55% of the patients (mean +/- SD, 7.8 +/- 7.6 mug Eq/mL) and were associated with cough, dyspnea, and abnormal chest radiographic findings. Levels (mean +/- SD) of TNF-alpha (1349.3 +/- 767.6 pg/mL), interleukin (IL)-1 (2683 +/- 1270 mug/mL), and IL-6 (382 +/- 52.3 pg/mL) were elevated in PBMC. Serum TNF-alpha levels were elevated in 87% of the patients and were associated with abdominal pain. Higher interferon-gamma levels were detected in PBMC of patients with acute disease than in those of patients with chronic schistosomiasis; IL-5 levels were higher in those with chronic disease. Low IL-5 levels were associated with weight loss. Proinflammatory cytokines and immune complexes with low Th2 responses might explain the immunopathogenesis of acute schistosomiasis.
C1 Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, BR-40110160 Salvador, Brazil.
   Univ Fed Sergipe, Dept Doencas Infecciosas, Sergipe, Brazil.
   Univ Fed Sao Paulo, Serv Doencas Infecciosas, Sao Paulo, Brazil.
   Cornell Univ, Coll Vet Med, Dept Microbiol Immunol & Parasitol, Ithaca, NY 14853 USA.
RP Carvalho, EM (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, BR-40110160 Salvador, Brazil.
RI almeida, roque/F-5609-2012; Burattini, Marcelo Nascimento/J-9272-2014
OI Burattini, Marcelo Nascimento/0000-0002-5407-6890
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-30639] Funding
   Source: Medline
CR ABDELWAHAB MF, 1992, AM J TROP MED HYG, V46, P403, DOI 10.4269/ajtmh.1992.46.403
   Angstwurm K, 1998, NEUROSCIENCE, V86, P627, DOI 10.1016/S0306-4522(98)00032-3
   Araujo MI, 1996, EUR J IMMUNOL, V26, P1399, DOI 10.1002/eji.1830260633
   ARAUJO MI, 1994, BRAZ J MED BIOL RES, V27, P1619
   BACH JF, 1997, LANCET, V350, P11
   BahiaOliveira LMG, 1996, PARASITE IMMUNOL, V18, P53, DOI 10.1046/j.1365-3024.1996.d01-49.x
   BARRALNETTO M, 1991, J INFECT DIS, V163, P853, DOI 10.1093/infdis/163.4.853
   Bina J. C., 1981, Revista de Patologia Tropical, V10, P221
   BOROS DL, 1970, J EXP MED, V132, P488, DOI 10.1084/jem.132.3.488
   Brunet LR, 1997, J IMMUNOL, V159, P777
   de Jesus AR, 2000, INFECT IMMUN, V68, P2797, DOI 10.1128/IAI.68.5.2797-2803.2000
   DEJESUS AMR, 1993, EUR J IMMUNOL, V23, P152, DOI 10.1002/eji.1830230125
   Dinarello CA, 2000, NEW ENGL J MED, V343, P732, DOI 10.1056/NEJM200009073431011
   Doumenge JP, 1987, ATLAS GLOBAL DISTRIB
   Fallon PG, 2000, EUR J IMMUNOL, V30, P470, DOI 10.1002/1521-4141(200002)30:2&lt;470::AID-IMMU470&gt;3.0.CO;2-T
   FARID Z, 1989, TROP GEOGR MED, V41, P172
   GAZZINELLI G, 1985, J IMMUNOL, V135, P2121
   GAZZINELLI RT, 1988, AM J TROP MED HYG, V39, P288, DOI 10.4269/ajtmh.1988.39.288
   GELFAND V, 1981, CENT AFR J MED, V27, P219
   Gryzch JM, 1991, J IMMUNOL, V146, P1322
   HIATT RA, 1979, J INFECT DIS, V139, P659, DOI 10.1093/infdis/139.6.659
   HIATT RA, 1980, J INFECT DIS, V142, P665, DOI 10.1093/infdis/142.5.665
   Hoffmann KF, 2000, J IMMUNOL, V164, P6406, DOI 10.4049/jimmunol.164.12.6406
   KATZ N, 1968, Revista do Instituto de Medicina Tropical de Sao Paulo, V10, P295
   KATZ N, 1970, J PARASITOL, V56, P1032, DOI 10.2307/3277532
   KATZ N, 1966, J PARASITOL, V52, P917, DOI 10.2307/3276534
   KEMENY DM, 1991, PRACTICAL GUIDE ELIS
   Kox WJ, 2000, INTENS CARE MED, V26, pS124, DOI 10.1007/s001340051129
   Kubler-Kielb J, 2000, Postepy Hig Med Dosw, V54, P119
   LAMBERTUCCI J, 1989, T R SOC MED HYG, V83, P76
   Lambertucci J. R., 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P399, DOI 10.1590/S0036-46651993000500003
   Lambertucci JR, 1997, MEM I OSWALDO CRUZ, V92, P631, DOI 10.1590/S0074-02761997000500013
   LAWLEY TJ, 1979, CLIN EXP IMMUNOL, V37, P221
   Montenegro SML, 1999, J INFECT DIS, V179, P1502, DOI 10.1086/314748
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045
   Mwatha JK, 1998, J IMMUNOL, V160, P1992
   Pearce EJ, 1996, EXP PARASITOL, V84, P295, DOI 10.1006/expr.1996.0116
   PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159
   PESSOA SB, 1977, PARASITOLOGIA MED, P399
   RABELLO A, 1995, MEM I OSWALDO CRUZ, V90, P277, DOI 10.1590/S0074-02761995000200026
   Rabello ALT, 1997, CLIN INFECT DIS, V24, P304, DOI 10.1093/clinids/24.3.304
   Sabin EA, 1996, J INFECT DIS, V173, P269, DOI 10.1093/infdis/173.1.269
   VANDEUREN M, 1995, J INFECT DIS, V172, P433, DOI 10.1093/infdis/172.2.433
   *WHO, 1985, REP WHO EXP COMM CON
   *WHO, 1995, WHO UNICEF JOINT PRO
   World Health Organization, 1993, WHO TECHN REP SER, V830
   Wynn TA, 1998, J IMMUNOL, V160, P4473
NR 48
TC 112
Z9 115
U1 0
U2 9
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 1
PY 2002
VL 185
IS 1
BP 98
EP 105
DI 10.1086/324668
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 502AZ
UT WOS:000172722600013
PM 11756987
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU BITTENCOURT, A
   BARRAL, A
   DEJESUS, AR
   DEALMEIDA, RP
   GRIMALDI, G
AF BITTENCOURT, A
   BARRAL, A
   DEJESUS, AR
   DEALMEIDA, RP
   GRIMALDI, G
TI INSITU IDENTIFICATION OF LEISHMANIA-AMAZONENSIS ASSOCIATED WITH DIFFUSE
   CUTANEOUS LEISHMANIASIS IN BAHIA, BRAZIL
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Note
C1 UNIV FED BAHIA,HOSP PROF EDGARD SANTOS,IMMUNOL LAB,BR-40140 SALVADOR,BA,BRAZIL.
   INST OSWALDO CRUZ,DEPT IMUNOL,BR-20001 RIO DE JANEIRO,RJ,BRAZIL.
RP BITTENCOURT, A (corresponding author), UNIV FED BAHIA,DEPT ANAT PATOL & MED LEGAL,R JOAO DAS BOTAS S-N,BR-40140 SALVADOR,BA,BRAZIL.
RI Barral, Aldina/B-4191-2009
OI Barral, Aldina/0000-0002-7177-464X
CR BARRAL A, 1989, IN PRESS AM J TROP M
   BITTENCOURT A. L., 1968, Medicina Cutanea, V2, P395
   FONSECA A, 1981, MED CUT ILA, V9, P317
   GRIMALDI G, 1987, AM J TROP MED HYG, V36, P270, DOI 10.4269/ajtmh.1987.36.270
   GRIMALDI G, 1983, 10 REUN AN PESQ BAS
   GRIMALDI G, 1989, IN PRESS AM J TROP M
   GUIMARAES FN, 1951, HOSPITAL, V40, P11
   LAINSON R, 1983, T ROY SOC TROP MED H, V77, P569, DOI 10.1016/0035-9203(83)90185-2
   Medina R., 1962, Archivos Venezolanos de Medicina Tropical y Parasitologia Medica, V4, P349
   MILES M, 1980, T R SOC TROP MED HYG, V74, P248
   PAN AA, 1988, J IMMUNOL, V140, P2406
   PORTUGAL H, 1960, Hospital (Rio J), V57, P813
   SILVA A. R., 1981, Revista do Instituto de Medicina Tropical de Sao Paulo, V23, P31
NR 13
TC 15
Z9 15
U1 0
U2 0
PU MEM INST OSWALDO CRUZ
PI RIO DE JANEIRO
PA SECRETARY CAIXA POSTAL 926, 20001 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD OCT-DEC
PY 1989
VL 84
IS 4
BP 585
EP 586
DI 10.1590/S0074-02761989000400022
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA CK218
UT WOS:A1989CK21800022
PM 2487456
OA DOAJ Gold
DA 2020-12-08
ER

EF